EP1532120B1 - Phenylpyridazine derivatives as ligands for gaba receptors - Google Patents
Phenylpyridazine derivatives as ligands for gaba receptors Download PDFInfo
- Publication number
- EP1532120B1 EP1532120B1 EP03784243A EP03784243A EP1532120B1 EP 1532120 B1 EP1532120 B1 EP 1532120B1 EP 03784243 A EP03784243 A EP 03784243A EP 03784243 A EP03784243 A EP 03784243A EP 1532120 B1 EP1532120 B1 EP 1532120B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- fluoro
- phenyl
- pyridazine
- difluoropyridin
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003446 ligand Substances 0.000 title abstract description 10
- XWSSUYOEOWLFEI-UHFFFAOYSA-N 3-phenylpyridazine Chemical class C1=CC=CC=C1C1=CC=CN=N1 XWSSUYOEOWLFEI-UHFFFAOYSA-N 0.000 title description 3
- 102000005915 GABA Receptors Human genes 0.000 title 1
- 108010005551 GABA Receptors Proteins 0.000 title 1
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 206
- -1 benzthienyl Chemical group 0.000 claims description 148
- 238000000034 method Methods 0.000 claims description 66
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 50
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 35
- 125000005843 halogen group Chemical group 0.000 claims description 34
- 239000001257 hydrogen Substances 0.000 claims description 33
- 229910052739 hydrogen Inorganic materials 0.000 claims description 33
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 31
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 125000001153 fluoro group Chemical group F* 0.000 claims description 28
- 239000003054 catalyst Substances 0.000 claims description 26
- 229910052723 transition metal Inorganic materials 0.000 claims description 25
- 150000003624 transition metals Chemical class 0.000 claims description 25
- 125000001072 heteroaryl group Chemical group 0.000 claims description 24
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 22
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 20
- 150000001204 N-oxides Chemical class 0.000 claims description 19
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 19
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 17
- 230000008569 process Effects 0.000 claims description 17
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 15
- 125000004802 cyanophenyl group Chemical group 0.000 claims description 15
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 15
- 125000004076 pyridyl group Chemical group 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical group 0.000 claims description 12
- 125000001425 triazolyl group Chemical group 0.000 claims description 12
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 11
- 125000000335 thiazolyl group Chemical group 0.000 claims description 11
- 125000002541 furyl group Chemical group 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 125000001544 thienyl group Chemical group 0.000 claims description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 10
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 229910003827 NRaRb Inorganic materials 0.000 claims description 8
- 229910052721 tungsten Inorganic materials 0.000 claims description 8
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims description 7
- 125000006323 alkenyl amino group Chemical group 0.000 claims description 7
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims description 7
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims description 7
- 125000005059 halophenyl group Chemical group 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 6
- 239000004215 Carbon black (E152) Substances 0.000 claims description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 6
- 229930195733 hydrocarbon Natural products 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- AHHSTGLUTRNWRJ-UHFFFAOYSA-N 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2,4,6-trifluorophenyl)pyridazine Chemical compound FC1=CC(F)=CN=C1C1=CC(C=2C=C(N=NC=2)C=2C(=CC(F)=CC=2F)F)=CC=C1F AHHSTGLUTRNWRJ-UHFFFAOYSA-N 0.000 claims description 5
- 125000005620 boronic acid group Chemical group 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- ZKNFRVHGJHOQPA-UHFFFAOYSA-N 2-[2-fluoro-5-[6-(2-oxopyridin-1-yl)pyridazin-4-yl]phenyl]benzonitrile Chemical compound FC1=CC=C(C=2C=C(N=NC=2)N2C(C=CC=C2)=O)C=C1C1=CC=CC=C1C#N ZKNFRVHGJHOQPA-UHFFFAOYSA-N 0.000 claims description 4
- LZCAFFRHORQIDK-UHFFFAOYSA-N 2-[2-fluoro-5-[6-(2-oxopyrrolidin-1-yl)pyridazin-4-yl]phenyl]benzonitrile Chemical compound FC1=CC=C(C=2C=C(N=NC=2)N2C(CCC2)=O)C=C1C1=CC=CC=C1C#N LZCAFFRHORQIDK-UHFFFAOYSA-N 0.000 claims description 4
- FUGLSZXUUCIKLV-UHFFFAOYSA-N 2-[5-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]-2-fluorophenyl]-3-fluorobenzonitrile Chemical compound FC1=CC(F)=CN=C1C1=CC(C=2C=C(C(F)=CC=2)C=2C(=CC=CC=2F)C#N)=CN=N1 FUGLSZXUUCIKLV-UHFFFAOYSA-N 0.000 claims description 4
- GZESPDYVAVEYQQ-UHFFFAOYSA-N 2-[5-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]-2-fluorophenyl]-5-fluorobenzonitrile Chemical compound N#CC1=CC(F)=CC=C1C1=CC(C=2C=C(N=NC=2)C=2C(=CC(F)=CN=2)F)=CC=C1F GZESPDYVAVEYQQ-UHFFFAOYSA-N 0.000 claims description 4
- FCEZMVMTOIGDTH-UHFFFAOYSA-N 2-[5-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]-2-fluorophenyl]benzonitrile Chemical compound FC1=CC(F)=CN=C1C1=CC(C=2C=C(C(F)=CC=2)C=2C(=CC=CC=2)C#N)=CN=N1 FCEZMVMTOIGDTH-UHFFFAOYSA-N 0.000 claims description 4
- UMEZFCXFSXDNKZ-UHFFFAOYSA-N 2-[5-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]-2-fluorophenyl]pyridine-3-carbonitrile Chemical compound FC1=CC(F)=CN=C1C1=CC(C=2C=C(C(F)=CC=2)C=2C(=CC=CN=2)C#N)=CN=N1 UMEZFCXFSXDNKZ-UHFFFAOYSA-N 0.000 claims description 4
- ZMJFKCXABAQDGY-UHFFFAOYSA-N 2-[5-[6-(3,5-difluoropyridin-4-yl)pyridazin-4-yl]-2-fluorophenyl]-5-fluorobenzonitrile Chemical compound N#CC1=CC(F)=CC=C1C1=CC(C=2C=C(N=NC=2)C=2C(=CN=CC=2F)F)=CC=C1F ZMJFKCXABAQDGY-UHFFFAOYSA-N 0.000 claims description 4
- HNQWQFNABCSIOY-UHFFFAOYSA-N 2-[5-[6-(3,5-difluoropyridin-4-yl)pyridazin-4-yl]-2-fluorophenyl]benzonitrile Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2C(=CN=CC=2F)F)C=C1C1=CC=CC=C1C#N HNQWQFNABCSIOY-UHFFFAOYSA-N 0.000 claims description 4
- QVHLZTJVMBCMFL-UHFFFAOYSA-N 2-[5-[6-(3,5-difluoropyridin-4-yl)pyridazin-4-yl]-2-fluorophenyl]pyridine-3-carbonitrile Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2C(=CN=CC=2F)F)C=C1C1=NC=CC=C1C#N QVHLZTJVMBCMFL-UHFFFAOYSA-N 0.000 claims description 4
- PYXJKYJAFMLYMS-UHFFFAOYSA-N 3-(3,5-difluoropyridin-2-yl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine Chemical compound FC1=CC(F)=CN=C1C1=CC(C=2C=C(C(F)=CC=2)C=2C(=CC(F)=CN=2)F)=CN=N1 PYXJKYJAFMLYMS-UHFFFAOYSA-N 0.000 claims description 4
- ZRVISZYEZNNSPK-UHFFFAOYSA-N 3-(3,5-difluoropyridin-2-yl)-5-[4-fluoro-3-(2-fluorophenyl)phenyl]pyridazine Chemical compound FC1=CC(F)=CN=C1C1=CC(C=2C=C(C(F)=CC=2)C=2C(=CC=CC=2)F)=CN=N1 ZRVISZYEZNNSPK-UHFFFAOYSA-N 0.000 claims description 4
- IPBXYXQZSUGQTK-UHFFFAOYSA-N 3-(3,5-difluoropyridin-2-yl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine Chemical compound FC1=CC(F)=CN=C1C1=CC(C=2C=C(C(F)=CC=2)C=2C(=CC=CN=2)F)=CN=N1 IPBXYXQZSUGQTK-UHFFFAOYSA-N 0.000 claims description 4
- AWAQLOPTUAWWNN-UHFFFAOYSA-N 3-(3,5-difluoropyridin-2-yl)-5-[4-fluoro-3-(trifluoromethyl)phenyl]pyridazine Chemical compound FC1=CC(F)=CN=C1C1=CC(C=2C=C(C(F)=CC=2)C(F)(F)F)=CN=N1 AWAQLOPTUAWWNN-UHFFFAOYSA-N 0.000 claims description 4
- UODUIHRODBYPOD-UHFFFAOYSA-N 3-(3,5-difluoropyridin-4-yl)-5-[3-(3,5-difluoropyridin-2-yl)-2,4-difluorophenyl]pyridazine Chemical compound FC1=CC(F)=CN=C1C1=C(F)C=CC(C=2C=C(N=NC=2)C=2C(=CN=CC=2F)F)=C1F UODUIHRODBYPOD-UHFFFAOYSA-N 0.000 claims description 4
- DNSPBVIIBSAYPW-UHFFFAOYSA-N 3-(3,5-difluoropyridin-4-yl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine Chemical compound FC1=CC(F)=CN=C1C1=CC(C=2C=C(N=NC=2)C=2C(=CN=CC=2F)F)=CC=C1F DNSPBVIIBSAYPW-UHFFFAOYSA-N 0.000 claims description 4
- PJRLLIRJVWKEOB-UHFFFAOYSA-N 3-(4-chloro-2-fluorophenyl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine Chemical compound FC1=CC(F)=CN=C1C1=CC(C=2C=C(N=NC=2)C=2C(=CC(Cl)=CC=2)F)=CC=C1F PJRLLIRJVWKEOB-UHFFFAOYSA-N 0.000 claims description 4
- WNKKIUKBSHOJCF-UHFFFAOYSA-N 3-tert-butylsulfanyl-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine Chemical compound N1=NC(SC(C)(C)C)=CC(C=2C=C(C(F)=CC=2)C=2C(=CC=CN=2)F)=C1 WNKKIUKBSHOJCF-UHFFFAOYSA-N 0.000 claims description 4
- DYNOVGUQVWFKRH-UHFFFAOYSA-N 5-[3-(2,4-difluorophenyl)-4-fluorophenyl]-3-(3,5-difluoropyridin-2-yl)pyridazine Chemical compound FC1=CC(F)=CC=C1C1=CC(C=2C=C(N=NC=2)C=2C(=CC(F)=CN=2)F)=CC=C1F DYNOVGUQVWFKRH-UHFFFAOYSA-N 0.000 claims description 4
- NMVKPVLTEGUVRF-UHFFFAOYSA-N 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluoro-4-methylphenyl)pyridazine Chemical class FC1=CC(C)=CC=C1C1=CC(C=2C=C(C(F)=CC=2)C=2C(=CC(F)=CN=2)F)=CN=N1 NMVKPVLTEGUVRF-UHFFFAOYSA-N 0.000 claims description 4
- CMRJVDJLBFKXKL-UHFFFAOYSA-N 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluorophenyl)pyridazine Chemical compound FC1=CC(F)=CN=C1C1=CC(C=2C=C(N=NC=2)C=2C(=CC=CC=2)F)=CC=C1F CMRJVDJLBFKXKL-UHFFFAOYSA-N 0.000 claims description 4
- IBIAGNJTCFFVTB-UHFFFAOYSA-N 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-fluoropyridin-4-yl)pyridazine Chemical compound FC1=CC(F)=CN=C1C1=CC(C=2C=C(N=NC=2)C=2C(=CN=CC=2)F)=CC=C1F IBIAGNJTCFFVTB-UHFFFAOYSA-N 0.000 claims description 4
- GUPNBVRLAJLGAF-UHFFFAOYSA-N 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-[2-fluoro-4-(trifluoromethyl)phenyl]pyridazine Chemical compound FC1=CC(F)=CN=C1C1=CC(C=2C=C(N=NC=2)C=2C(=CC(=CC=2)C(F)(F)F)F)=CC=C1F GUPNBVRLAJLGAF-UHFFFAOYSA-N 0.000 claims description 4
- BGVDDMWFMIAGGF-UHFFFAOYSA-N 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoropyridin-2-yl)pyridazine Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2C(=CC=CN=2)F)C=C1C1=NC=CC=C1F BGVDDMWFMIAGGF-UHFFFAOYSA-N 0.000 claims description 4
- MNTGRSPARUFALM-UHFFFAOYSA-N 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoropyridin-4-yl)pyridazine Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2C(=CN=CC=2)F)C=C1C1=NC=CC=C1F MNTGRSPARUFALM-UHFFFAOYSA-N 0.000 claims description 4
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 claims description 4
- XIESMTSNLVSEHP-UHFFFAOYSA-N [5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazin-3-yl] trifluoromethanesulfonate Chemical compound FC1=CC=C(C=2C=C(OS(=O)(=O)C(F)(F)F)N=NC=2)C=C1C1=NC=CC=C1F XIESMTSNLVSEHP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 229910052705 radium Inorganic materials 0.000 claims description 4
- 229910052701 rubidium Inorganic materials 0.000 claims description 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 3
- DMQGEWOSIVQBPR-UHFFFAOYSA-N 2-[3-(6-ethoxypyridazin-4-yl)phenyl]-5-fluorobenzonitrile Chemical compound N1=NC(OCC)=CC(C=2C=C(C=CC=2)C=2C(=CC(F)=CC=2)C#N)=C1 DMQGEWOSIVQBPR-UHFFFAOYSA-N 0.000 claims description 3
- DOKRNNGQSIBWOU-UHFFFAOYSA-N 2-[3-[6-(benzylamino)pyridazin-4-yl]phenyl]-5-fluorobenzonitrile Chemical compound N#CC1=CC(F)=CC=C1C1=CC=CC(C=2C=C(NCC=3C=CC=CC=3)N=NC=2)=C1 DOKRNNGQSIBWOU-UHFFFAOYSA-N 0.000 claims description 3
- BFHVDYUBFLVJMU-UHFFFAOYSA-N 2-[3-[6-(ethylamino)pyridazin-4-yl]phenyl]-5-fluorobenzonitrile Chemical compound N1=NC(NCC)=CC(C=2C=C(C=CC=2)C=2C(=CC(F)=CC=2)C#N)=C1 BFHVDYUBFLVJMU-UHFFFAOYSA-N 0.000 claims description 3
- YCHNYTDFQXUQFS-UHFFFAOYSA-N 2-[5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazin-3-yl]-5-fluorobenzonitrile Chemical compound N#CC1=CC(F)=CC=C1C1=CC(C=2C=C(C(F)=CC=2)C=2C(=CC(F)=CN=2)F)=CN=N1 YCHNYTDFQXUQFS-UHFFFAOYSA-N 0.000 claims description 3
- BZVKPALMNVYFOU-UHFFFAOYSA-N 2-[5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazin-3-yl]-1,3-thiazole Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2SC=CN=2)C=C1C1=NC=CC=C1F BZVKPALMNVYFOU-UHFFFAOYSA-N 0.000 claims description 3
- CPFHPKMRLHADOJ-UHFFFAOYSA-N 2-[5-[6-(2-chlorophenyl)pyridazin-4-yl]-2-fluorophenyl]-3-fluorobenzonitrile Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2C(=CC=CC=2)Cl)C=C1C1=C(F)C=CC=C1C#N CPFHPKMRLHADOJ-UHFFFAOYSA-N 0.000 claims description 3
- UDBURXSAAWUBAF-UHFFFAOYSA-N 2-[5-[6-(3-chlorophenyl)pyridazin-4-yl]-2-fluorophenyl]-3-fluorobenzonitrile Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2C=C(Cl)C=CC=2)C=C1C1=C(F)C=CC=C1C#N UDBURXSAAWUBAF-UHFFFAOYSA-N 0.000 claims description 3
- SLQGJFSVYKNYLY-UHFFFAOYSA-N 2-[5-[6-(4-chlorophenyl)pyridazin-4-yl]-2-fluorophenyl]-3-fluorobenzonitrile Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2C=CC(Cl)=CC=2)C=C1C1=C(F)C=CC=C1C#N SLQGJFSVYKNYLY-UHFFFAOYSA-N 0.000 claims description 3
- DPJCCKLIESXDBI-UHFFFAOYSA-N 2-fluoro-6-[2-fluoro-5-(6-phenylpyridazin-4-yl)phenyl]benzonitrile Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2C=CC=CC=2)C=C1C1=CC=CC(F)=C1C#N DPJCCKLIESXDBI-UHFFFAOYSA-N 0.000 claims description 3
- IPONVYKHUZMUQT-UHFFFAOYSA-N 3-(2,3-difluorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine Chemical compound FC1=CC=CC(C=2N=NC=C(C=2)C=2C=C(C(F)=CC=2)C=2C(=CC=CN=2)F)=C1F IPONVYKHUZMUQT-UHFFFAOYSA-N 0.000 claims description 3
- MMZOMTNDPGKUIA-UHFFFAOYSA-N 3-(2,4-difluorophenyl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine Chemical compound FC1=CC(F)=CC=C1C1=CC(C=2C=C(C(F)=CC=2)C=2C(=CC(F)=CN=2)F)=CN=N1 MMZOMTNDPGKUIA-UHFFFAOYSA-N 0.000 claims description 3
- LCDOZBPYZHDFGO-UHFFFAOYSA-N 3-(2,6-difluorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2C(=CC=CC=2F)F)C=C1C1=NC=CC=C1F LCDOZBPYZHDFGO-UHFFFAOYSA-N 0.000 claims description 3
- VOGNRMAJKYKKEC-UHFFFAOYSA-N 3-(3,4-difluorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine Chemical compound C1=C(F)C(F)=CC=C1C1=CC(C=2C=C(C(F)=CC=2)C=2C(=CC=CN=2)F)=CN=N1 VOGNRMAJKYKKEC-UHFFFAOYSA-N 0.000 claims description 3
- JENXLKVGJDGIQV-UHFFFAOYSA-N 3-(3,5-difluoropyridin-2-yl)-5-[4-fluoro-3-[2-(trifluoromethyl)phenyl]phenyl]pyridazine Chemical compound FC1=CC(F)=CN=C1C1=CC(C=2C=C(C(F)=CC=2)C=2C(=CC=CC=2)C(F)(F)F)=CN=N1 JENXLKVGJDGIQV-UHFFFAOYSA-N 0.000 claims description 3
- CVOASAXXOXOGQG-UHFFFAOYSA-N 3-(3,5-difluoropyridin-4-yl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2C(=CN=CC=2F)F)C=C1C1=NC=CC=C1F CVOASAXXOXOGQG-UHFFFAOYSA-N 0.000 claims description 3
- LHSAPPUBKKYDOJ-UHFFFAOYSA-N 3-(4-chlorophenyl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine Chemical compound FC1=CC(F)=CN=C1C1=CC(C=2C=C(N=NC=2)C=2C=CC(Cl)=CC=2)=CC=C1F LHSAPPUBKKYDOJ-UHFFFAOYSA-N 0.000 claims description 3
- BQJCMGYQYTXNQU-UHFFFAOYSA-N 3-(4-chlorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2C=CC(Cl)=CC=2)C=C1C1=NC=CC=C1F BQJCMGYQYTXNQU-UHFFFAOYSA-N 0.000 claims description 3
- IUMPOZMYYFRQNH-UHFFFAOYSA-N 3-ethylsulfanyl-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine Chemical compound N1=NC(SCC)=CC(C=2C=C(C(F)=CC=2)C=2C(=CC=CN=2)F)=C1 IUMPOZMYYFRQNH-UHFFFAOYSA-N 0.000 claims description 3
- BOEGIFDWHVQQFQ-UHFFFAOYSA-N 3-fluoro-2-[2-fluoro-5-(6-phenylpyridazin-4-yl)phenyl]benzonitrile Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2C=CC=CC=2)C=C1C1=C(F)C=CC=C1C#N BOEGIFDWHVQQFQ-UHFFFAOYSA-N 0.000 claims description 3
- UDUDIUDTMDWXEC-UHFFFAOYSA-N 3-fluoro-2-[2-fluoro-5-(6-pyridin-4-ylpyridazin-4-yl)phenyl]benzonitrile Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2C=CN=CC=2)C=C1C1=C(F)C=CC=C1C#N UDUDIUDTMDWXEC-UHFFFAOYSA-N 0.000 claims description 3
- ZSCLBSVLVALOFL-UHFFFAOYSA-N 3-fluoro-2-[2-fluoro-5-(6-thiophen-2-ylpyridazin-4-yl)phenyl]benzonitrile Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2SC=CC=2)C=C1C1=C(F)C=CC=C1C#N ZSCLBSVLVALOFL-UHFFFAOYSA-N 0.000 claims description 3
- ZYKWSISGYHTQHW-UHFFFAOYSA-N 3-fluoro-2-[2-fluoro-5-[6-(2-fluorophenyl)pyridazin-4-yl]phenyl]benzonitrile Chemical compound FC1=CC=CC=C1C1=CC(C=2C=C(C(F)=CC=2)C=2C(=CC=CC=2F)C#N)=CN=N1 ZYKWSISGYHTQHW-UHFFFAOYSA-N 0.000 claims description 3
- SRTABGWBSLDQKD-UHFFFAOYSA-N 3-fluoro-2-[2-fluoro-5-[6-(3-fluorophenyl)pyridazin-4-yl]phenyl]benzonitrile Chemical compound FC1=CC=CC(C=2N=NC=C(C=2)C=2C=C(C(F)=CC=2)C=2C(=CC=CC=2F)C#N)=C1 SRTABGWBSLDQKD-UHFFFAOYSA-N 0.000 claims description 3
- GZQWGMFTAIRXDB-UHFFFAOYSA-N 3-fluoro-2-[2-fluoro-5-[6-(4-methoxyphenyl)pyridazin-4-yl]phenyl]benzonitrile Chemical compound C1=CC(OC)=CC=C1C1=CC(C=2C=C(C(F)=CC=2)C=2C(=CC=CC=2F)C#N)=CN=N1 GZQWGMFTAIRXDB-UHFFFAOYSA-N 0.000 claims description 3
- NHKLWLOWZMQINX-UHFFFAOYSA-N 3-phenyl-5-(3-pyridin-3-ylphenyl)pyridazine Chemical compound C1=CC=CC=C1C1=CC(C=2C=C(C=CC=2)C=2C=NC=CC=2)=CN=N1 NHKLWLOWZMQINX-UHFFFAOYSA-N 0.000 claims description 3
- HFBNPUMOGKQWKC-UHFFFAOYSA-N 3-phenyl-5-[3-(pyridin-2-ylmethoxy)phenyl]pyridazine Chemical compound C=1C=CC=NC=1COC(C=1)=CC=CC=1C(C=1)=CN=NC=1C1=CC=CC=C1 HFBNPUMOGKQWKC-UHFFFAOYSA-N 0.000 claims description 3
- RNJJCVQOUYKEMW-UHFFFAOYSA-N 4-[5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazin-3-yl]benzonitrile Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2C=CC(=CC=2)C#N)C=C1C1=NC=CC=C1F RNJJCVQOUYKEMW-UHFFFAOYSA-N 0.000 claims description 3
- YONIXXLZGVKECL-UHFFFAOYSA-N 4-fluoro-2-[2-fluoro-5-(6-phenylpyridazin-4-yl)phenyl]benzonitrile Chemical compound FC1=CC=C(C#N)C(C=2C(=CC=C(C=2)C=2C=C(N=NC=2)C=2C=CC=CC=2)F)=C1 YONIXXLZGVKECL-UHFFFAOYSA-N 0.000 claims description 3
- RYBHZCJYBDPYBY-UHFFFAOYSA-N 5-(2,4-difluoro-3-pyridin-4-ylphenyl)-3-phenylpyridazine Chemical compound FC1=C(C=2C=CN=CC=2)C(F)=CC=C1C(C=1)=CN=NC=1C1=CC=CC=C1 RYBHZCJYBDPYBY-UHFFFAOYSA-N 0.000 claims description 3
- JXKBZQKHIQYQJN-UHFFFAOYSA-N 5-(2-fluoro-3-pyridin-3-ylphenyl)-3-phenylpyridazine Chemical compound FC1=C(C=2C=NC=CC=2)C=CC=C1C(C=1)=CN=NC=1C1=CC=CC=C1 JXKBZQKHIQYQJN-UHFFFAOYSA-N 0.000 claims description 3
- HIRVBDSPZJPUHI-UHFFFAOYSA-N 5-(2-fluoro-3-pyridin-4-ylphenyl)-3-phenylpyridazine Chemical compound FC1=C(C=2C=CN=CC=2)C=CC=C1C(C=1)=CN=NC=1C1=CC=CC=C1 HIRVBDSPZJPUHI-UHFFFAOYSA-N 0.000 claims description 3
- LCHOZFHSKKRXLI-UHFFFAOYSA-N 5-(4-fluoro-3-pyridin-4-ylphenyl)-3-phenylpyridazine Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2C=CC=CC=2)C=C1C1=CC=NC=C1 LCHOZFHSKKRXLI-UHFFFAOYSA-N 0.000 claims description 3
- NFSJWCBOVHYOKK-UHFFFAOYSA-N 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluorophenyl)-1-oxidopyridazin-1-ium Chemical compound N=1[N+]([O-])=CC(C=2C=C(C(F)=CC=2)C=2C(=CC(F)=CN=2)F)=CC=1C1=CC=CC=C1F NFSJWCBOVHYOKK-UHFFFAOYSA-N 0.000 claims description 3
- BCEWAHBYIZQWJY-UHFFFAOYSA-N 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-fluoropyridin-2-yl)pyridazine Chemical compound FC1=CC(F)=CN=C1C1=CC(C=2C=C(N=NC=2)C=2C(=CC=CN=2)F)=CC=C1F BCEWAHBYIZQWJY-UHFFFAOYSA-N 0.000 claims description 3
- LYPUFDPLDWHPMC-UHFFFAOYSA-N 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-methoxyphenyl)pyridazine Chemical compound COC1=CC=CC(C=2N=NC=C(C=2)C=2C=C(C(F)=CC=2)C=2C(=CC(F)=CN=2)F)=C1 LYPUFDPLDWHPMC-UHFFFAOYSA-N 0.000 claims description 3
- JFYGJOLVYDKFJM-UHFFFAOYSA-N 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(4-methoxyphenyl)pyridazine Chemical compound C1=CC(OC)=CC=C1C1=CC(C=2C=C(C(F)=CC=2)C=2C(=CC(F)=CN=2)F)=CN=N1 JFYGJOLVYDKFJM-UHFFFAOYSA-N 0.000 claims description 3
- OPFVAJVJSDSHCF-UHFFFAOYSA-N 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-phenylpyridazine Chemical compound FC1=CC(F)=CN=C1C1=CC(C=2C=C(N=NC=2)C=2C=CC=CC=2)=CC=C1F OPFVAJVJSDSHCF-UHFFFAOYSA-N 0.000 claims description 3
- PXCVVFWVLHUINV-UHFFFAOYSA-N 5-[3-[(2-methyl-1,2,4-triazol-3-yl)methoxy]phenyl]-3-phenylpyridazine Chemical compound CN1N=CN=C1COC1=CC=CC(C=2C=C(N=NC=2)C=2C=CC=CC=2)=C1 PXCVVFWVLHUINV-UHFFFAOYSA-N 0.000 claims description 3
- ZXLYLHOZFFPXRU-UHFFFAOYSA-N 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(2-fluoro-4-methoxyphenyl)pyridazine Chemical compound FC1=CC(OC)=CC=C1C1=CC(C=2C=C(C(F)=CC=2)C=2C(=CC=CN=2)F)=CN=N1 ZXLYLHOZFFPXRU-UHFFFAOYSA-N 0.000 claims description 3
- UJBOQYCZTOTBAN-UHFFFAOYSA-N 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(2-fluorophenyl)pyridazine Chemical compound FC1=CC=CC=C1C1=CC(C=2C=C(C(F)=CC=2)C=2C(=CC=CN=2)F)=CN=N1 UJBOQYCZTOTBAN-UHFFFAOYSA-N 0.000 claims description 3
- IMFAXTURBARICN-UHFFFAOYSA-N 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(2h-triazol-4-yl)pyridazine Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2N=NNC=2)C=C1C1=NC=CC=C1F IMFAXTURBARICN-UHFFFAOYSA-N 0.000 claims description 3
- IDMWBQJWKXQREC-UHFFFAOYSA-N 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoropyridin-4-yl)-1-oxidopyridazin-1-ium Chemical compound N=1[N+]([O-])=CC(C=2C=C(C(F)=CC=2)C=2C(=CC=CN=2)F)=CC=1C1=CC=NC=C1F IDMWBQJWKXQREC-UHFFFAOYSA-N 0.000 claims description 3
- DMGVKONFMWEGSK-UHFFFAOYSA-N 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(furan-2-yl)pyridazine Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2OC=CC=2)C=C1C1=NC=CC=C1F DMGVKONFMWEGSK-UHFFFAOYSA-N 0.000 claims description 3
- SFWRYKRMUCNNPR-UHFFFAOYSA-N 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(furan-3-yl)pyridazine Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C2=COC=C2)C=C1C1=NC=CC=C1F SFWRYKRMUCNNPR-UHFFFAOYSA-N 0.000 claims description 3
- UXOJOZLXHIVSMP-UHFFFAOYSA-N 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-phenylpyridazine Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2C=CC=CC=2)C=C1C1=NC=CC=C1F UXOJOZLXHIVSMP-UHFFFAOYSA-N 0.000 claims description 3
- QANSXBKBORASEX-UHFFFAOYSA-N 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-pyridin-2-ylpyridazine Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2N=CC=CC=2)C=C1C1=NC=CC=C1F QANSXBKBORASEX-UHFFFAOYSA-N 0.000 claims description 3
- DPBHIMSMDFWJFZ-UHFFFAOYSA-N 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-pyridin-3-ylpyridazine Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2C=NC=CC=2)C=C1C1=NC=CC=C1F DPBHIMSMDFWJFZ-UHFFFAOYSA-N 0.000 claims description 3
- SFTKTJBIXRHVRY-UHFFFAOYSA-N 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-pyridin-4-ylpyridazine Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2C=CN=CC=2)C=C1C1=NC=CC=C1F SFTKTJBIXRHVRY-UHFFFAOYSA-N 0.000 claims description 3
- KGAPRGAOYSYAFS-UHFFFAOYSA-N 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-thiophen-2-ylpyridazine Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2SC=CC=2)C=C1C1=NC=CC=C1F KGAPRGAOYSYAFS-UHFFFAOYSA-N 0.000 claims description 3
- AYAWNVZWANMPNH-UHFFFAOYSA-N 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-thiophen-3-ylpyridazine Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C2=CSC=C2)C=C1C1=NC=CC=C1F AYAWNVZWANMPNH-UHFFFAOYSA-N 0.000 claims description 3
- BIYPBWFDLVWBRH-UHFFFAOYSA-N 5-[4-fluoro-3-(3-fluoropyridin-4-yl)phenyl]-3-phenylpyridazine Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2C=CC=CC=2)C=C1C1=CC=NC=C1F BIYPBWFDLVWBRH-UHFFFAOYSA-N 0.000 claims description 3
- SZXYBFOJMJMSLF-UHFFFAOYSA-N 5-[4-fluoro-3-(pyridin-3-ylmethoxy)phenyl]-3-phenylpyridazine Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2C=CC=CC=2)C=C1OCC1=CC=CN=C1 SZXYBFOJMJMSLF-UHFFFAOYSA-N 0.000 claims description 3
- KPINTNPNXCOWCW-UHFFFAOYSA-N 5-[4-fluoro-3-(pyridin-4-ylmethoxy)phenyl]-3-phenylpyridazine Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2C=CC=CC=2)C=C1OCC1=CC=NC=C1 KPINTNPNXCOWCW-UHFFFAOYSA-N 0.000 claims description 3
- HLCWTCPPVRLHOL-UHFFFAOYSA-N 5-[4-fluoro-3-[(2-methyl-1,2,4-triazol-3-yl)methoxy]phenyl]-3-phenylpyridazine Chemical compound CN1N=CN=C1COC1=CC(C=2C=C(N=NC=2)C=2C=CC=CC=2)=CC=C1F HLCWTCPPVRLHOL-UHFFFAOYSA-N 0.000 claims description 3
- LPIMOTPVVOJVNO-UHFFFAOYSA-N 5-[4-fluoro-3-[[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]methoxy]phenyl]-3-phenylpyridazine Chemical compound FC(F)(F)C1=NN(C)C=C1COC1=CC(C=2C=C(N=NC=2)C=2C=CC=CC=2)=CC=C1F LPIMOTPVVOJVNO-UHFFFAOYSA-N 0.000 claims description 3
- JCUSQNIWPUXCTC-UHFFFAOYSA-N 5-fluoro-2-[2-fluoro-5-(6-phenylpyridazin-4-yl)phenyl]benzonitrile Chemical compound N#CC1=CC(F)=CC=C1C1=CC(C=2C=C(N=NC=2)C=2C=CC=CC=2)=CC=C1F JCUSQNIWPUXCTC-UHFFFAOYSA-N 0.000 claims description 3
- DMNYENLJENVWHB-UHFFFAOYSA-N 5-fluoro-2-[3-(6-methoxypyridazin-4-yl)phenyl]benzonitrile Chemical compound N1=NC(OC)=CC(C=2C=C(C=CC=2)C=2C(=CC(F)=CC=2)C#N)=C1 DMNYENLJENVWHB-UHFFFAOYSA-N 0.000 claims description 3
- CHYYMCPIPRLFMQ-UHFFFAOYSA-N 5-fluoro-2-[3-(6-phenylmethoxypyridazin-4-yl)phenyl]benzonitrile Chemical compound N#CC1=CC(F)=CC=C1C1=CC=CC(C=2C=C(OCC=3C=CC=CC=3)N=NC=2)=C1 CHYYMCPIPRLFMQ-UHFFFAOYSA-N 0.000 claims description 3
- UYMMFBXQYWPOEL-UHFFFAOYSA-N 5-fluoro-2-[3-(6-phenylpyridazin-4-yl)phenyl]benzonitrile Chemical compound N#CC1=CC(F)=CC=C1C1=CC=CC(C=2C=C(N=NC=2)C=2C=CC=CC=2)=C1 UYMMFBXQYWPOEL-UHFFFAOYSA-N 0.000 claims description 3
- YPQPEJDERHIIMR-UHFFFAOYSA-N 5-fluoro-2-[3-[6-(4-methoxyphenyl)pyridazin-4-yl]phenyl]benzonitrile Chemical compound C1=CC(OC)=CC=C1C1=CC(C=2C=C(C=CC=2)C=2C(=CC(F)=CC=2)C#N)=CN=N1 YPQPEJDERHIIMR-UHFFFAOYSA-N 0.000 claims description 3
- PHOFKOQFUJIFLY-UHFFFAOYSA-N 5-fluoro-2-[3-[6-(methylamino)pyridazin-4-yl]phenyl]benzonitrile Chemical compound N1=NC(NC)=CC(C=2C=C(C=CC=2)C=2C(=CC(F)=CC=2)C#N)=C1 PHOFKOQFUJIFLY-UHFFFAOYSA-N 0.000 claims description 3
- CZXGYPYHZCFCSK-UHFFFAOYSA-N 5-fluoro-2-[3-[6-(propan-2-ylamino)pyridazin-4-yl]phenyl]benzonitrile Chemical compound N1=NC(NC(C)C)=CC(C=2C=C(C=CC=2)C=2C(=CC(F)=CC=2)C#N)=C1 CZXGYPYHZCFCSK-UHFFFAOYSA-N 0.000 claims description 3
- QLYUZAYKGCHSTL-UHFFFAOYSA-N 5-fluoro-2-[3-[6-(propylamino)pyridazin-4-yl]phenyl]benzonitrile Chemical compound N1=NC(NCCC)=CC(C=2C=C(C=CC=2)C=2C(=CC(F)=CC=2)C#N)=C1 QLYUZAYKGCHSTL-UHFFFAOYSA-N 0.000 claims description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004987 dibenzofuryl group Chemical group C1(=CC=CC=2OC3=C(C21)C=CC=C3)* 0.000 claims description 3
- CQLXCXJUCLOOFI-UHFFFAOYSA-N ethyl 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine-3-carboxylate Chemical compound N1=NC(C(=O)OCC)=CC(C=2C=C(C(F)=CC=2)C=2C(=CC=CN=2)F)=C1 CQLXCXJUCLOOFI-UHFFFAOYSA-N 0.000 claims description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 3
- 125000001041 indolyl group Chemical group 0.000 claims description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 3
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 3
- 125000002971 oxazolyl group Chemical group 0.000 claims description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 3
- 238000010561 standard procedure Methods 0.000 claims description 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 3
- 229910052720 vanadium Inorganic materials 0.000 claims description 3
- CHUIKVYJLOPWHP-UHFFFAOYSA-N 2-[3-[6-(cyclopropylamino)pyridazin-4-yl]phenyl]-5-fluorobenzonitrile Chemical compound N#CC1=CC(F)=CC=C1C1=CC=CC(C=2C=C(NC3CC3)N=NC=2)=C1 CHUIKVYJLOPWHP-UHFFFAOYSA-N 0.000 claims description 2
- YCKPYYSQBBNZQM-UHFFFAOYSA-N 3-(2,5-difluorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine Chemical compound FC1=CC=C(F)C(C=2N=NC=C(C=2)C=2C=C(C(F)=CC=2)C=2C(=CC=CN=2)F)=C1 YCKPYYSQBBNZQM-UHFFFAOYSA-N 0.000 claims description 2
- LKSLCTCRDPGUSW-UHFFFAOYSA-N 3-fluoro-2-[2-fluoro-5-(6-pyridin-3-ylpyridazin-4-yl)phenyl]benzonitrile Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2C=NC=CC=2)C=C1C1=C(F)C=CC=C1C#N LKSLCTCRDPGUSW-UHFFFAOYSA-N 0.000 claims description 2
- UYYQEPKTHKJVQZ-UHFFFAOYSA-N 3-fluoro-2-[2-fluoro-5-[6-(4-fluorophenyl)pyridazin-4-yl]phenyl]benzonitrile Chemical compound C1=CC(F)=CC=C1C1=CC(C=2C=C(C(F)=CC=2)C=2C(=CC=CC=2F)C#N)=CN=N1 UYYQEPKTHKJVQZ-UHFFFAOYSA-N 0.000 claims description 2
- ALSMBMGEQNFGHV-UHFFFAOYSA-N 3-phenyl-5-[3-(1,2,4-triazol-4-yl)phenyl]pyridazine Chemical compound C1=NN=CN1C1=CC=CC(C=2C=C(N=NC=2)C=2C=CC=CC=2)=C1 ALSMBMGEQNFGHV-UHFFFAOYSA-N 0.000 claims description 2
- MLVQTOYCPCJFIN-UHFFFAOYSA-N 5-(4-fluoro-3-pyridin-3-ylphenyl)-3-phenylpyridazine Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2C=CC=CC=2)C=C1C1=CC=CN=C1 MLVQTOYCPCJFIN-UHFFFAOYSA-N 0.000 claims description 2
- CHPSHRSRWMBQAW-UHFFFAOYSA-N 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluoro-4-methoxyphenyl)pyridazine Chemical compound FC1=CC(OC)=CC=C1C1=CC(C=2C=C(C(F)=CC=2)C=2C(=CC(F)=CN=2)F)=CN=N1 CHPSHRSRWMBQAW-UHFFFAOYSA-N 0.000 claims description 2
- BEUFUKHUURWENE-UHFFFAOYSA-N 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(4-fluorophenyl)pyridazine Chemical compound C1=CC(F)=CC=C1C1=CC(C=2C=C(C(F)=CC=2)C=2C(=CC(F)=CN=2)F)=CN=N1 BEUFUKHUURWENE-UHFFFAOYSA-N 0.000 claims description 2
- XPLJAWBHDNQXGF-UHFFFAOYSA-N 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-pyrazin-2-ylpyridazine Chemical compound FC1=CC=C(C=2C=C(N=NC=2)C=2N=CC=NC=2)C=C1C1=NC=CC=C1F XPLJAWBHDNQXGF-UHFFFAOYSA-N 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 150000002009 diols Chemical class 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 2
- 229910002092 carbon dioxide Inorganic materials 0.000 claims 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000005604 azodicarboxylate group Chemical group 0.000 claims 1
- 239000001569 carbon dioxide Substances 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 claims 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract description 11
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract description 6
- 208000019901 Anxiety disease Diseases 0.000 abstract description 5
- 206010010904 Convulsion Diseases 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 4
- 230000036506 anxiety Effects 0.000 abstract description 3
- 210000003169 central nervous system Anatomy 0.000 abstract description 3
- 208000010877 cognitive disease Diseases 0.000 abstract description 3
- 230000036461 convulsion Effects 0.000 abstract description 3
- VYPDRJDYVPYUJY-UHFFFAOYSA-N 4-phenylpyridazine Chemical class C1=CC=CC=C1C1=CC=NN=C1 VYPDRJDYVPYUJY-UHFFFAOYSA-N 0.000 abstract description 2
- 230000002411 adverse Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 135
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 112
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 89
- 239000007787 solid Substances 0.000 description 67
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 57
- 239000000203 mixture Substances 0.000 description 56
- 238000006243 chemical reaction Methods 0.000 description 44
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 43
- 239000000243 solution Substances 0.000 description 40
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 38
- 108020003175 receptors Proteins 0.000 description 38
- 102000005962 receptors Human genes 0.000 description 36
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 33
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 28
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- 239000002904 solvent Substances 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 22
- 239000000377 silicon dioxide Substances 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 19
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 230000027455 binding Effects 0.000 description 17
- 239000003480 eluent Substances 0.000 description 17
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 17
- 229910000029 sodium carbonate Inorganic materials 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 13
- 238000003818 flash chromatography Methods 0.000 description 13
- 235000019341 magnesium sulphate Nutrition 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- 239000000543 intermediate Substances 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- JTOSYJZWTBKFTP-UHFFFAOYSA-N 3-chloro-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine Chemical compound FC1=CC(F)=CN=C1C1=CC(C=2C=C(Cl)N=NC=2)=CC=C1F JTOSYJZWTBKFTP-UHFFFAOYSA-N 0.000 description 10
- KGCXTQNJQNITRE-UHFFFAOYSA-N 3-chloro-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine Chemical compound FC1=CC=C(C=2C=C(Cl)N=NC=2)C=C1C1=NC=CC=C1F KGCXTQNJQNITRE-UHFFFAOYSA-N 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 125000001207 fluorophenyl group Chemical group 0.000 description 10
- NHMLZGFOEYLZEN-UHFFFAOYSA-N 4-chloro-1h-pyridazin-6-one Chemical compound ClC=1C=NNC(=O)C=1 NHMLZGFOEYLZEN-UHFFFAOYSA-N 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229940049706 benzodiazepine Drugs 0.000 description 9
- 125000001309 chloro group Chemical group Cl* 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 125000004212 difluorophenyl group Chemical group 0.000 description 8
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 7
- 239000000556 agonist Substances 0.000 description 7
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 7
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 7
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 7
- 239000004810 polytetrafluoroethylene Substances 0.000 description 7
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 7
- 238000001953 recrystallisation Methods 0.000 description 7
- NDOVWYNGPIOJMH-UHFFFAOYSA-N (3,5-difluoropyridin-4-yl)-trimethylstannane Chemical compound C[Sn](C)(C)C1=C(F)C=NC=C1F NDOVWYNGPIOJMH-UHFFFAOYSA-N 0.000 description 6
- 125000006325 2-propenyl amino group Chemical group [H]C([H])=C([H])C([H])([H])N([H])* 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 206010012289 Dementia Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- BXURMSJYELYDQG-UHFFFAOYSA-M [Cl-].C[Si](C)(C)C1=C(F)C=NC([Zn+])=C1F Chemical compound [Cl-].C[Si](C)(C)C1=C(F)C=NC([Zn+])=C1F BXURMSJYELYDQG-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000005336 allyloxy group Chemical group 0.000 description 6
- 230000000949 anxiolytic effect Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000012131 assay buffer Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 6
- 125000000068 chlorophenyl group Chemical group 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- 150000004892 pyridazines Chemical class 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 6
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 5
- TXQNXVJFKWCXRV-UHFFFAOYSA-N 2-[5-(6-chloropyridazin-4-yl)-2-fluorophenyl]benzonitrile Chemical compound FC1=CC=C(C=2C=C(Cl)N=NC=2)C=C1C1=CC=CC=C1C#N TXQNXVJFKWCXRV-UHFFFAOYSA-N 0.000 description 5
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 5
- 230000000712 assembly Effects 0.000 description 5
- 238000000429 assembly Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 5
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 125000004043 oxo group Chemical group O=* 0.000 description 5
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 0 **(/C=C(\*)/C/C(/N)=C1)/C=C1\C1=C**C(I)=C1* Chemical compound **(/C=C(\*)/C/C(/N)=C1)/C=C1\C1=C**C(I)=C1* 0.000 description 4
- OMLBIRXLEQTFLT-UHFFFAOYSA-N 5-(3-bromo-4-fluorophenyl)-3-(3,5-difluoropyridin-2-yl)pyridazine Chemical compound FC1=CC(F)=CN=C1C1=CC(C=2C=C(Br)C(F)=CC=2)=CN=N1 OMLBIRXLEQTFLT-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000002249 anxiolytic agent Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229960004381 flumazenil Drugs 0.000 description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 238000012746 preparative thin layer chromatography Methods 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 4
- 125000004360 trifluorophenyl group Chemical group 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- MDNDJMCSXOXBFZ-UHFFFAOYSA-N 2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane Chemical compound O1CC(C)(C)COB1B1OCC(C)(C)CO1 MDNDJMCSXOXBFZ-UHFFFAOYSA-N 0.000 description 3
- HUFDWWINCFZPFK-UHFFFAOYSA-N 2-[5-(6-chloropyridazin-4-yl)-2-fluorophenyl]-5-fluorobenzonitrile Chemical compound N#CC1=CC(F)=CC=C1C1=CC(C=2C=C(Cl)N=NC=2)=CC=C1F HUFDWWINCFZPFK-UHFFFAOYSA-N 0.000 description 3
- PTELDYUBMOOURQ-UHFFFAOYSA-N 2-[5-(6-chloropyridazin-4-yl)-2-fluorophenyl]pyridine-3-carbonitrile Chemical compound FC1=CC=C(C=2C=C(Cl)N=NC=2)C=C1C1=NC=CC=C1C#N PTELDYUBMOOURQ-UHFFFAOYSA-N 0.000 description 3
- PAYLLTXDCVQGLW-UHFFFAOYSA-N 2-bromo-3,5-difluoropyridine Chemical compound FC1=CN=C(Br)C(F)=C1 PAYLLTXDCVQGLW-UHFFFAOYSA-N 0.000 description 3
- XSEMCNNTINIOJP-UHFFFAOYSA-N 2-fluoro-5-(6-phenylpyridazin-4-yl)phenol Chemical compound C1=C(F)C(O)=CC(C=2C=C(N=NC=2)C=2C=CC=CC=2)=C1 XSEMCNNTINIOJP-UHFFFAOYSA-N 0.000 description 3
- OBRWKTBQEPBGIM-UHFFFAOYSA-N 3-fluoro-2-[2-fluoro-5-(6-oxo-1h-pyridazin-4-yl)phenyl]benzonitrile Chemical compound FC1=CC=C(C2=CC(=O)NN=C2)C=C1C1=C(F)C=CC=C1C#N OBRWKTBQEPBGIM-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- PTRDPZMWROYHNC-UHFFFAOYSA-N CCCCP(C1=CC=CC=C1)(C1=CC=CC=C1)=O.CCCCP(C1=CC=CC=C1)(C1=CC=CC=C1)=O.Cl.Cl Chemical compound CCCCP(C1=CC=CC=C1)(C1=CC=CC=C1)=O.CCCCP(C1=CC=CC=C1)(C1=CC=CC=C1)=O.Cl.Cl PTRDPZMWROYHNC-UHFFFAOYSA-N 0.000 description 3
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 3
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 206010039897 Sedation Diseases 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000019771 cognition Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- LETVJWLLIMJADE-UHFFFAOYSA-N pyridazin-3-amine Chemical class NC1=CC=CN=N1 LETVJWLLIMJADE-UHFFFAOYSA-N 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 3
- 239000002287 radioligand Substances 0.000 description 3
- 239000000018 receptor agonist Substances 0.000 description 3
- 229940044601 receptor agonist Drugs 0.000 description 3
- 230000036280 sedation Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- BXSXKTMFWRWBDG-UHFFFAOYSA-N (3,5-difluoro-1-oxidopyridin-1-ium-4-yl)-trimethylstannane Chemical compound C[Sn](C)(C)C1=C(F)C=[N+]([O-])C=C1F BXSXKTMFWRWBDG-UHFFFAOYSA-N 0.000 description 2
- VBIRRLMVQSHXAZ-UHFFFAOYSA-N 2-(2,6-difluorophenyl)-3,5-difluoropyridine Chemical compound FC1=CC(F)=CN=C1C1=C(F)C=CC=C1F VBIRRLMVQSHXAZ-UHFFFAOYSA-N 0.000 description 2
- SWVTWTQLKDLBJJ-UHFFFAOYSA-N 2-(3-bromo-2,6-difluorophenyl)-3,5-difluoropyridine Chemical compound FC1=CC(F)=CN=C1C1=C(F)C=CC(Br)=C1F SWVTWTQLKDLBJJ-UHFFFAOYSA-N 0.000 description 2
- PTEXGUJQQVHVSG-UHFFFAOYSA-N 2-[2-fluoro-5-(6-oxo-1h-pyridazin-4-yl)phenyl]benzonitrile Chemical compound FC1=CC=C(C2=CC(=O)NN=C2)C=C1C1=CC=CC=C1C#N PTEXGUJQQVHVSG-UHFFFAOYSA-N 0.000 description 2
- ACRJHHKBOQMQOZ-UHFFFAOYSA-N 2-[2-fluoro-5-(6-oxo-1h-pyridazin-4-yl)phenyl]pyridine-3-carbonitrile Chemical compound FC1=CC=C(C2=CC(=O)NN=C2)C=C1C1=NC=CC=C1C#N ACRJHHKBOQMQOZ-UHFFFAOYSA-N 0.000 description 2
- JELQRJKOVALBBR-UHFFFAOYSA-N 2-[3-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-2,6-difluorophenyl]-3,5-difluoropyridine Chemical compound O1CC(C)(C)COB1C1=CC=C(F)C(C=2C(=CC(F)=CN=2)F)=C1F JELQRJKOVALBBR-UHFFFAOYSA-N 0.000 description 2
- HBWFLLUNSKVHLV-UHFFFAOYSA-N 2-[5-(6-chloropyridazin-4-yl)-2-fluorophenyl]-3-fluorobenzonitrile Chemical compound FC1=CC=C(C=2C=C(Cl)N=NC=2)C=C1C1=C(F)C=CC=C1C#N HBWFLLUNSKVHLV-UHFFFAOYSA-N 0.000 description 2
- DUWNBOHKTIJJRA-UHFFFAOYSA-N 2-[5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazin-3-yl]ethynyl-trimethylsilane Chemical compound N1=NC(C#C[Si](C)(C)C)=CC(C=2C=C(C(F)=CC=2)C=2C(=CC=CN=2)F)=C1 DUWNBOHKTIJJRA-UHFFFAOYSA-N 0.000 description 2
- PZBSPSOGEVCRQI-UHFFFAOYSA-N 2-bromo-1,3,5-trifluorobenzene Chemical compound FC1=CC(F)=C(Br)C(F)=C1 PZBSPSOGEVCRQI-UHFFFAOYSA-N 0.000 description 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 2
- WLPATYNQCGVFFH-UHFFFAOYSA-N 2-phenylbenzonitrile Chemical compound N#CC1=CC=CC=C1C1=CC=CC=C1 WLPATYNQCGVFFH-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- HDVMJDMXPULAOD-UHFFFAOYSA-N 3-chloro-5-(4-fluorophenyl)pyridazine Chemical compound C1=CC(F)=CC=C1C1=CN=NC(Cl)=C1 HDVMJDMXPULAOD-UHFFFAOYSA-N 0.000 description 2
- GEPUOZNLVARXOY-UHFFFAOYSA-N 3-chloro-5-[4-fluoro-3-(trifluoromethyl)phenyl]pyridazine Chemical compound C1=C(C(F)(F)F)C(F)=CC=C1C1=CN=NC(Cl)=C1 GEPUOZNLVARXOY-UHFFFAOYSA-N 0.000 description 2
- JVUKCNGSJOCNQM-UHFFFAOYSA-N 4-(4-fluorophenyl)-1h-pyridazin-6-one Chemical compound C1=CC(F)=CC=C1C1=CC(=O)NN=C1 JVUKCNGSJOCNQM-UHFFFAOYSA-N 0.000 description 2
- FHGNUMOPLZZUAJ-UHFFFAOYSA-N 4-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-1h-pyridazin-6-one Chemical compound FC1=CC(F)=CN=C1C1=CC(C2=CC(=O)NN=C2)=CC=C1F FHGNUMOPLZZUAJ-UHFFFAOYSA-N 0.000 description 2
- XVWBWEGXGBWEBF-UHFFFAOYSA-N 4-[4-fluoro-3-(trifluoromethyl)phenyl]-1h-pyridazin-6-one Chemical compound C1=C(C(F)(F)F)C(F)=CC=C1C1=CC(=O)NN=C1 XVWBWEGXGBWEBF-UHFFFAOYSA-N 0.000 description 2
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 2
- XEVBELVRPZQLCB-UHFFFAOYSA-N 5-chloro-3-(3,5-difluoropyridin-4-yl)pyridazine Chemical compound FC1=CN=CC(F)=C1C1=CC(Cl)=CN=N1 XEVBELVRPZQLCB-UHFFFAOYSA-N 0.000 description 2
- CUYOSDSCDNFPEF-UHFFFAOYSA-N 5-fluoro-2-[2-fluoro-5-(6-oxo-1h-pyridazin-4-yl)phenyl]benzonitrile Chemical compound N#CC1=CC(F)=CC=C1C1=CC(C2=CC(=O)NN=C2)=CC=C1F CUYOSDSCDNFPEF-UHFFFAOYSA-N 0.000 description 2
- IHKQCLSGLAYHIS-UHFFFAOYSA-N 6-(3,5-difluoropyridin-4-yl)-1h-pyridazin-4-one Chemical compound FC1=CN=CC(F)=C1C1=CC(=O)C=NN1 IHKQCLSGLAYHIS-UHFFFAOYSA-N 0.000 description 2
- 208000008811 Agoraphobia Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 206010012218 Delirium Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102000004300 GABA-A Receptors Human genes 0.000 description 2
- 108090000839 GABA-A Receptors Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- USVZFSNDGFNNJT-UHFFFAOYSA-N cyclopenta-1,4-dien-1-yl(diphenyl)phosphane (2,3-dichlorocyclopenta-1,4-dien-1-yl)-diphenylphosphane iron(2+) Chemical compound [Fe++].c1cc[c-](c1)P(c1ccccc1)c1ccccc1.Clc1c(cc[c-]1Cl)P(c1ccccc1)c1ccccc1 USVZFSNDGFNNJT-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- VRLDVERQJMEPIF-UHFFFAOYSA-N dbdmh Chemical compound CC1(C)N(Br)C(=O)N(Br)C1=O VRLDVERQJMEPIF-UHFFFAOYSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000001839 endoscopy Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229960002200 flunitrazepam Drugs 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005567 liquid scintillation counting Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 2
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- KXCAEQNNTZANTK-UHFFFAOYSA-N stannane Chemical compound [SnH4] KXCAEQNNTZANTK-UHFFFAOYSA-N 0.000 description 2
- 229910000080 stannane Inorganic materials 0.000 description 2
- 201000009032 substance abuse Diseases 0.000 description 2
- 231100000736 substance abuse Toxicity 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- UXVPRACGTKNFAB-UHFFFAOYSA-N tributyl-(3-fluoro-1-oxidopyridin-1-ium-4-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=[N+]([O-])C=C1F UXVPRACGTKNFAB-UHFFFAOYSA-N 0.000 description 2
- NXAOTUZKJHXTSD-UHFFFAOYSA-N tributyl-(3-fluoropyridin-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=NC=CC=C1F NXAOTUZKJHXTSD-UHFFFAOYSA-N 0.000 description 2
- KKOFZNIMGWDVQS-UHFFFAOYSA-N tributyl-(3-fluoropyridin-4-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=NC=C1F KKOFZNIMGWDVQS-UHFFFAOYSA-N 0.000 description 2
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 2
- CCRMAATUKBYMPA-UHFFFAOYSA-N trimethyltin Chemical compound C[Sn](C)C.C[Sn](C)C CCRMAATUKBYMPA-UHFFFAOYSA-N 0.000 description 2
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- QQLRSCZSKQTFGY-UHFFFAOYSA-N (2,4-difluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C=C1F QQLRSCZSKQTFGY-UHFFFAOYSA-N 0.000 description 1
- DBZAICSEFBVFHL-UHFFFAOYSA-N (2,6-difluorophenyl)boronic acid Chemical compound OB(O)C1=C(F)C=CC=C1F DBZAICSEFBVFHL-UHFFFAOYSA-N 0.000 description 1
- NCDVVQSPNXSWHF-UHFFFAOYSA-N (2-fluoro-3-pyridin-3-ylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C=2C=NC=CC=2)=C1F NCDVVQSPNXSWHF-UHFFFAOYSA-N 0.000 description 1
- QCSLIRFWJPOENV-UHFFFAOYSA-N (2-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1F QCSLIRFWJPOENV-UHFFFAOYSA-N 0.000 description 1
- QUAQZVSGXQVIEP-UHFFFAOYSA-N (2-methyl-1,2,4-triazol-3-yl)methanol Chemical compound CN1N=CN=C1CO QUAQZVSGXQVIEP-UHFFFAOYSA-N 0.000 description 1
- CMIBUZBMZCBCAT-HZPDHXFCSA-N (2r,3r)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1 CMIBUZBMZCBCAT-HZPDHXFCSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- SUTAHDHLNHTVQT-UHFFFAOYSA-N (3,5-difluoropyridin-2-yl)-trimethylstannane Chemical compound C[Sn](C)(C)C1=NC=C(F)C=C1F SUTAHDHLNHTVQT-UHFFFAOYSA-N 0.000 description 1
- AXNHACKEUUNOMC-UHFFFAOYSA-N (3,5-difluoropyridin-4-yl)-trimethylsilane Chemical compound C[Si](C)(C)C1=C(F)C=NC=C1F AXNHACKEUUNOMC-UHFFFAOYSA-N 0.000 description 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- BKWQKVJYXODDAC-UHFFFAOYSA-N 1,2-dihydropyridazine Chemical class N1NC=CC=C1 BKWQKVJYXODDAC-UHFFFAOYSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- XCTQZIUCYJVRLJ-UHFFFAOYSA-N 1-bromo-2-fluoro-4-(trifluoromethyl)benzene Chemical compound FC1=CC(C(F)(F)F)=CC=C1Br XCTQZIUCYJVRLJ-UHFFFAOYSA-N 0.000 description 1
- SLFNGVGRINFJLK-UHFFFAOYSA-N 1-bromo-2-fluoro-4-methylbenzene Chemical compound CC1=CC=C(Br)C(F)=C1 SLFNGVGRINFJLK-UHFFFAOYSA-N 0.000 description 1
- FPNVMCMDWZNTEU-UHFFFAOYSA-N 1-bromo-4-chloro-2-fluorobenzene Chemical compound FC1=CC(Cl)=CC=C1Br FPNVMCMDWZNTEU-UHFFFAOYSA-N 0.000 description 1
- JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical class NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 1
- MUOAXGAXXXKHEK-UHFFFAOYSA-N 2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5-fluorobenzonitrile Chemical compound O1CC(C)(C)COB1C1=CC=C(F)C=C1C#N MUOAXGAXXXKHEK-UHFFFAOYSA-N 0.000 description 1
- PELFSPIQQQEARZ-UHFFFAOYSA-N 2-[2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]benzonitrile Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(F)C(C=2C(=CC=CC=2)C#N)=C1 PELFSPIQQQEARZ-UHFFFAOYSA-N 0.000 description 1
- FVXBRXDDWFYSOL-UHFFFAOYSA-N 2-[2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyridine-3-carbonitrile Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(F)C(C=2C(=CC=CN=2)C#N)=C1 FVXBRXDDWFYSOL-UHFFFAOYSA-N 0.000 description 1
- AXAFEQSUJBNBJX-UHFFFAOYSA-N 2-[3-(3-amino-6-cyclopropylpyridazin-4-yl)phenyl]-5-fluorobenzonitrile Chemical compound NC1=NN=C(C2CC2)C=C1C(C=1)=CC=CC=1C1=CC=C(F)C=C1C#N AXAFEQSUJBNBJX-UHFFFAOYSA-N 0.000 description 1
- PJZYJEYWGXBLNE-UHFFFAOYSA-N 2-[3-(6-chloropyridazin-4-yl)phenyl]-5-fluorobenzonitrile Chemical compound N#CC1=CC(F)=CC=C1C1=CC=CC(C=2C=C(Cl)N=NC=2)=C1 PJZYJEYWGXBLNE-UHFFFAOYSA-N 0.000 description 1
- JGMQFPUMJCFTAR-UHFFFAOYSA-N 2-[4-fluoro-3-(trifluoromethyl)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(F)C(C(F)(F)F)=C1 JGMQFPUMJCFTAR-UHFFFAOYSA-N 0.000 description 1
- HCFAZFACSDEUEL-UHFFFAOYSA-N 2-[5-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-2-fluorophenyl]-3-fluorobenzonitrile Chemical compound O1CC(C)(C)COB1C1=CC=C(F)C(C=2C(=CC=CC=2F)C#N)=C1 HCFAZFACSDEUEL-UHFFFAOYSA-N 0.000 description 1
- HRZTZLCMURHWFY-UHFFFAOYSA-N 2-bromo-1,3-difluorobenzene Chemical compound FC1=CC=CC(F)=C1Br HRZTZLCMURHWFY-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- RTNPJCQBMCRDSE-UHFFFAOYSA-N 3,5-diphenylpyridazine Chemical compound C1=CC=CC=C1C1=CN=NC(C=2C=CC=CC=2)=C1 RTNPJCQBMCRDSE-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- HXEKHJUROQOFTJ-UHFFFAOYSA-N 3-(3,5-difluoropyridin-2-yl)-5-(4-fluorophenyl)pyridazine Chemical compound C1=CC(F)=CC=C1C1=CN=NC(C=2C(=CC(F)=CN=2)F)=C1 HXEKHJUROQOFTJ-UHFFFAOYSA-N 0.000 description 1
- AGDUEEBXVICAII-UHFFFAOYSA-N 3-(3,5-difluoropyridin-4-yl)-5-methoxypyridazine Chemical compound COC1=CN=NC(C=2C(=CN=CC=2F)F)=C1 AGDUEEBXVICAII-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- XLGRINRFBNCHQS-UHFFFAOYSA-N 3-chloro-5-methoxypyridazine Chemical compound COC1=CN=NC(Cl)=C1 XLGRINRFBNCHQS-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 239000003140 4 aminobutyric acid A receptor blocking agent Substances 0.000 description 1
- WZBXFVXMBWZDDU-UHFFFAOYSA-N 4-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-1h-pyridazin-6-one Chemical compound FC1=CC=C(C2=CC(=O)NN=C2)C=C1C1=NC=CC=C1F WZBXFVXMBWZDDU-UHFFFAOYSA-N 0.000 description 1
- LTHVSWHJTLMNJS-UHFFFAOYSA-N 4-phenyl-4,5-dihydro-1h-pyridazin-6-one Chemical class C1=NNC(=O)CC1C1=CC=CC=C1 LTHVSWHJTLMNJS-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- UOYBEURVYWDNBS-UHFFFAOYSA-N 5-(3-bromophenyl)-n-ethylpyridazin-3-amine Chemical compound N1=NC(NCC)=CC(C=2C=C(Br)C=CC=2)=C1 UOYBEURVYWDNBS-UHFFFAOYSA-N 0.000 description 1
- NAQMDFMSYZEUEQ-UHFFFAOYSA-N 5-(4-fluoro-3-methoxyphenyl)-3-phenylpyridazine Chemical compound C1=C(F)C(OC)=CC(C=2C=C(N=NC=2)C=2C=CC=CC=2)=C1 NAQMDFMSYZEUEQ-UHFFFAOYSA-N 0.000 description 1
- QDEMDWDTLRXSIM-UHFFFAOYSA-N 5-(4-fluoro-3-pyridin-3-ylphenyl)-3-phenylpyridazine;pyridazine Chemical compound C1=CC=NN=C1.FC1=CC=C(C=2C=C(N=NC=2)C=2C=CC=CC=2)C=C1C1=CC=CN=C1 QDEMDWDTLRXSIM-UHFFFAOYSA-N 0.000 description 1
- HQPVRZJFXARGML-UHFFFAOYSA-N 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-fluorophenyl)pyridazine Chemical compound FC1=CC=CC(C=2N=NC=C(C=2)C=2C=C(C(F)=CC=2)C=2C(=CC(F)=CN=2)F)=C1 HQPVRZJFXARGML-UHFFFAOYSA-N 0.000 description 1
- PEYURMPXMJCPFZ-UHFFFAOYSA-N 5-fluoro-2-[2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]benzonitrile Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(F)C(C=2C(=CC(F)=CC=2)C#N)=C1 PEYURMPXMJCPFZ-UHFFFAOYSA-N 0.000 description 1
- DLZUGLNGVPJQJI-UHFFFAOYSA-N 5-fluoro-2-[3-(6-oxo-1h-pyridazin-4-yl)phenyl]benzonitrile Chemical compound N#CC1=CC(F)=CC=C1C1=CC=CC(C2=CC(=O)NN=C2)=C1 DLZUGLNGVPJQJI-UHFFFAOYSA-N 0.000 description 1
- HSKREQKDTASANS-UHFFFAOYSA-N 5-iodo-3-phenylpyridazine Chemical compound IC1=CN=NC(C=2C=CC=CC=2)=C1 HSKREQKDTASANS-UHFFFAOYSA-N 0.000 description 1
- RTEPNEJQSYBQHF-UHFFFAOYSA-N 5-methyl-4-phenyl-1,7-dihydrodiazepin-6-one Chemical compound C1=NNCC(=O)C(C)=C1C1=CC=CC=C1 RTEPNEJQSYBQHF-UHFFFAOYSA-N 0.000 description 1
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 1
- XZLIYCQRASOFQM-UHFFFAOYSA-N 5h-imidazo[4,5-d]triazine Chemical class N1=NC=C2NC=NC2=N1 XZLIYCQRASOFQM-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002650 Anorexia nervosa and bulimia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 208000016621 Hearing disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 238000012347 Morris Water Maze Methods 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- 208000031649 Postoperative Nausea and Vomiting Diseases 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229910020929 Sn-Sn Inorganic materials 0.000 description 1
- 229910008827 Sn—Sn Inorganic materials 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000003028 Stuttering Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
- 241000663810 Tingidae Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- YKOWBJJOJNGCAD-SHYZEUOFSA-N [(2r,3s,5r)-3-hydroxy-5-[4-(hydroxyamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methyl dihydrogen phosphate Chemical compound O=C1N=C(NO)C=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 YKOWBJJOJNGCAD-SHYZEUOFSA-N 0.000 description 1
- JJYUUFIIBBRUQV-UHFFFAOYSA-N [1-methyl-3-(trifluoromethyl)pyrazol-4-yl]methanol Chemical compound CN1C=C(CO)C(C(F)(F)F)=N1 JJYUUFIIBBRUQV-UHFFFAOYSA-N 0.000 description 1
- JNSBEPKGFVENFS-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC=C1C(F)(F)F JNSBEPKGFVENFS-UHFFFAOYSA-N 0.000 description 1
- JVHNKZBMDNRVRP-UHFFFAOYSA-N [3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]boronic acid Chemical compound OB(O)C1=CC=C(F)C(C=2C(=CC(F)=CN=2)F)=C1 JVHNKZBMDNRVRP-UHFFFAOYSA-N 0.000 description 1
- MUBVHFXIZHDEGM-UHFFFAOYSA-N [4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(F)C(C=2C(=CC=CN=2)F)=C1 MUBVHFXIZHDEGM-UHFFFAOYSA-N 0.000 description 1
- IHOVEXSYINAURL-UHFFFAOYSA-N [5-[3-(2-cyano-6-fluorophenyl)-4-fluorophenyl]pyridazin-3-yl] trifluoromethanesulfonate Chemical compound FC1=CC=C(C=2C=C(OS(=O)(=O)C(F)(F)F)N=NC=2)C=C1C1=C(F)C=CC=C1C#N IHOVEXSYINAURL-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026345 acute stress disease Diseases 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 208000014646 age-related hearing impairment Diseases 0.000 description 1
- 208000029650 alcohol withdrawal Diseases 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- JRTIDHTUMYMPRU-UHFFFAOYSA-N alpidem Chemical compound N1=C2C=CC(Cl)=CN2C(CC(=O)N(CCC)CCC)=C1C1=CC=C(Cl)C=C1 JRTIDHTUMYMPRU-UHFFFAOYSA-N 0.000 description 1
- 229950008673 alpidem Drugs 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000454 anti-cipatory effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940075522 antidotes Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 208000026725 cyclothymic disease Diseases 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- BLEBFDYUDVZRFG-UHFFFAOYSA-N dichloromethane;propan-2-ol Chemical compound ClCCl.CC(C)O BLEBFDYUDVZRFG-UHFFFAOYSA-N 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- FDLDWKIEWAWOSL-UHFFFAOYSA-N ethyl acetate;2-methylpentane Chemical compound CCCC(C)C.CCOC(C)=O FDLDWKIEWAWOSL-UHFFFAOYSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000004129 indan-1-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])([H])C2([H])* 0.000 description 1
- 125000004130 indan-2-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])(*)C2([H])[H] 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960005152 pentetrazol Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- JQRYUMGHOUYJFW-UHFFFAOYSA-N pyridine;trihydrobromide Chemical compound [Br-].[Br-].[Br-].C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1 JQRYUMGHOUYJFW-UHFFFAOYSA-N 0.000 description 1
- 125000006513 pyridinyl methyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- TUZFIWBNGKNFPW-UHFFFAOYSA-M sodium;2-methylpropane-2-thiolate Chemical compound [Na+].CC(C)(C)[S-] TUZFIWBNGKNFPW-UHFFFAOYSA-M 0.000 description 1
- QJDUDPQVDAASMV-UHFFFAOYSA-M sodium;ethanethiolate Chemical compound [Na+].CC[S-] QJDUDPQVDAASMV-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 208000027765 speech disease Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 125000003638 stannyl group Chemical group [H][Sn]([H])([H])* 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960003188 temazepam Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000005302 thiazolylmethyl group Chemical group [H]C1=C([H])N=C(S1)C([H])([H])* 0.000 description 1
- 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 description 1
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 208000018726 traumatic encephalopathy Diseases 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- UNEPXPMBVGDXGH-UHFFFAOYSA-N tributyl(pyridin-4-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=NC=C1 UNEPXPMBVGDXGH-UHFFFAOYSA-N 0.000 description 1
- WJEHTCDQPMBCEN-UHFFFAOYSA-N tributyl-(6-phenylpyridazin-4-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CN=NC(C=2C=CC=CC=2)=C1 WJEHTCDQPMBCEN-UHFFFAOYSA-N 0.000 description 1
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the present invention relates to a class of substituted pyridazine derivatives and to their use in therapy. More particularly, this invention is concerned with 4-phenylpyridazine analogues. These compounds are ligands for GABA A receptors and are therefore useful in the therapy of deleterious neurological complaints.
- GABA gamma-aminobutyric acid
- GABA A receptors which are members of the ligand-gated ion channel superfamily
- GABA B receptors which may be members of the G-protein linked receptor superfamily. Since the first cDNAs encoding individual GABA A receptor subunits were cloned the number of known members of the mammalian family has grown to include at least six ⁇ subunits, four ⁇ subunits, three ⁇ subunits, one ⁇ subunit, one ⁇ subunit and two ⁇ subunits.
- Receptor subtype assemblies which do exist include, amongst many others, ⁇ 1 ⁇ 2 ⁇ 2, ⁇ 2 ⁇ 1, ⁇ 2 ⁇ 2/3 ⁇ 2, ⁇ 3 ⁇ 2/3, ⁇ 4 ⁇ , ⁇ 5 ⁇ 3 ⁇ 2/3, ⁇ 6 ⁇ 2 and ⁇ 6 ⁇ .
- Subtype assemblies containing an ⁇ 1 subunit are present in most areas of the brain and are thought to account for over 40% of GABA A receptors in the rat.
- Subtype assemblies containing ⁇ 2 and ⁇ 3 subunits respectively are thought to account for about 25% and 17% of GABA A receptors in the rat.
- Subtype assemblies containing an ⁇ 5 subunit are expressed predominantly in the hippocampus and cortex and are thought to represent about 4% of GABA A receptors in the rat.
- a characteristic property of all known GABA A receptors is the presence of a number of modulatory sites, one of which is the benzodiazepine (BZ) binding site.
- the BZ binding site is the most explored of the GABA A receptor modulatory sites, and is the site through which anxiolytic drugs such as diazepam and temazepam exert their effect.
- the benzodiazepine binding site was historically subdivided into two subtypes, BZ1 and BZ2, on the basis of radioligand binding studies.
- the BZ1 subtype has been shown to be pharmacologically equivalent to a GABA A receptor comprising the ⁇ 1 subunit in combination with a ⁇ subunit and ⁇ 2. This is the most abundant GABA A receptor subtype, and is believed to represent almost half of all GABA A receptors in the brain.
- GABA A receptor agonists Compounds which are modulators of the benzodiazepine binding site of the GABA A receptor by acting as BZ agonists are referred to hereinafter as "GABA A receptor agonists".
- GABA A receptor agonists Compounds which are modulators of the benzodiazepine binding site of the GABA A receptor by acting as BZ agonists are referred to hereinafter as "GABA A receptor agonists".
- the ⁇ 1-selective GABA A receptor agonists alpidem and zolpidem are clinically prescribed as hypnotic agents, suggesting that at least some of the sedation associated with known anxiolytic drugs which act at the BZ1 binding site is mediated through GABA A receptors containing the ⁇ 1 subunit.
- GABA A receptor agonists which interact more favourably with the ⁇ 2 and/or ⁇ 3 subunit than with ⁇ 1 will be effective in the treatment of anxiety with a reduced propensity to cause sedation.
- agents which are inverse agonists of the ⁇ 5 subunit are likely to be beneficial in enhancing cognition, for example in subjects suffering from dementing conditions such as Alzheimer's disease.
- agents which are antagonists or inverse agonists at ⁇ 1 might be employed to reverse sedation or hypnosis caused by ⁇ 1 agonists.
- WO-A-0238568 discloses imidazo-triazine derivatives as ligands for GABA-A receptors containing the ⁇ 2 and/or ⁇ 3 and/or ⁇ 5 submit, mainly for treating anxiety, convulsions and cognitive disorders.
- WO-A-0222605 discloses substituted aminopyrazoles as protein kinase inhibitors for treating cancer, diabetes and AD.
- EP-A-0072726 (Sanofi s.a.) discloses aminopyridazine derivatives active on the CNS.
- Harris et al, Pestic. Sci., 1980, 11, 439-444 discloses pyridazine derivatives as plant geotropic response inhibitors.
- US-A-4810705 discloses 7-substituted 1,2,4-triazolo[4,3-b]pyridazines as antidotes to benzodiazepines.
- US-B-6255305 discloses substituted triazolopyridazines as ligands for GABA-A receptors containing ⁇ 2 and/or ⁇ 3 submits.
- the compounds of the present invention being selective ligands for GABA A receptors, are therefore of use in the treatment and/or prevention of a variety of disorders of the central nervous system.
- disorders include anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, animal and other phobias including social phobias, obsessive-compulsive disorder, stress disorders including post-traumatic and acute stress disorder, and generalized or substance-induced anxiety disorder; neuroses; convulsions; migraine; depressive or bipolar disorders, for example single-episode or recurrent major depressive disorder, dysthymic disorder, bipolar I and bipolar II manic disorders, and cyclothymic disorder; psychotic disorders including schizophrenia; neurodegeneration arising from cerebral ischemia; attention deficit hyperactivity disorder; Tourette's syndrome; speech disorders, including stuttering; and disorders of circadian rhythm, e.g. in subjects suffering from the effects of jet lag or shift work.
- disorders for which selective ligands for GABA A receptors may be of benefit include pain and nociception; emesis, including acute, delayed and anticipatory emesis, in particular emesis induced by chemotherapy or radiation, as well as motion sickness, and post-operative nausea and vomiting; eating disorders including anorexia nervosa and bulimia nervosa; premenstrual syndrome; muscle spasm or spasticity, e.g. in paraplegic patients; hearing disorders, including tinnitus and age-related hearing impairment; urinary incontinence; and the effects of substance abuse or dependency, including alcohol withdrawal.
- Selective ligands for GABA A receptors may be beneficial in enhancing cognition, for example in subjects suffering from dementing conditions such as Alzheimer's disease; and may also be effective as pre-medication prior to anaesthesia or minor procedures such as endoscopy, including gastric endoscopy.
- the compounds in accordance with the present invention may be useful as radioligands in assays for detecting compounds capable of binding to the human GABA A receptor.
- the present invention provides a class of pyridazine derivatives which possess desirable binding properties at various GABA A receptor subtypes.
- the compounds in accordance with the present invention have good affinity as ligands for the ⁇ 2 and/or ⁇ 3 and/or ⁇ 5 subunit of the human GABA A receptor.
- the compounds of this invention may interact more favourably with the ⁇ 2 and/or ⁇ 3 subunit than with the ⁇ 1 subunit; and/or may interact more favourably with the ⁇ 5 subunit than with the ⁇ 1 subunit.
- the compounds of the present invention are GABA A receptor subtype ligands having a binding affinity (K i ) for the ⁇ 2 and/or ⁇ 3 and/or ⁇ 5 subunit, as measured in the assay described hereinbelow, of 200 nM or less, typically of 100 nM or less, and ideally of 20 nM or less.
- the compounds in accordance with this invention may possess at least a 2-fold, suitably at least a 5-fold, and advantageously at least a 10-fold, selective affinity for the ⁇ 2 and/or ⁇ 3 and/or ⁇ 5 subunit relative to the ⁇ 1 subunit.
- compounds which are not selective in terms of their binding affinity for the ⁇ 2 and/or ⁇ 3 and/or ⁇ 5 subunit relative to the ⁇ 1 subunit are also encompassed within the scope of the present invention; such compounds will desirably exhibit functional selectivity in terms of zero or weak (positive or negative) efficacy at the ⁇ 1 subunit and (i) a full or partial agonist profile at the ⁇ 2 and/or ⁇ 3 subunit, and/or (ii) an inverse agonist profile at the ⁇ 5 subunit.
- the present invention provides a compound of formula I, or an N-oxide thereof or a pharmaceutically acceptable salt thereof: wherein X 1 represents hydrogen, halogen, C 1-6 alkyl, trifluoromethyl or C 1-6 alkoxy; X 2 represents hydrogen or halogen; Z represents an optionally substituted aryl or heteroaryl group; R 1 represents hydrocarbon, a heterocyclic group -OR a , -OSO 2 CF 3 , -SR a , -NR a R b or -CO 2 R a ; R 2 represents hydrogen or C 2-6 alkoxycarbonyl; R a is C 1-6 alkyl, C 2-6 alkenyl, C 3-7 cycloalkyl or aryl(C 1-6 )alkyl (optionally substituted by C 1-6 alkoxy); R b is hydrogen or C 1-6 alkyl; heteroaryl is pyridinyl, quinolinyl, isoquinolinyl, pyridazinyl
- Z in the compounds of formula I above represents aryl or heteroaryl this group may be unsubstituted, or substituted by one or more substituents. Typically, the group Z will be unsubstituted, or substituted by one or two substituents.
- Illustrative substituents on Z include halogen, cyano, trifluoromethyl and C 1-6 alkyl.
- the salts of the compounds of formula I will be pharmaceutically acceptable salts.
- Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts.
- Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
- a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
- suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.
- hydrocarbon as used herein includes straight-chained, branched and cyclic groups containing up to 18 carbon atoms, suitably up to 15 carbon atoms, and conveniently up to 12 carbon atoms. Suitable hydrocarbon groups include C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 3-7 cyloalkyl(C 1-6 )alkyl, indanyl, aryl and aryl(C 1-6 )akyl.
- a heterocyclic group includes cyclic groups containing up to 18 carbon atoms and at least one heteroatom preferably selected from oxygen, nitrogen and sulphur.
- the heterocyclic group suitably contains up to 15 carbon atoms and conveniently up to 12 carbon atoms, and is preferably linked through carbon.
- suitable heterocyclic groups include C 3-7 heterocycloalkyl, C 3-7 heterocycloalkenyl, C 3-7 heterocyloakyl(C 1-6 )akyl, heteroaryl and heteroaryl(C 1-6 )alkyl groups.
- Suitable alkyl groups include straight-chained and branched alkyl groups containing from 1 to 6 carbon atoms. Typical examples include methyl and ethyl groups, and straight-chained or branched propyl, butyl and pentyl groups. Particular alkyl groups are methyl, ethyl, n-propyl, isopropyl, isobutyl, tert-butyl and 2,2-dimethylpropyl. Derived expressions such as "C 1-6 alkoxy", “C 1-6 alkylamino” and "C 1-6 alkylsulphonyl” are to be construed accordingly.
- Suitable alkenyl groups include straight-chained and branched alkenyl groups containing from 2 to 6 carbon atoms. Typical examples include vinyl, allyl and dimethylallyl groups.
- Suitable alkynyl groups include straight-chained and branched alkynyl groups containing from 2 to 6 carbon atoms. Typical examples include ethynyl and propargyl groups.
- Suitable cycloalkyl groups include groups containing from 3 to 7 carbon atoms. Particular cycloalkyl groups are cyclopropyl and cyclohexyl.
- C 3-7 cyloalkyl(C 1-6 )alkyl groups include cyclopropylmethyl, cyclohexylmethyl and cyclohexylethyl.
- Particular indanyl groups include indan-1-yl and indan-2-yl.
- Particular aryl groups include phenyl and naphthyl, preferably phenyl.
- Particular aryl(C 1-6 )alkyl groups include benzyl, phenylethyl, phenylpropyl and naphthylmethyl.
- Suitable heterocycloalkyl groups include azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and thiomorpholinyl groups.
- a typical heterocycloalkenyl group is dihydropyrrolyl.
- Suitable heteroaryl groups include pyridinyl, quinolinyl, isoquinolinyl, pyridazinyl, pyrimidinyl, pyrazinyl, furyl, benzofuryl, dibenzofuryl, thienyl, benzthienyl, pyrrolyl, indolyl, pyrazolyl, indazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, benzimidazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl groups.
- heteroaryl(C 1-6 )alkyl includes furylmethyl, furylethyl, thienylmethyl, thienylethyl, pyrazolylmethyl, oxazolylmethyl, oxazolylethyl, thiazolylmethyl, thiazolylethyl, imidazolylmethyl, imidazolylethyl, oxadiazolylmethyl, oxadiazolylethyl, thiadiazolylmethyl, thiadiazolylethyl, triazolylmethyl, triazolylethyl, tetrazolylmethyl, tetrazolylethyl, pyridinylmethyl, pyridinylethyl, pyrimidinylmethyl, pyrazinylmethyl, quinolinylmethyl and isoquinolinylmethyl.
- the hydrocarbon and heterocyclic groups may in turn be optionally substituted by one or more groups selected from C 1-6 alkyl, adamantyl, phenyl, halogen, C 1-6 haloalkyl, C 1-6 aminoalkyl, trifluoromethyl, hydroxy, C 1-6 alkoxy, aryloxy, keto, C 1-3 alkylenedioxy, nitro, cyano, carboxy, C 2-6 alkoxycarbonyl, C 2-6 alkoxycarbonyl(C 1-6 )alkyl, C 2-6 alkylcarbonyloxy, arylcarbonyloxy, aminocarbonyloxy, C 2-6 alkylcarbonyl, arylcarbonyl, C 1-6 alkylthio, C 1-6 alkylsulphinyl, C 1-6 alkylsulphonyl, arylsulphonyl, -NR v R w , -NR v COR w , -NR v CO 2 R w ,
- halogen as used herein includes fluorine, chlorine, bromine and iodine especially fluoro or chloro.
- the compounds according to the invention may accordingly exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centres, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present invention.
- Suitable values for the X 1 substituent include hydrogen, fluoro, chloro, methyl, trifluoromethyl and methoxy; in particular hydrogen or fluoro; and especially fluoro.
- Typical values of X 2 include hydrogen and fluoro, especially hydrogen.
- Z represents an optionally substituted phenyl group, in particular monosubstituted or disubstituted phenyl.
- Z represents optionally substituted pyridinyl, especially unsubstituted, monosubstituted or disubstituted pyridin-2-yl, pyridin-3-yl or pyridin-4-yl.
- substituents on the group Z include fluoro, cyano, trifluoromethyl and methyl, especially fluoro or cyano.
- Z Representative values include fluorophenyl, difluorophenyl, cyanophenyl, (cyano)(fluoro)phenyl, trifluoromethyl-phenyl, pyridinyl, fluoro-pyridinyl, difluoro-pyridinyl, cyano-pyridinyl and triazolyl
- Z examples include (cyano)(fluoro)phenyl, pyridinyl, fluoro-pyridinyl, difluoro-pyridinyl and triazoly
- R 1 represents hydrocarbon, a heterocyclic group, -OR a , -NR a R b or -CO 2 R a .
- R a represents methyl, ethyl, n -propyl, isopropyl, allyl, cyclopropyl, cyclohexyl, benzyl or methoxybenzyl. Additionally; R a may represent tert -butyl.
- R b represents hydrogen or methyl, especially hydrogen.
- R 1 represents aryl or heteroaryl, either of which groups may be substituted by one or more substituents.
- the aryl or heteroaryl group R 1 will be unsubstituted, or substituted by one or two substituents.
- Typical substituents include halogen, C 1-6 alkyl, trifluoromethyl, C 1-6 alkoxy, cyano and oxo.
- Suitable substituents include halogen, C 1-6 alkyl, trifluoromethyl, C 1-6 alkoxy and cyano.
- Particular substituents include fluoro, chloro, methyl, trifluoromethyl, methoxy and cyano, especially fluoro.
- R 1 Illustrative values of R 1 include phenyl, halophenyl, dihalophenyl, trihalophenyl, (C 1-6 alkyl)(halo)phenyl, (trifluoromethyl)(halo)phenyl, C 1-6 alkoxyphenyl, (C 1-6 alkoxy)(halo)phenyl, cyanophenyl, (cyano)(halo)phenyl, C 3-7 heterocycloalkyl (optionally substituted by oxo), C 3-7 heterocycloalkenyl, heteroaryl (optionally substituted by one or more halogen atoms, and/or by oxo), C 1-6 alkoxy, C 2-6 alkenyloxy, aryl(C 1-6 )alkoxy, triflyloxy, C 1-6 alkylthio, C 1-6 alkylamino, C 2-6 alkenylamino, C 3-7 cycloalkylamino, aryl(C 1-6
- R 1 Typical values of R 1 include phenyl, halophenyl, dihalophenyl, (C 1-6 alkyl)(halo)phenyl, (trifluoromethyl)(halo)phenyl, C 1-6 alkoxyphenyl, (C 1-6 alkoxy)(halo)phenyl, cyanophenyl, (cyano)(halo)phenyl, C 3-7 heterocycloalkenyl, heteroaryl, (optionally substituted by one or more halogen atoms), C 1-6 alkoxy, C 2-6 alkenyloxy, aryl(C 1-6 )alkoxy, triflyloxy, C 1-6 alkylthio, C 1-6 alkylamino, C 2-6 alkenylamino, C 3-7 cycloalkylamino, aryl(C 1-6 )alkylamino (optionally substituted by C 1-6 alkoxy) and C 2-6 alkoxycarbonyl.
- Suitable values of R 1 include phenyl, halophenyl, dihalophenyl, C 1-6 alkoxyphenyl, cyanophenyl, (cyano)(halo)phenyl, C 3-7 heterocycloalkenyl, heteroaryl (optionally substituted by halo), C 1-6 alkoxy, C 2-6 alkenyloxy, aryl(C 1-6 )alkoxy, C 1-6 alkylamino, C 2-6 alkenylamino, C 3-7 cycloalkylamino, aryl(C 1-6 )alkylamino (optionally substituted by C 1-6 alkoxy) and C 2-6 alkoxycarbonyl.
- R 1 Representative values of R 1 include phenyl, fluorophenyl, chlorophenyl, difluorophenyl, (chloro)(fluoro)phenyl, trifluorophenyl, (fluoro)(methyl)phenyl, (fluoro)(triffuoromethyl)phenyl, methoxyphenyl, (fluoro)(methoxy)phenyl, cyanophenyl, (cyano)(fluoro)phenyl, oxo-pyrrolidinyl, dihydropyrrolyl, pyridinyl, fluoro-pyridinyl, difluoro-pyridinyl, oxo-pyridinyl, pyrazinyl, furyl, thienyl, thiazolyl, triazolyl, methoxy, ethoxy, allyloxy, benzyloxy, triflyloxy, ethylthio, tert-butylthi
- R 1 Particular values of R 1 include phenyl, fluorophenyl, chlorophenyl, difluorophenyl, (chloro)(fluoro)phenyl, (fluoro)(methyl)phenyl, (fluoro)(trifluoromethyl)phenyl, methoxyphenyl, (fluoro)(methoxy)phenyl, cyanophenyl, (cyano)(fluoro)phenyl, dihydropyrrolyl, pyridinyl, fluoro-pyridinyl, difluoro-pyridinyl, pyrazinyl, furyl, thienyl, thiazolyl, triazolyl, methoxy, ethoxy, allyloxy, benzyloxy, triflyloxy, ethylthio, tert-butylthio, methylamino, ethylamino, propylamino, isopropylamino, ally
- R 1 Individual values of R 1 include phenyl, fluorophenyl, chlorophenyl, difluorophenyl, methoxyphenyl, cyanophenyl, (cyano)(fluoro)phenyl, dihydropyrrolyl, pyridinyl, fluoro-pyridinyl, pyrazinyl, furyl, thienyl, thiazolyl, triazolyl, methoxy, ethoxy, allyloxy, benzyloxy, methylamino, ethylamino, propylamino, isopropylamino, allylamino, cyclopropylamino, cyclohexylamino, benzylamino, methoxybenzyl-amino and ethoxycarbonyl.
- R 1 represents fluorophenyl (especially 2-fluorophenyl).
- R 1 represents fluoro-pyridinyl (especially 3-fluoropyridin-2-yl).
- R 1 represents difluoro-pyridinyl. In one aspect of this embodiment, R 1 represents 3,5-diffuoropyridin-4-yl. In another aspect of this embodiment, R 1 represents 3,5-difluoropyridin-2-yl.
- R 1 represents trifluorophenyl (especially 2,4,6-trifluorophenyl).
- R 2 represents hydrogen, methoxycarbonyl or ethoxycarbonyl. In a particular embodiment, R 2 represents hydrogen.
- a particular sub-class of compounds according to the invention is represented by the compounds of formula IIA, and N-oxides thereof and pharmaceutically acceptable salts thereof: wherein Z is as defined above; X 11 represents hydrogen, fluoro, chloro, methyl, trifluoromethyl or methoxy; X 12 represents hydrogen or fluoro; and R 11 represents phenyl, halophenyl, dihalophenyl, trihalophenyl, (C 1-6 alkyl)(halo)phenyl, (trifluoromethyl)(halo)phenyl, C 1-6 alkoxyphenyl, (C 1-6 alkoxy)(halo)phenyl, cyanophenyl, (cyano)(halo)phenyl, C 3-7 heterocycloalkyl (optionally substituted by oxo), C 3-7 heterocycloalkenyl, heteroaryl (optionally substituted by one or more halogen atoms, and/or by oxo), C 1-6 alkoxy, C 2
- the present invention also provides a compound of formula IIA as depicted above, or an N-oxide thereof or a pharmaceutically acceptable salt thereof, wherein R 11 represents phenyl, halophenyl, dihalophenyl, (C 1-6 alkyl)-(halo)phenyl, (trifluoromethyl)(halo)phenyl, C 1-6 alkoxyphenyl, (C 1-6 alkoxy)(halo)phenyl, cyanophenyl, (cyano)(halo)phenyl, C 3-7 heterocycloalkenyl, heteroaryl (optionally substituted by one or more halogen atoms), C 1-6 alkoxy, C 2-6 alkenyloxy, aryl(C 1-6 )alkoxy, triflyloxy, C 1-6 alkylthio, C 1-6 alkylamino, C 2-6 alkenylamino, C 3-7 cycloalkylamino, aryl(C 1-6 )alkylamino
- the present invention further provides a compound of formula IIA as depicted above, or an N-oxide thereof or a pharmaceutically acceptable salt thereof, wherein R 11 represents phenyl, halophenyl, dihalophenyl, C 1-6 alkoxyphenyl, cyanophenyl, (cyano)(halo)phenyl, C 3-7 heterocycloalkenyl, heteroaryl (optionally substituted by halo), C 1-6 alkoxy, C 2-6 alkenyloxy, aryl(C 1-6 )alkoxy, C 1-6 alkylamino, C 2-6 alkenylamino, C 3-7 cycloalkylamino, aryl(C 1-6 )alkylamino (optionally substituted by C 1-6 alkoxy) or C 2-6 alkoxycarbonyl; and Z, X 11 and X 12 are as defined above.
- Suitable values of X 11 include hydrogen and fluoro, especially fluoro.
- X 12 represents hydrogen. In another embodiment, X 12 represents fluoro.
- R 11 represents heteroaryl
- this group is suitably pyridinyl, pyrazinyl, furyl, thienyl, thiazolyl or triazolyl, especially pyridinyl.
- R 11 Representative values of R 11 include phenyl, fluorophenyl, chlorophenyl, difluorophenyl, (chloro)(fluoro)phenyl, trifluorophenyl, (fluoro)(methyl)phenyl, (fluoro)(tritluoromethyl)phenyl, methoxyphenyl, (fluoro)(methoxy)phenyl, cyanophenyl, (cyano)(fluoro)phenyl, oxo-pyrrolidinyl, dihydropyrrolyl, pyridinyl, fluoro-pyridinyl, difluoro-pyridinyl, oxo-pyridinyl, pyrazinyl, furyl, thienyl, thiazolyl, triazolyl, methoxy, ethoxy, allyloxy, benzyloxy, triflyloxy, ethylthio, tert-butyl
- R 11 Particular values of R 11 include phenyl, fluorophenyl, chlorophenyl, difluorophenyl, (chloro)(fluoro)phenyl, (fluoro)(methyl)phenyl, (fluoro)(tritluoromethyl)phenyl, methoxyphenyl, (fluoro)(methoxy)phenyl, cyanophenyl, (cyano)(fluoro)phenyl, dihydropyrrolyl, pyridinyl, fluoro-pyridinyl, difluoro-pyridinyl, pyrazinyl, furyl, thienyl, thiazolyl, triazolyl, methoxy, ethoxy, allyloxy, benzyloxy, triflyloxy, ethylthio, tert-butylthio, methylamino, ethylamino, propylamino, isopropylamino,
- R 11 Individual values of R 11 include phenyl, fluorophenyl, chlorophenyl, difluorophenyl, methoxyphenyl, cyanophenyl, (cyano)(fluoro)phenyl, dihydropyrrolyl, pyridinyl, fluoro-pyridinyl, pyrazinyl, furyl, thienyl, thiazolyl, triazolyl, methoxy, ethoxy, allyloxy, benzyloxy, methylamino, ethylamino, propylamino, isopropylamino, allylamino, cyclopropylamino, cyclohexylamino, benzylamino, methoxybenzyl-amino and ethoxycarbonyl.
- R 11 represents fluorophenyl (especially 2-fluorophenyl).
- R 11 represents fluoro-pyridinyl (especially 3-fluoropyridin-2-yl).
- R 11 represents difluoro-pyridinyl. In one aspect of this embodiment, R 11 represents 3,5-difluoropyridin-4-yl. In another aspect of this embodiment, R 11 represents 3,5-diffuoropyridin-2-yl.
- R 11 represents trifluorophenyl (especially 2,4,6-trifluorophenyl).
- R 3 represents hydrogen or fluoro. In one embodiment, R 3 is hydrogen.
- R 3 is fluoro, in which case the fluorine atom R 3 is favourably attached to the phenyl ring at the 4-, 5- or 6-position (relative to the cyano group at position 2).
- R 4 is hydrogen
- R 4 is fluoro
- R 4 is cyano
- R 4 is methyl
- a further representative subset of the compounds of formula IIA above is represented by the compounds of formula IID, and N-oxides thereof and pharmaceutically acceptable salts thereof: wherein X 11 , X 12 , R 4 and R 11 are as defined above; and R 5 represents hydrogen or fluoro.
- R 5 represents hydrogen
- R 5 represents fluoro
- a favoured subset of the compounds of formula IID above is represented by the compounds of formula IIE, and N -oxides thereof and pharmaceutically acceptable salts thereof: wherein V represents N and W represents CF; or V represents CF and W represents N; or V and W both represent CF; and X 12 and R 5 are as defined above.
- the present invention also provides a compound of formula IIE as depicted above, or an N-oxide thereof or a pharmaceutically acceptable salt thereof, wherein V represents N and W represents CF; or V represents CF and W represents N; and X 12 and R 5 are as defined above.
- V is N and W is CF.
- V is CF and W is N.
- V and W are both CF.
- the binding affinity (K i ) of the compounds according to the present invention for the ⁇ 3 subunit of the human GABA A receptor is conveniently as measured in the assay described hereinbelow.
- the ⁇ 3 subunit binding affinity (K i ) of the anxiolytic compounds of the invention is ideally 50 nM or less, preferably 10 nM or less, and more preferably 5 nM or less.
- the anxiolytic compounds according to the present invention will ideally elicit at least a 40%, preferably at least a 50%, and more preferably at least a 60%, potentiation of the GABA EC 20 response in stably transfected recombinant cell lines expressing the ⁇ 3 subunit of the human GABA A receptor. Moreover, the compounds of the invention will ideally elicit at most a 30%, preferably at most a 20%, and more preferably at most a 10%, potentiation of the GABA EC 20 response in stably transfected recombinant cell lines expressing the ⁇ 1 subunit of the human GABA A receptor.
- the potentiation of the GABA EC 20 response in stably transfected cell lines expressing the ⁇ 3 and ⁇ 1 subunits of the human GABA A receptor can conveniently be measured by procedures analogous to the protocol described in Wafford et al., Mol. Pharmacol., 1996, 50, 670-678 .
- the procedure will suitably be carried out utilising cultures of stably transfected eukaryotic cells, typically of stably transfected mouse Ltk-fibroblast cells.
- the compounds according to the present invention may exhibit anxiolytic activity, as may be demonstrated by a positive response in the elevated plus maze and conditioned suppression of drinking tests (cf. Dawson et al., Psychopharmacology, 1995, 121, 109-117 ). Moreover, the compounds of the invention are likely to be substantially non-sedating, as may be confirmed by an appropriate result obtained from the response sensitivity (chain-pulling) test (cf. Bayley et al., J. Psychopharmacol., 1996, 10, 206-213 ).
- the compounds according to the present invention may also exhibit anticonvulsant activity. This can be demonstrated by the ability to block pentylenetetrazole-induced seizures in rats and mice, following a protocol analogous to that described by Bristol et al. in J. Pharmacol. Exp. Ther., 1996, 279, 492-501 .
- Cognition enhancement can be shown by testing the compounds in the Morris watermaze as reported by McNamara and Skelton, Psychobiology, 1993, 21, 101-108 . Further details of relevant methodology are described in WO 96/25948 .
- Cognitive disorders for which the compounds of the present invention may be of benefit include delirium, dementia, amnestic disorders, and cognition deficits, including age-related memory deficits, due to traumatic injury, stroke, Parkinson's disease and Down Syndrome. Any of these conditions may be attributable to substance abuse or withdrawal.
- dementia include dementia of the Alzheimer's type with early or late onset, and vascular dementia, any of which may be uncomplicated or accompanied by delirium, delusions or depressed mood; and dementia due to HIV disease, head trauma, Parkinson's disease or Creutzfeld-Jakob disease.
- the compounds of the invention will ideally be brain-penetrant; in other words, these compounds will be capable of crossing the so-called "blood-brain barrier".
- the compounds of the invention will be capable of exerting their beneficial therapeutic action following administration by the oral route.
- compositions comprising one or more compounds of this invention in association with a pharmaceutically acceptable carrier.
- these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation.
- a pharmaceutical carrier e.g.
- a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof.
- preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
- This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention.
- Typical unit dosage forms contain from 1 to 100 mg, for example 1, 2, 5, 10, 25, 50 or 100 mg, of the active ingredient.
- the tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
- the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
- the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release.
- enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
- liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
- Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.
- a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.05 to 100 mg/kg per day, and especially about 0.05 to 5 mg/kg per day.
- the compounds may be administered on a regimen of 1 to 4 times per day.
- the compounds in accordance with the present invention may be prepared by a process which comprises reacting a compound of formula III with a compound of formula IV: wherein X 1 , X 2 , Z, R 1 and R 2 are as defined above, L 1 represents a suitable leaving group, and M 1 represents a boronic acid moiety -B(OH) 2 or a cyclic ester thereof formed with an organic diol, e.g.
- M 1 represents -Sn(Alk) 3 in which Alk represents a C 1-6 alkyl group, typically n -butyl or methyl, or M 1 represents -ZnHal in which Hal represents a halogen atom, e.g. chloro; in the presence of a transition metal catalyst.
- the leaving group L 1 is typically a halogen atom, e.g. iodo, bromo or chloro.
- the transition metal catalyst of use in the reaction between compounds III and IV is suitably tetrakis(triphenylphosphine)-palladium(0).
- the reaction is conveniently carried out at an elevated temperature in a solvent such as N,N- dimethylacetamide, 1,4-dioxane or tetrahydrofuran, advantageously in the presence of potassium phosphate, copper(I) iodide, sodium carbonate or cesium carbonate.
- the transition metal catalyst employed may be dichloro[1,1'-bis(diphenyl-phosphino)ferrocene]palladium(II), in which case the reaction is conveniently effected at an elevated temperature in a solvent such as N,N- dimethylformamide, advantageously in the presence of potassium phosphate.
- the compounds according to the present invention may be prepared by a process which comprises reacting a compound of formula V with a compound of formula VI: wherein X 1 , X 2 , Z, R 1 , R 2 , L 1 and M 1 are as defined above; in the presence of a transition metal catalyst; under conditions analogous to those described above for the reaction between compounds III and IV.
- the compounds according to the present invention may be prepared by a process which comprises reacting a compound of formula VII with a compound of formula VIII: wherein X 1 , X 2 , Z, R 1 , R 2 , L 1 and M 1 are as defined above; in the presence of a transition metal catalyst; under conditions analogous to those described above for the reaction between compounds III and IV.
- the leaving group L 1 is typically trifluoromethanesulfonyloxy (triflyloxy); or a halogen atom, e.g. bromo.
- the compounds according to the present invention may be prepared by a process which comprises reacting a compound of formula IX with a compound of formula X: wherein X 1 , X 2 , Z, R 1 , R 2 , L 1 and M 1 are as defined above; in the presence of a transition metal catalyst; under conditions analogous to those described above for the reaction between compounds III and IV.
- M 1 in the intermediates of formula IV and IX above represents a boronic acid moiety -B(OH) 2 or a cyclic ester thereof formed with pinacol or neopentyl glycol
- the relevant compound IV or IX may be prepared by reacting bis(pinacolato)diboron or bis(neopentyl glycolato)diborane respectively with a compound of formula VI or VII as defined above; in the presence of a transition metal catalyst.
- the transition metal catalyst of use in the reaction between bis(pinacolato)diboron or bis(neopentyl glycolato)diborane and compound VI or VII is suitably dichloro[1,1'-bis(diphenylphosphino)ferrocene]-palladium(II).
- the reaction is conveniently carried out at an elevated temperature in a solvent such as 1,4-dioxane, optionally in admixture with dimethylsulfoxide, typically in the presence of 1,1'-bis(diphenylphosphino)ferrocene and/or potassium acetate.
- the relevant compound VII may be prepared by reacting the appropriate compound of formula XI: with triflic anhydride, typically in the presence of pyridine. Analogous conditions may be utilised for preparing a compound of formula VI wherein L 1 represents triflyloxy from the corresponding hydroxy precursor.
- the intermediates of formula XI above may suitably be prepared from the appropriate methoxy-substituted precursor of formula XIII: wherein X 1 , X 2 , R 1 and R 2 are as defined above; by treatment with boron tribromide, typically in chloroform or dichloromethane; or with hydrogen bromide, typically in acetic acid at reflux.
- this compound may be prepared by reacting a compound of formula III as defined above with a reagent of formula (Alk) 3 Sn-Hal, in which Hal represents a halogen atom, typically chloro.
- a reagent of formula (Alk) 3 Sn-Hal in which Hal represents a halogen atom, typically chloro.
- the reaction is conveniently effected by treating compound III with isopropylmagnesium chloride, typically in a solvent such as tetrahydrofuran, with subsequent addition of the stannyl reagent (Alk) 3 Sn-Hal.
- the compounds according to the present invention wherein R 1 represents an aryl or heteroaryl moiety may be prepared by a process which comprises reacting a compound of formula XIV with a compound of formula XV: wherein X 1 , X 2 , Z, R 2 , L 1 and M 1 are as defined above, and R 1a represents an aryl or heteroaryl moiety; in the presence of a transition metal catalyst; under conditions analogous to those described above for the reaction between compounds III and IV.
- the leaving group L 1 is typically triflyloxy; or a halogen atom, e.g. chloro.
- the transition metal catalyst of use in the reaction between compounds XIV and XV is suitably tetrakis(triphenylphosphine)-palladium(O), in which case the reaction is conveniently effected at an elevated temperature in a solvent such as tetrahydrofuran, 1,4-dioxane or N,N- dimethylformamide, typically in the presence of sodium carbonate.
- the transition metal catalyst may suitably be palladium bis(diphenylphosphinylbutane)dichloride, in which case the reaction is conveniently effected at an elevated temperature in a solvent such as tetrahydrofuran, typically in the presence of sodium carbonate.
- the compounds according to the present invention wherein R 1 represents an aryl or heteroaryl moiety may be prepared by a process which comprises reacting a compound of formula XVI with a compound of formula XVII: wherein X 1 , X 2 , Z, R 1a , R 2 , L 1 and M 1 are as defined above; in the presence of a transition metal catalyst; under conditions analogous to those described above for the reaction between compounds III and IV.
- the intermediates of formula XVII wherein M 1 represents -Sn(Alk)3 and Alk represents C 1-6 alkyl, e.g. methyl, may be prepared by reacting a compound of formula XV as defined above with a reagent of formula (Alk) 3 Sn-Sn(Alk) 3 .
- the reaction is conveniently effected in the presence of a transition metal catalyst, e.g. tetrakis(triphenylphosphine)palladium(O), with heating in a solvent such as 1,4-dioxane, typically in the presence of lithium chloride.
- the compounds according to the present invention wherein R 1 represents 1 H -[1,2,3]triazol-4-yl may be prepared by a process which comprises reacting a compound of formula XVIII: wherein X 1 , X 2 , Z and R 2 are as defined above, and TMS is an abbreviation for trimethylsilanyl; with sodium azide.
- the reaction is conveniently effected by stirring the reactants in a solvent such as N,N- dimethylformamide.
- the intermediates of formula XVIII may be prepared by reacting a compound of formula XV with TMS-acetylene, in the presence of a transition metal catalyst such as bis(triphenylphosphine)palladium(II) chloride.
- a transition metal catalyst such as bis(triphenylphosphine)palladium(II) chloride.
- the reaction is conveniently effected by stirring in a solvent such as tetrahydrofuran, typically in the presence of triethylamine, triphenylphosphine and copper(I) chloride.
- R 1 represents -OR a
- R 1 represents -OR a
- R 1 represents -OR a
- the compounds according to the present invention wherein R 1 represents -OR a may be prepared by a process which comprises reacting a compound of formula XV as defined above with a compound of formula R a -OH, wherein R a is as defined above.
- the reaction is conveniently carried out in the presence of a base such as sodium hydride or sodium ethoxide.
- R 1 represents -SR a
- R 1 represents -SR a
- R 1 represents -SR a
- R 1 represents -SR a
- the reaction is conveniently carried out in the presence of a solvent such as N,N -dimethylformamide.
- R 1 represents -NR a R b
- R 1 represents -NR a R b
- the compounds according to the present invention wherein R 1 represents -NR a R b may be prepared by a process which comprises reacting a compound of formula XV as defined above with a compound of formula H-NR a R b , wherein R a and R b are as defined above.
- the reaction is conveniently effected by stirring at an elevated temperature, typically in a solvent such as tetrahydrofuran.
- R 1 represents -CO 2 R a
- R 1 represents -CO 2 R a
- R a is as defined above; in the presence of a transition metal catalyst.
- the transition metal catalyst of use in the foregoing reaction is ideally [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) chloride, in which case the reaction is conveniently carried out at an elevated temperature in a solvent such as N,N- dimethylformamide, optionally in admixture with dichloromethane, typically in the presence of sodium acetate.
- the intermediates of formula XV wherein L 1 represents triflyloxy may be prepared by reacting a compound of formula XIX: wherein X 1 , X 2 , Z and R 2 are as defined above; with N- phenyltriflylimide, typically in the presence of triethylamine, in a solvent such as dichloromethane; or with triflic anhydride, typically in the presence of pyridine.
- the intermediates of formula XV wherein L 1 represents chloro may be prepared by treating the requisite compound of formula XIX with phosphorus oxychloride at an elevated temperature.
- the intermediates of formula XIX may be prepared by reacting a compound of formula IV as defined above with a compound of formula XX: wherein R 2 and L 1 are as defined above; in the presence of a transition metal catalyst; under conditions analogous to those described above for the reaction between compounds III and IV.
- the intermediates of formula XIX may be prepared by reacting a compound of formula XXI: wherein X 1 , X 2 , Z and R 2 are as defined above; with hydrazine hydrate, typically in ethanol at reflux.
- R 2 represents methoxycarbonyl
- R 2 represents methoxycarbonyl
- reaction is conveniently accomplished by stirring in a solvent such as diethyl ether.
- the intermediates of formula XXII may be prepared by saponifying a compound of formula I wherein R 2 represents C 2-6 alkoxycarbonyl, typically by treatment with potassium hydroxide in refluxing aqueous methanol.
- R 2 represents C 2-6 alkoxycarbonyl
- R 2a represents C 2-6 alkoxycarbonyl
- the reaction is conveniently effected by stirring in a solvent such as diethyl ether.
- the compounds of formula XI and XIII may therefore be prepared by any of the methods described above for the preparation of the compounds according to the invention.
- any compound of formula I initially obtained from any of the above processes may, where appropriate, subsequently be elaborated into a further compound of formula I by techniques known from the art.
- a compound of formula I initially obtained may be converted into the N- oxide derivative thereof by treatment with m-chloroperbenzoic acid.
- a compound of formula I wherein R 1 represents C 2-6 alkoxycarbonyl may be reduced with lithium aluminium hydride to the corresponding compound of formula I wherein R 1 represents hydroxymethyl.
- a compound wherein R 1 represents formyl may be reacted with a Grignard reagent of formula R a MgBr to afford a compound of formula I wherein R 1 represents -CH(OH)R a .
- a compound of formula I wherein R 1 represents -CH(OH)R a may be converted into the corresponding compound of formula I wherein R 1 represents -CHFR a by treatment with (diethylamino)sulfur trifluoride (DAST).
- DAST diethylamino)sulfur trifluoride
- a compound wherein R 1 represents -COR a may be converted into the corresponding compound of formula I wherein R 1 represents -CF 2 R a by treatment with DAST.
- a compound wherein R 1 represents -COCH 3 may be treated with thioacetamide in the presence of pyridinium tribromide to furnish the corresponding compound of formula I wherein R 1 represents 2-methylthiazol-5-yl.
- a compound wherein R 1 is formyl may be treated with (p-tolylsulfonyl)methyl isocyanide (TosMIC) in the presence of potassium carbonate to afford the corresponding compound of formula I wherein R 1 represents oxazol-5-yl.
- TosMIC (p-tolylsulfonyl)methyl isocyanide
- a compound of formula I wherein R 1 represents hydroxymethyl may be treated with carbon tetrabromide and triphenylphosphine to afford the corresponding compound of formula I wherein R 1 represents bromomethyl.
- a compound wherein R 1 represents chloro may be converted into the corresponding compound wherein R 1 represents 2-oxopyrrolidin-1-yl by treatment with pyrrolidin-2-one in the presence of sodium hydride.
- a compound wherein R 1 represents chloro may be converted into the corresponding compound wherein R 1 represents 2-oxopyridin-1-yl by treatment with 2-hydroxypyridine in the presence of copper(I) iodide.
- a compound of formula I wherein Z is substituted with methoxy may be converted to the corresponding compound wherein Z is substituted with hydroxy by treatment with boron tribromide.
- the desired product can be separated therefrom at an appropriate stage by conventional methods such as preparative HPLC; or column chromatography utilising, for example, silica and/or alumina in conjunction with an appropriate solvent system.
- novel compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution.
- the novel compounds may, for example, be resolved into their component enantiomers by standard techniques such as preparative HPLC, or the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di- p -toluoyl-1-tartaric acid, followed by fractional crystallization and regeneration of the free base.
- the novel compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.
- any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973 ; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 3rd edition, 1999 .
- the protecting groups may be removed at a convenient subsequent stage using methods known from the art.
- the compounds in accordance with this invention potently inhibit the binding of [ 3 H]-flumazenil to the benzodiazepine binding site of human GABA A receptors containing the ⁇ 2 and/or ⁇ 3 and/or ⁇ 5 subunit stably expressed in Ltk- cells.
- Supernatant is removed from cells.
- PBS approximately 20 ml
- the cells are scraped and placed in a 50 ml centrifuge tube. The procedure is repeated with a further 10 ml of PBS to ensure that most of the cells are removed.
- the cells are pelleted by centrifuging for 20 min at 3000 rpm in a benchtop centrifuge, and then frozen if desired. The pellets are resuspended in 10 ml of buffer per tray (25 cm x 25 cm) of cells.
- Each tube contains:
- Assays are incubated for 1 hour at 40°C, then filtered using either a Tomtec or Brandel cell harvester onto GF/B filters followed by 3 x 3 ml washes with ice cold assay buffer. Filters are dried and counted by liquid scintillation counting. Expected values for total binding are 3000-4000 dpm for total counts and less than 200 dpm for non-specific binding if using liquid scintillation counting, or 1500-2000 dpm for total counts and less than 200 dpm for non-specific binding if counting with meltilex solid scintillant. Binding parameters are determined by non-linear least squares regression analysis, from which the inhibition constant K i can be calculated for each test compound.
- the reaction was diluted with CH 2 Cl 2 (6 ml) and NH 4 Cl (2 ml) then poured into a PTFE (5 ⁇ M) fritted syringe barrel.
- the organic phase was concentrated while loading onto silica and purified by column chromatography using 50% ethyl acetate/hexanes followed by ethyl acetate as eluent.
- the title compound was obtained as a white solid by recrystallising from ethyl acetate (46 mg).
- reaction mixture was adsorbed onto silica and purified by flash chromatography using a gradient elution of isohexane/ethyl acetate 20:1 to 1:20 as eluent. The appropriate fractions were combined and evaporated under reduced pressure to give a solid which was recrystallized from acetonitrile to give the title compound (45 mg).
- Table 4 EX. NO. PRODUCT ⁇ H (400 MHz, CDCL 3 ) m / z (ES + ) 60 5-[4-Fluoro-3-(pyridin-4-ylmethoxy)phenyl]-3-phenylpyridazine 5.27 (2H, s), 7.28-7.34 (3H, m), 7.42 (2H, d, J 6.3), 7.51-7.59 (3H, m), 7.88 (1H, d, J 2.0), 8.11-8.13 (2H, m), 8.66-8.68 (2H, m), 9.32 (1H, d, J 2.0).
- 358 61 5-[4-Fluoro-3-(pyridin-3-ylmethoxy)phenyl]-3-phenylpyridazine 5.26 (2H, s), 7.27-7.39 (4H, m), 7.51-7.59 (3H, m), 7.83-7.86 (1H, m), 7.90 (1H, d, J 2.3), 8.12-8.14 (2H, m), 8.63 (1H, d, J 3.9), 8.74 (1H, s), 9.33 (1H, d, J 2.0).
- Table 5A EX. NO. PRODUCT ⁇ H m / z (ES + ) 86 3-(3,5-Difluoropyridin-4-yl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine (400 MHz, d 6 DMSO) 7.63-7.68 (2H, m), 7.95 (1H, m), 8.23-8.29 (2H, m), 8.55 (1H, br s), 8.64 (1H, m), 8.81 (2H, s), 9.88 (1H, d, J 1.8).
- 3-Chloro-5-(4-fluorophenyl)pyridazine was coupled to 3,5-difluoro-4-trimethylsilylpyridin-2-ylzinc chloride using the method in Example 128 to give 3-(3,5-difluoropylidin-2-yl)-5-(4-fluorophenyl)pyridazine: m / z (ES + ) 288.
- 3-Chloro-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine was prepared via the coupling of 5-chloro-2 H -pyridazin-3-one with 3-(3-fluoropyridin-2-yl)-4-fluorophenylboronic acid (prepared according to WO 0238568 ), according to the method of Example 126.
- the reaction was cooled to ambient temperature, diluted with dichloromethane (30 ml), and washed with 25% aqueous ammonium hydroxide (30 ml). The organic phase was separated and evaporated at reduced pressure. The residue was subjected to chromatography on silica gel eluent 5% methanol in dichloromethane. The product was dissolved in warm methanol and applied to an SCX acidic ion exchange resin cartridge. Elution with methanol, followed by a solution of ammonia in methanol (2 molar), afforded clean product, which was recrystallised from hot aqueous methanol.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
- The present invention relates to a class of substituted pyridazine derivatives and to their use in therapy. More particularly, this invention is concerned with 4-phenylpyridazine analogues. These compounds are ligands for GABAA receptors and are therefore useful in the therapy of deleterious neurological complaints.
- Receptors for the major inhibitory neurotransmitter, gamma-aminobutyric acid (GABA), are divided into two main classes: (1) GABAA receptors, which are members of the ligand-gated ion channel superfamily; and (2) GABAB receptors, which may be members of the G-protein linked receptor superfamily. Since the first cDNAs encoding individual GABAA receptor subunits were cloned the number of known members of the mammalian family has grown to include at least six α subunits, four β subunits, three γ subunits, one δ subunit, one ε subunit and two ρ subunits.
- Although knowledge of the diversity of the GABAA receptor gene family represents a huge step forward in our understanding of this ligand-gated ion channel, insight into the extent of subtype diversity is still at an early stage. It has been indicated that an α subunit, a β subunit and a γ subunit constitute the minimum requirement for forming a fully functional GABAA receptor expressed by transiently transfecting cDNAs into cells. As indicated above, δ, ε and ρ subunits also exist, but are present only to a minor extent in GABAA receptor populations.
- Studies of receptor size and visualisation by electron microscopy conclude that, like other members of the ligand-gated ion channel family, the native GABAA receptor exists in pentameric form. The selection of at least one α, one β and one γ subunit from a repertoire of seventeen allows for the possible existence of more than 10,000 pentameric subunit combinations. Moreover, this calculation overlooks the additional permutations that would be possible if the arrangement of subunits around the ion channel had no constraints (i.e. there could be 120 possible variants for a receptor composed of five different subunits).
- Receptor subtype assemblies which do exist include, amongst many others, α1β2γ2, α2βγ1, α2β2/3γ2, α3βγ2/3, α4βδ, α5β3γ2/3, α6βγ2 and α6βδ. Subtype assemblies containing an α1 subunit are present in most areas of the brain and are thought to account for over 40% of GABAA receptors in the rat. Subtype assemblies containing α2 and α3 subunits respectively are thought to account for about 25% and 17% of GABAA receptors in the rat. Subtype assemblies containing an α5 subunit are expressed predominantly in the hippocampus and cortex and are thought to represent about 4% of GABAA receptors in the rat.
- A characteristic property of all known GABAA receptors is the presence of a number of modulatory sites, one of which is the benzodiazepine (BZ) binding site. The BZ binding site is the most explored of the GABAA receptor modulatory sites, and is the site through which anxiolytic drugs such as diazepam and temazepam exert their effect. Before the cloning of the GABAA receptor gene family, the benzodiazepine binding site was historically subdivided into two subtypes, BZ1 and BZ2, on the basis of radioligand binding studies. The BZ1 subtype has been shown to be pharmacologically equivalent to a GABAA receptor comprising the α1 subunit in combination with a β subunit and γ2. This is the most abundant GABAA receptor subtype, and is believed to represent almost half of all GABAA receptors in the brain.
- Two other major populations are the α2βγ2 and α3βγ2/3 subtypes. Together these constitute approximately a further 35% of the total GABAA receptor repertoire. Pharmacologically this combination appears to be equivalent to the BZ2 subtype as defined previously by radioligand binding, although the BZ2 subtype may also include certain α5-containing subtype assemblies. The physiological role of these subtypes has hitherto been unclear because no sufficiently selective agonists or antagonists were known.
- It is now believed that agents acting as BZ agonists at α1βγ2, α2βγ2 or α3βγ2 subtypes will possess desirable anxiolytic properties. Compounds which are modulators of the benzodiazepine binding site of the GABAA receptor by acting as BZ agonists are referred to hereinafter as "GABAA receptor agonists". The α1-selective GABAA receptor agonists alpidem and zolpidem are clinically prescribed as hypnotic agents, suggesting that at least some of the sedation associated with known anxiolytic drugs which act at the BZ1 binding site is mediated through GABAA receptors containing the α1 subunit. Accordingly, it is considered that GABAA receptor agonists which interact more favourably with the α2 and/or α3 subunit than with α1 will be effective in the treatment of anxiety with a reduced propensity to cause sedation. Moreover, agents which are inverse agonists of the α5 subunit are likely to be beneficial in enhancing cognition, for example in subjects suffering from dementing conditions such as Alzheimer's disease. Also, agents which are antagonists or inverse agonists at α1 might be employed to reverse sedation or hypnosis caused by α1 agonists.
-
WO-A-0238568 -
WO-A-0222605 -
EP-A-0072726 (Sanofi s.a.) discloses aminopyridazine derivatives active on the CNS. - Wermuth et al, J. Med. Chem., 1987, 30, 239-249 discloses a series of aminopyridazine derivatives which are selective GABA-A antagonists.
- Auricchio et al, Eur. J. Org. Chem., 2001, 1183-1187 discloses 2H-pyridazines but no pharmaceutical indication is given.
- Rival et al, J. Med. Chem., 1998, 41, 311-317 discloses aminopyridazine derivatives as 5-HT3 (and muscarinic M1) agonists.
- South et al, J. Org. Chem., 1996, 61, 8921-8934 discloses substituted pyridazines but no pharmaceutical indication is given.
- Bly et al, J. Org. Chem., 1964, 29, 2128-35 discloses rearrangement of 2,3-dihydro-5-methyl-6-phenyl-4H-1,2-diazepin-4-one to a pyridazine. No pharmaceutical indication is given.
- Atkinson and Rodway, J. Chem. Soc. Abstracts, 1959, 1-5, discloses phenylpyridazines as antibiotics.
- Samsonov et al, Khim. Geterosikl. Soedin., 1996, 8, 1055-1061 discloses one pyridazine derivative. No pharmaceutical indication is given.
- Harris et al, Pestic. Sci., 1980, 11, 439-444 discloses pyridazine derivatives as plant geotropic response inhibitors.
- Oliver et al, J. Org. Chem., 1989, 54, 4970-4973 discloses substituted pyridazines derived from setal exudates of lace bugs.
- Breukelman et al, J. Chem. Soc. Perkin Trans., 1985, 1627-1635 discloses 4- and 5-phenyl-4,5-dihydropyridazin-3(2H)-ones.
- Jojima et al, Chem. Pharm. Bull., 20(10), 1972, 2191-2203 discloses a phenylpyridazine but no activity for it is given.
-
US-A-4810705 (Sanofi) discloses 7-substituted 1,2,4-triazolo[4,3-b]pyridazines as antidotes to benzodiazepines. -
US-B-6255305 discloses substituted triazolopyridazines as ligands for GABA-A receptors containing α2 and/or α3 submits. - None of the above documents discloses compounds of the present invention.
- The compounds of the present invention, being selective ligands for GABAA receptors, are therefore of use in the treatment and/or prevention of a variety of disorders of the central nervous system. Such disorders include anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, animal and other phobias including social phobias, obsessive-compulsive disorder, stress disorders including post-traumatic and acute stress disorder, and generalized or substance-induced anxiety disorder; neuroses; convulsions; migraine; depressive or bipolar disorders, for example single-episode or recurrent major depressive disorder, dysthymic disorder, bipolar I and bipolar II manic disorders, and cyclothymic disorder; psychotic disorders including schizophrenia; neurodegeneration arising from cerebral ischemia; attention deficit hyperactivity disorder; Tourette's syndrome; speech disorders, including stuttering; and disorders of circadian rhythm, e.g. in subjects suffering from the effects of jet lag or shift work.
- Further disorders for which selective ligands for GABAA receptors may be of benefit include pain and nociception; emesis, including acute, delayed and anticipatory emesis, in particular emesis induced by chemotherapy or radiation, as well as motion sickness, and post-operative nausea and vomiting; eating disorders including anorexia nervosa and bulimia nervosa; premenstrual syndrome; muscle spasm or spasticity, e.g. in paraplegic patients; hearing disorders, including tinnitus and age-related hearing impairment; urinary incontinence; and the effects of substance abuse or dependency, including alcohol withdrawal. Selective ligands for GABAA receptors may be beneficial in enhancing cognition, for example in subjects suffering from dementing conditions such as Alzheimer's disease; and may also be effective as pre-medication prior to anaesthesia or minor procedures such as endoscopy, including gastric endoscopy.
- In addition, the compounds in accordance with the present invention may be useful as radioligands in assays for detecting compounds capable of binding to the human GABAA receptor.
- The present invention provides a class of pyridazine derivatives which possess desirable binding properties at various GABAA receptor subtypes. The compounds in accordance with the present invention have good affinity as ligands for the α2 and/or α3 and/or α5 subunit of the human GABAA receptor. The compounds of this invention may interact more favourably with the α2 and/or α3 subunit than with the α1 subunit; and/or may interact more favourably with the α5 subunit than with the α1 subunit.
- The compounds of the present invention are GABAA receptor subtype ligands having a binding affinity (Ki) for the α2 and/or α3 and/or α5 subunit, as measured in the assay described hereinbelow, of 200 nM or less, typically of 100 nM or less, and ideally of 20 nM or less. The compounds in accordance with this invention may possess at least a 2-fold, suitably at least a 5-fold, and advantageously at least a 10-fold, selective affinity for the α2 and/or α3 and/or α5 subunit relative to the α1 subunit. However, compounds which are not selective in terms of their binding affinity for the α2 and/or α3 and/or α5 subunit relative to the α1 subunit are also encompassed within the scope of the present invention; such compounds will desirably exhibit functional selectivity in terms of zero or weak (positive or negative) efficacy at the α1 subunit and (i) a full or partial agonist profile at the α2 and/or α3 subunit, and/or (ii) an inverse agonist profile at the α5 subunit.
- The present invention provides a compound of formula I, or an N-oxide thereof or a pharmaceutically acceptable salt thereof:
X1 represents hydrogen, halogen, C1-6alkyl, trifluoromethyl or C1-6 alkoxy;
X2 represents hydrogen or halogen;
Z represents an optionally substituted aryl or heteroaryl group;
R1 represents hydrocarbon, a heterocyclic group -ORa, -OSO2CF3, -SRa, -NRaRb or -CO2Ra;
R2 represents hydrogen or C2-6 alkoxycarbonyl;
Ra is C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl or aryl(C1-6)alkyl (optionally substituted by C1-6alkoxy);
Rb is hydrogen or C1-6alkyl;
heteroaryl is pyridinyl, quinolinyl, isoquinolinyl, pyridazinyl, pyrimidinyl, pyrazinyl, furyl, benzofuryl, dibenzofuryl, thienyl, benzthienyl, pyrrolyl, indolyl, pyrazolyl, indazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, benzimidazolyl, oxadiazolyl, thiadiazolyl, triazolyl or tetrazolyl. - The present invention also provides a compound of formula I as depicted above, or an N-oxide thereof or a pharmaceutically acceptable salt thereof, wherein
R1 represents hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, -ORa, -SRa, -SORa, -SO2Ra, -SO2NRaRb, -NRaRb, -NRaCORb, -NRaCO2Rb, -CORa, -CO2Ra, -CONRaRb or -CRa=NORb; and
X1, X2, Z, R2, Ra and Rb are as defined above. - Where Z in the compounds of formula I above represents aryl or heteroaryl this group may be unsubstituted, or substituted by one or more substituents. Typically, the group Z will be unsubstituted, or substituted by one or two substituents. Typical substituents on the group Z include halogen, cyano, trifluoromethyl, nitro, C1-6 alkyl, hydroxy, C1-6 alkoxy, oxy, C1-6 alkylsulphonyl, amino, aminocarbonyl, formyl, C2-6 alkoxycarbonyl and -CR8=NORb, wherein Ra and Rb are as defined above. Illustrative substituents on Z include halogen, cyano, trifluoromethyl and C1-6 alkyl.
- For use in medicine, the salts of the compounds of formula I will be pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.
- The term "hydrocarbon" as used herein includes straight-chained, branched and cyclic groups containing up to 18 carbon atoms, suitably up to 15 carbon atoms, and conveniently up to 12 carbon atoms. Suitable hydrocarbon groups include C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C3-7 cyloalkyl(C1-6)alkyl, indanyl, aryl and aryl(C1-6)akyl.
- The expression "a heterocyclic group" as used herein includes cyclic groups containing up to 18 carbon atoms and at least one heteroatom preferably selected from oxygen, nitrogen and sulphur. The heterocyclic group suitably contains up to 15 carbon atoms and conveniently up to 12 carbon atoms, and is preferably linked through carbon. Examples of suitable heterocyclic groups include C3-7 heterocycloalkyl, C3-7 heterocycloalkenyl, C3-7 heterocyloakyl(C1-6)akyl, heteroaryl and heteroaryl(C1-6)alkyl groups.
- Suitable alkyl groups include straight-chained and branched alkyl groups containing from 1 to 6 carbon atoms. Typical examples include methyl and ethyl groups, and straight-chained or branched propyl, butyl and pentyl groups. Particular alkyl groups are methyl, ethyl, n-propyl, isopropyl, isobutyl, tert-butyl and 2,2-dimethylpropyl. Derived expressions such as "C1-6 alkoxy", "C1-6 alkylamino" and "C1-6 alkylsulphonyl" are to be construed accordingly.
- Suitable alkenyl groups include straight-chained and branched alkenyl groups containing from 2 to 6 carbon atoms. Typical examples include vinyl, allyl and dimethylallyl groups.
- Suitable alkynyl groups include straight-chained and branched alkynyl groups containing from 2 to 6 carbon atoms. Typical examples include ethynyl and propargyl groups.
- Suitable cycloalkyl groups include groups containing from 3 to 7 carbon atoms. Particular cycloalkyl groups are cyclopropyl and cyclohexyl.
- Typical examples of C3-7 cyloalkyl(C1-6)alkyl groups include cyclopropylmethyl, cyclohexylmethyl and cyclohexylethyl.
- Particular indanyl groups include indan-1-yl and indan-2-yl.
- Particular aryl groups include phenyl and naphthyl, preferably phenyl.
- Particular aryl(C1-6)alkyl groups include benzyl, phenylethyl, phenylpropyl and naphthylmethyl.
- Suitable heterocycloalkyl groups include azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and thiomorpholinyl groups.
- A typical heterocycloalkenyl group is dihydropyrrolyl.
- Suitable heteroaryl groups include pyridinyl, quinolinyl, isoquinolinyl, pyridazinyl, pyrimidinyl, pyrazinyl, furyl, benzofuryl, dibenzofuryl, thienyl, benzthienyl, pyrrolyl, indolyl, pyrazolyl, indazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, benzimidazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl groups.
- The expression "heteroaryl(C1-6)alkyl" as used herein includes furylmethyl, furylethyl, thienylmethyl, thienylethyl, pyrazolylmethyl, oxazolylmethyl, oxazolylethyl, thiazolylmethyl, thiazolylethyl, imidazolylmethyl, imidazolylethyl, oxadiazolylmethyl, oxadiazolylethyl, thiadiazolylmethyl, thiadiazolylethyl, triazolylmethyl, triazolylethyl, tetrazolylmethyl, tetrazolylethyl, pyridinylmethyl, pyridinylethyl, pyrimidinylmethyl, pyrazinylmethyl, quinolinylmethyl and isoquinolinylmethyl.
- The hydrocarbon and heterocyclic groups may in turn be optionally substituted by one or more groups selected from C1-6 alkyl, adamantyl, phenyl, halogen, C1-6 haloalkyl, C1-6 aminoalkyl, trifluoromethyl, hydroxy, C1-6 alkoxy, aryloxy, keto, C1-3 alkylenedioxy, nitro, cyano, carboxy, C2-6 alkoxycarbonyl, C2-6 alkoxycarbonyl(C1-6)alkyl, C2-6 alkylcarbonyloxy, arylcarbonyloxy, aminocarbonyloxy, C2-6 alkylcarbonyl, arylcarbonyl, C1-6 alkylthio, C1-6 alkylsulphinyl, C1-6 alkylsulphonyl, arylsulphonyl, -NRvRw, -NRvCORw, -NRvCO2Rw, -NRvSO2Rw, -CH2NRvSO2Rw, -NHCONRvRw, -CONRvRw, -SO2NRvRw and -CH2SO2NRvRw, in which Rv and Rw independently represent hydrogen, C1-6 alkyl, aryl or aryl(C1-6)alkyl.
- The term "halogen" as used herein includes fluorine, chlorine, bromine and iodine especially fluoro or chloro.
- Where the compounds according to the invention have at least one asymmetric centre, they may accordingly exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centres, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present invention.
- Suitable values for the X1 substituent include hydrogen, fluoro, chloro, methyl, trifluoromethyl and methoxy; in particular hydrogen or fluoro; and especially fluoro.
- Typical values of X2 include hydrogen and fluoro, especially hydrogen.
- In one favoured embodiment, Z represents an optionally substituted phenyl group, in particular monosubstituted or disubstituted phenyl. In another favoured embodiment, Z represents optionally substituted pyridinyl, especially unsubstituted, monosubstituted or disubstituted pyridin-2-yl, pyridin-3-yl or pyridin-4-yl.
- Examples of suitable substituents on the group Z include fluoro, chloro, cyano, trifluoromethyl, nitro, methyl, hydroxy, methoxy, oxy, metlianesulphonyl, amino, aminocarbonyl, formyl, methoxycarbonyl and -CH=NOH.
- Examples of particular substituents on the group Z include fluoro, cyano, trifluoromethyl and methyl, especially fluoro or cyano.
- Detailed values of Z include cyanophenyl, (cyano)(fluoro)phenyl, (chloro)(cyano)phenyl, nitrophenyl, methoxyphenyl, methanesulphonylphenyl, pyridinyl, fluoro-pyridinyl, difluoro-pyridinyl, (amino)(chloro)pyridinyl, cyano-pyridinyl, methyl-pyridinyl, hydroxy-pyridinyl, methoxy-pyridinyl, oxy-pyridinyl, aminocarbonyl-pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, cyano-thienyl, aminocarbonyl-thienyl, formyl-thienyl, methoxycarbonyl-thienyl, thienyl-CH=NOH, thiazolyl, isothiazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl and methyl-tetrazolyl. Additional values of Z include fluorophenyl, difluorophenyl and trifluoromethyl-phenyl.
- Representative values of Z include fluorophenyl, difluorophenyl, cyanophenyl, (cyano)(fluoro)phenyl, trifluoromethyl-phenyl, pyridinyl, fluoro-pyridinyl, difluoro-pyridinyl, cyano-pyridinyl and triazolyl
- Specific values of Z include (cyano)(fluoro)phenyl, pyridinyl, fluoro-pyridinyl, difluoro-pyridinyl and triazoly
- Typically, R1 represents hydrocarbon, a heterocyclic group, -ORa, -NRaRb or -CO2Ra.
- Suitably, Ra represents methyl, ethyl, n-propyl, isopropyl, allyl, cyclopropyl, cyclohexyl, benzyl or methoxybenzyl. Additionally; Ra may represent tert-butyl.
- Suitably, Rb represents hydrogen or methyl, especially hydrogen.
- Favourably, R1 represents aryl or heteroaryl, either of which groups may be substituted by one or more substituents. Typically, the aryl or heteroaryl group R1 will be unsubstituted, or substituted by one or two substituents. Typical substituents include halogen, C1-6 alkyl, trifluoromethyl, C1-6 alkoxy, cyano and oxo. Suitable substituents include halogen, C1-6 alkyl, trifluoromethyl, C1-6 alkoxy and cyano. Particular substituents include fluoro, chloro, methyl, trifluoromethyl, methoxy and cyano, especially fluoro.
- Illustrative values of R1 include phenyl, halophenyl, dihalophenyl, trihalophenyl, (C1-6alkyl)(halo)phenyl, (trifluoromethyl)(halo)phenyl, C1-6 alkoxyphenyl, (C1-6 alkoxy)(halo)phenyl, cyanophenyl, (cyano)(halo)phenyl, C3-7 heterocycloalkyl (optionally substituted by oxo), C3-7 heterocycloalkenyl, heteroaryl (optionally substituted by one or more halogen atoms, and/or by oxo), C1-6 alkoxy, C2-6 alkenyloxy, aryl(C1-6)alkoxy, triflyloxy, C1-6 alkylthio, C1-6 alkylamino, C2-6 alkenylamino, C3-7 cycloalkylamino, aryl(C1-6)alkylamino (optionally substituted by C1-6 alkoxy) and C2-6 alkoxycarbonyl.
- Typical values of R1 include phenyl, halophenyl, dihalophenyl, (C1-6 alkyl)(halo)phenyl, (trifluoromethyl)(halo)phenyl, C1-6 alkoxyphenyl, (C1-6 alkoxy)(halo)phenyl, cyanophenyl, (cyano)(halo)phenyl, C3-7 heterocycloalkenyl, heteroaryl, (optionally substituted by one or more halogen atoms), C1-6 alkoxy, C2-6 alkenyloxy, aryl(C1-6)alkoxy, triflyloxy, C1-6 alkylthio, C1-6 alkylamino, C2-6 alkenylamino, C3-7 cycloalkylamino, aryl(C1-6)alkylamino (optionally substituted by C1-6 alkoxy) and C2-6 alkoxycarbonyl.
- Suitable values of R1 include phenyl, halophenyl, dihalophenyl, C1-6 alkoxyphenyl, cyanophenyl, (cyano)(halo)phenyl, C3-7 heterocycloalkenyl, heteroaryl (optionally substituted by halo), C1-6 alkoxy, C2-6 alkenyloxy, aryl(C1-6)alkoxy, C1-6 alkylamino, C2-6 alkenylamino, C3-7 cycloalkylamino, aryl(C1-6)alkylamino (optionally substituted by C1-6 alkoxy) and C2-6 alkoxycarbonyl.
- Representative values of R1 include phenyl, fluorophenyl, chlorophenyl, difluorophenyl, (chloro)(fluoro)phenyl, trifluorophenyl, (fluoro)(methyl)phenyl, (fluoro)(triffuoromethyl)phenyl, methoxyphenyl, (fluoro)(methoxy)phenyl, cyanophenyl, (cyano)(fluoro)phenyl, oxo-pyrrolidinyl, dihydropyrrolyl, pyridinyl, fluoro-pyridinyl, difluoro-pyridinyl, oxo-pyridinyl, pyrazinyl, furyl, thienyl, thiazolyl, triazolyl, methoxy, ethoxy, allyloxy, benzyloxy, triflyloxy, ethylthio, tert-butylthio, methylamino, ethylamino, propylamino, isopropylamino, allylamino, cyclopropylamino, cyclohexylamino, benzylamino, methoxybenzyl-amino and ethoxycarbonyl.
- Particular values of R1 include phenyl, fluorophenyl, chlorophenyl, difluorophenyl, (chloro)(fluoro)phenyl, (fluoro)(methyl)phenyl, (fluoro)(trifluoromethyl)phenyl, methoxyphenyl, (fluoro)(methoxy)phenyl, cyanophenyl, (cyano)(fluoro)phenyl, dihydropyrrolyl, pyridinyl, fluoro-pyridinyl, difluoro-pyridinyl, pyrazinyl, furyl, thienyl, thiazolyl, triazolyl, methoxy, ethoxy, allyloxy, benzyloxy, triflyloxy, ethylthio, tert-butylthio, methylamino, ethylamino, propylamino, isopropylamino, allylamino, cyclopropylamino, cyclohexylamino, benzylamino, methoxybenzyl-amino and ethoxycarbonyl.
- Individual values of R1 include phenyl, fluorophenyl, chlorophenyl, difluorophenyl, methoxyphenyl, cyanophenyl, (cyano)(fluoro)phenyl, dihydropyrrolyl, pyridinyl, fluoro-pyridinyl, pyrazinyl, furyl, thienyl, thiazolyl, triazolyl, methoxy, ethoxy, allyloxy, benzyloxy, methylamino, ethylamino, propylamino, isopropylamino, allylamino, cyclopropylamino, cyclohexylamino, benzylamino, methoxybenzyl-amino and ethoxycarbonyl.
- In one embodiment, R1 represents fluorophenyl (especially 2-fluorophenyl).
- In another embodiment, R1 represents fluoro-pyridinyl (especially 3-fluoropyridin-2-yl).
- In a further embodiment, R1 represents difluoro-pyridinyl. In one aspect of this embodiment, R1 represents 3,5-diffuoropyridin-4-yl. In another aspect of this embodiment, R1 represents 3,5-difluoropyridin-2-yl.
- In an additional embodiment, R1 represents trifluorophenyl (especially 2,4,6-trifluorophenyl).
- Suitably, R2 represents hydrogen, methoxycarbonyl or ethoxycarbonyl. In a particular embodiment, R2 represents hydrogen.
- A particular sub-class of compounds according to the invention is represented by the compounds of formula IIA, and N-oxides thereof and pharmaceutically acceptable salts thereof:
Z is as defined above;
X11 represents hydrogen, fluoro, chloro, methyl, trifluoromethyl or methoxy;
X12 represents hydrogen or fluoro; and
R11 represents phenyl, halophenyl, dihalophenyl, trihalophenyl, (C1-6 alkyl)(halo)phenyl, (trifluoromethyl)(halo)phenyl, C1-6 alkoxyphenyl, (C1-6 alkoxy)(halo)phenyl, cyanophenyl, (cyano)(halo)phenyl, C3-7 heterocycloalkyl (optionally substituted by oxo), C3-7 heterocycloalkenyl, heteroaryl (optionally substituted by one or more halogen atoms, and/or by oxo), C1-6 alkoxy, C2-6 alkenyloxy, aryl(C1-6)alkoxy, triflyloxy, C1-6 alkylthio, C1-6 alkylamino, C2-6 alkenylamino, C3-7 cycloalkylamino, aryl(C1-6)alkylamino (optionally substituted by C1-6 alkoxy) or C2-6 alkoxycarbonyl. - The present invention also provides a compound of formula IIA as depicted above, or an N-oxide thereof or a pharmaceutically acceptable salt thereof, wherein
R11 represents phenyl, halophenyl, dihalophenyl, (C1-6 alkyl)-(halo)phenyl, (trifluoromethyl)(halo)phenyl, C1-6 alkoxyphenyl, (C1-6 alkoxy)(halo)phenyl, cyanophenyl, (cyano)(halo)phenyl, C3-7 heterocycloalkenyl, heteroaryl (optionally substituted by one or more halogen atoms), C1-6 alkoxy, C2-6 alkenyloxy, aryl(C1-6)alkoxy, triflyloxy, C1-6 alkylthio, C1-6 alkylamino, C2-6 alkenylamino, C3-7 cycloalkylamino, aryl(C1-6)alkylamino (optionally substituted by C1-6 alkoxy) or C2-6 alkoxycarbonyl; and
Z, X11 and X12 are as defined above. - The present invention further provides a compound of formula IIA as depicted above, or an N-oxide thereof or a pharmaceutically acceptable salt thereof, wherein
R11 represents phenyl, halophenyl, dihalophenyl, C1-6 alkoxyphenyl, cyanophenyl, (cyano)(halo)phenyl, C3-7 heterocycloalkenyl, heteroaryl (optionally substituted by halo), C1-6 alkoxy, C2-6 alkenyloxy, aryl(C1-6)alkoxy, C1-6 alkylamino, C2-6 alkenylamino, C3-7 cycloalkylamino, aryl(C1-6)alkylamino (optionally substituted by C1-6 alkoxy) or C2-6 alkoxycarbonyl; and
Z, X11 and X12 are as defined above. - Suitable values of X11 include hydrogen and fluoro, especially fluoro.
- In a favoured embodiment, X12 represents hydrogen. In another embodiment, X12 represents fluoro.
- Where R11 represents heteroaryl, this group is suitably pyridinyl, pyrazinyl, furyl, thienyl, thiazolyl or triazolyl, especially pyridinyl.
- Representative values of R11 include phenyl, fluorophenyl, chlorophenyl, difluorophenyl, (chloro)(fluoro)phenyl, trifluorophenyl, (fluoro)(methyl)phenyl, (fluoro)(tritluoromethyl)phenyl, methoxyphenyl, (fluoro)(methoxy)phenyl, cyanophenyl, (cyano)(fluoro)phenyl, oxo-pyrrolidinyl, dihydropyrrolyl, pyridinyl, fluoro-pyridinyl, difluoro-pyridinyl, oxo-pyridinyl, pyrazinyl, furyl, thienyl, thiazolyl, triazolyl, methoxy, ethoxy, allyloxy, benzyloxy, triflyloxy, ethylthio, tert-butylthio, methylamino, ethylamino, propylamino, isopropylamino, allylamino, cyclopropylamino, cyclohexylamino, benzylamino, methoxybenzyl-amino and ethoxycarbonyl.
- Particular values of R11 include phenyl, fluorophenyl, chlorophenyl, difluorophenyl, (chloro)(fluoro)phenyl, (fluoro)(methyl)phenyl, (fluoro)(tritluoromethyl)phenyl, methoxyphenyl, (fluoro)(methoxy)phenyl, cyanophenyl, (cyano)(fluoro)phenyl, dihydropyrrolyl, pyridinyl, fluoro-pyridinyl, difluoro-pyridinyl, pyrazinyl, furyl, thienyl, thiazolyl, triazolyl, methoxy, ethoxy, allyloxy, benzyloxy, triflyloxy, ethylthio, tert-butylthio, methylamino, ethylamino, propylamino, isopropylamino, allylamino, cyclopropylamino, cyclohexylamino, benzylamino, methoxybenzyl-amino and ethoxycarbonyl.
- Individual values of R11 include phenyl, fluorophenyl, chlorophenyl, difluorophenyl, methoxyphenyl, cyanophenyl, (cyano)(fluoro)phenyl, dihydropyrrolyl, pyridinyl, fluoro-pyridinyl, pyrazinyl, furyl, thienyl, thiazolyl, triazolyl, methoxy, ethoxy, allyloxy, benzyloxy, methylamino, ethylamino, propylamino, isopropylamino, allylamino, cyclopropylamino, cyclohexylamino, benzylamino, methoxybenzyl-amino and ethoxycarbonyl.
- In one embodiment, R11 represents fluorophenyl (especially 2-fluorophenyl).
- In another embodiment, R11 represents fluoro-pyridinyl (especially 3-fluoropyridin-2-yl).
- In a further embodiment, R11 represents difluoro-pyridinyl. In one aspect of this embodiment, R11 represents 3,5-difluoropyridin-4-yl. In another aspect of this embodiment, R11 represents 3,5-diffuoropyridin-2-yl.
- In an additional embodiment, R11 represents trifluorophenyl (especially 2,4,6-trifluorophenyl).
-
- In another embodiment, R3 is fluoro, in which case the fluorine atom R3 is favourably attached to the phenyl ring at the 4-, 5- or 6-position (relative to the cyano group at position 2).
-
- In one embodiment, R4 is hydrogen.
- In an additional embodiment, R4 is fluoro.
- In another embodiment, R4 is cyano.
- In a further embodiment, R4 is methyl.
-
- Suitably, R5 represents hydrogen.
- In another embodiment, R5 represents fluoro.
- A favoured subset of the compounds of formula IID above is represented by the compounds of formula IIE, and N-oxides thereof and pharmaceutically acceptable salts thereof:
V represents N and W represents CF; or
V represents CF and W represents N; or
V and W both represent CF; and
X12 and R5 are as defined above. - The present invention also provides a compound of formula IIE as depicted above, or an N-oxide thereof or a pharmaceutically acceptable salt thereof, wherein
V represents N and W represents CF; or
V represents CF and W represents N; and
X12 and R5 are as defined above. - In one embodiment, V is N and W is CF.
- In another embodiment, V is CF and W is N.
- In a further embodiment, V and W are both CF.
- Specific compounds within the scope of the present invention include:
- 5-[2-fluoro-3-(pyridin-3-yl)phenyl]3-phenylpyridazine;
- 4,2'-difluoro-5'-(6-phenylpyridazin-4yl)biphenyl-2-carbonitrile;
- 3-phenyl-5-[3-(pyridin-3-yl)phenyl]pyridazine;
- 3-phenyl-5-(3-[1,2,4]triazol-4-ylphenyl)pyridazine;
- 5-[2,4-difluoro-3-(pyridin-4-yl)phenyl]-3-phenylpyridazine;
- 5-[3-(2-methyl-2H-[1,2,4]triazol-3-ylmethoxy)phenyl]-3-phenylpyridazine;
- 6,2'-difluoro-5'-(6-phenylpyridazin-4-yl)biphenyl-2-carbonitrile;
- 5-[4-fluoro-3-(pyridin-4-yl)phenyl]-3-phenylpyridazine;
- 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-phenylpyridazine;
- 3-phenyl-5-[3-(pyridin-2-ylmethoxy)phenyl]pyridazine;
- 5-[4-fluoro-3-(3-fluoropyridin-4-yl)phenyl]-3-phenylpyridazine;
- 5-[2-fluoro-3-(pyridin-4-yl)phenyl]-3-phenylpyridazine;
- 5- [3-(3, 5-difluoropyridin- 2-yl)-4- fluorophenyl]-3-phenylpyridazine;
- 5-[4-fluoro-3-(pyridin-3-yl)phenyl]-3-phenylpyridazine;
- 5,2'-difluoro-5'-(6-phenylpyridazin-4-yl)biphenyl-2-carbonitrile;
- 3,2'-difluoro-5'-(6-phenylpyridazin-4-yl)biphenyl-2-carbonitrile;
- 6,2'-difluoro-5'-[6-(4-fluorophenyl)pyridazin-4-yl]biphenyl-2-carbonitrile;
- 4-fluoro-3'-(6-phenylpyridazin-4-yl)biphenyl-2-carbonitrile;
- 6,2'-difluoro-5'-[6-(thien-2-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;
- 6,2'-difluoro-5'-[6-(4-methoxyphenyl)pyridazin-4-yl]biphenyl-2-carbonitrile;
- 5'-[6-(3-chlorophenyl)pyridazin-4-yl]-6,2'-difluorobiphenyl-2-carbonitrile;
- 6,2'-difluoro-5'- [6-(pyridin-3-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;
- 5'-[6-(4-chlorophenyl)pyridazin-4-yl]-6,2'-difluorobiphenyl-2-carbonitrile;
- 6,2'-difluoro-5'-[6-(pyridin-4-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;
- 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(4-fluorophenyl)-pyridazine;
- 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(2-fluorophenyl)pyridazine;
- 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluorophenyl)-pyridazine;
- 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(pyridin-3-yl)pyridazine;
- 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-fluorophenyl)-pyridazine;
- 3-(2,4-difluorophenyl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-pyridazine;
- 5-[3-(3, 5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-methoxyphenyl)-pyridazine;
- 6,2'-difluoro-5'-[6-(2-fluorophenyl)pyridazin-4-yl]biphenyl-2-carbonitrile;
- 6,2'-difluoro-5'-[6-(3-fluorophenyl)pyridazin-4-yl]biphenyl-2-carbonitrile;
- 5'-[6-(2-chlorophenyl)pyridazin-4-yl]-6,2'-difluorobiphenyl-2-carbonitrile;
- 4-fluoro-3'-[6-(4-methoxyphenyl)pyridazin-4-yl]biphenyl-2-carbonitrile;
- 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(4-methoxyphenyl)-pyridazine;
- 3-(4-chlorophenyl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-pyridazine;
- 2-{5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazin-3-yl}-5-fluorobenzonitrile;
- 3-(4-chlorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine;
- 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(furan-3-yl)pyridazine;
- 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(furan-2-yl)pyridazine;
- 3-(2,3-difluorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-pyridazine;
- 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(thien-3-yl)pyridazine;
- 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(thien-2-yl)pyridazine;
- 3-(2,5-difluorophenyl).5-[4-fluoro-3.(3.fluoropyridin.2-yl)phenyl]-pyridazine;
- 3-(3,4-difluorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-pyridazine;
- 4-{5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazin-3-yl}benzonitrile;
- 3'-(6-ethylaminopyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile;
- 4-fluoro-3'-(6-isopropylaminopyridazin-4-yl)biphenyl-2-carbonitrile;
- 4-fluoro-3'-(6-propylaminopyridazin-4-yl)biphenyl-2-carbonitrile;
- 3'-(6-cyclopropylaminopyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile;
- 3'-(6-allylaminopyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile;
- 3'-(6-benzylaminopyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile;
- 4-fluoro-3'-(6-methylaminopyridazin-4-yl)biphenyl-2-carbonitrile;
- 4-fluoro-3'-(6-methoxypyridazin-4-yl)biphenyl-2-carbonitrile;
- 3'-(6-ethoxypyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile;
- 3'-(6-benzyloxypyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile;
- 5-[4-fluoro-3-(2-methyl-2H-[1,2,4]triazol-3-ylmethoxy)phenyl]-3-phenylpyridazine;
- 5- [4-fluoro-3-(1-methyl-3-trifluoromethyl-1H-pyrazol-4-ylmethoxy)phenyl]-3-phenylpyridazine;
- 5-[4-fluoro-3-(pyridin-4-ylmethoxy)phenyl]-3-phenylpyridazine;
- 5-[4-fluoro-3-(pyridin-3-ylmethoxy)phenyl]-3-phenylpyridazine;
- 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(pyridin-4-yl)pyridazine;
- 5-[4-fluoro-3-(3-ffuoropyridin-2-yl)phenyl]-3-(pyrazin-2-yl)pyridazine;
- 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(thiazol-2-yl)pyridazine;
- 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(pyridin-2-yl)pyridazine;
- 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoropyridin-4-yl)pyridazine;
- 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(1H-[1,2,3]triazol-4-yl)pyridazine;
- 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine-3-carboxylic acid ethyl ester;
- 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluorophenyl)-pyridazine-1-oxide;
- 3-(2,6-difluorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-pyridazine;
- 3-(4-chloro-2-fluorophenyl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine;
- 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluoro-4-trifluoromethylphenyl)pyridazine;
- 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluoro-4-methylphenyl)-pyridazine;
- 3-(3,5-difluoropyridin-2-yl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine;
- trifluoromethanesulfonic acid 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazin-3-yl ester;
- 3-ethylsulfanyl-5-[4-fluoro-3-(3-ffuoropyridin-2-yl)phenyl]pyridazine;
- 3-tert-butylsulfanyl-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine;
- 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-fluoropyridin-4-yl)-pyridazine;
- 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-fluoropyridin-2-yl)-pyridazine;
- 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoropyridin-2-yl)-pyridazine;
- 5-[4-fluoro-3-(3-ffuoropyridin-2-yl)phenyl]-3-(3-tluoropyridin-4-yl)-pyridazine 1-oxide;
- 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoro-1-oxypyridin-4-yl)-pyridazine;
- 5-[2,4-difluoro-3-(3,5-difluoropyridin-2-yl)phenyl]-3-(3,5-difluoropyridin-4-yl)pyridazine;
- 5-[3-(3,5-diffuoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluoro-4-methoxyphenyl)pyridazine;
- 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(2-fluoro-4-methoxyphenyl)-pyridazine;
- 3-(3,5-difluoropyridin-4-yl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine;
- 3-(3,5-difluoropyridin-2-yl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine;
- 3-(3,5-difluoropyridin-4-yl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine;
- 3-(3,5-difluoro-1-oxypyridin-4-yl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine;
- 5'-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]-2'-fluorobiphenyl-2-carbonitrile;
- 5'-[6-(3,5-difluoropyridin-4-yl)pyridazin-4-yl]-2'-fluorobiphenyl-2-carbonitrile;
- 4,2'-difluoro-5'-[6-(3,5-difluoropyridin-4-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;
- 4,2'-difluoro-5'-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;
- 2-{5-[6-(3,5-difluoropyridin-4-yl)pyridazin-4-yl]-2-fluorophenyl}-nicotinonitrile;
- 2-{5-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]-2-fluorophenyl}-nicotinonitrile;
- 2'-fluoro-5'-[6-(2-oxopyrrolidin-1-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;
- 2'-fluoro-5'-[6-(2-oxo-2H-pyridin-1-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;
- 6,2'-difluoro-5'-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;
- 3-(3,5-difluoropyridin-2-yl)-5-(4-fluoro-3-trifluoromethylphenyl)pyridazine;
- 3-(3,5-difluoropyridin-2-yl)-5-(6-fluoro-2'-trifluoromethylbiphenyl-3-yl)-pyridazine;
- 5-(6,2'-difluorobiphenyl-3-yl)-3-(3,5-difluoropyridin-2-yl)pyridazine;
- 3-(3,5-difluoropyridin-2-yl)-5-(6,2',4'-trifluorobiphenyl-3-yl)pyridazine;
- 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2,4,6-trifluorophenyl)-pyridazine;
- The binding affinity (Ki) of the compounds according to the present invention for the α3 subunit of the human GABAA receptor is conveniently as measured in the assay described hereinbelow. The α3 subunit binding affinity (Ki) of the anxiolytic compounds of the invention is ideally 50 nM or less, preferably 10 nM or less, and more preferably 5 nM or less.
- The anxiolytic compounds according to the present invention will ideally elicit at least a 40%, preferably at least a 50%, and more preferably at least a 60%, potentiation of the GABA EC20 response in stably transfected recombinant cell lines expressing the α3 subunit of the human GABAA receptor. Moreover, the compounds of the invention will ideally elicit at most a 30%, preferably at most a 20%, and more preferably at most a 10%, potentiation of the GABA EC20 response in stably transfected recombinant cell lines expressing the α1 subunit of the human GABAA receptor.
- The potentiation of the GABA EC20 response in stably transfected cell lines expressing the α3 and α1 subunits of the human GABAA receptor can conveniently be measured by procedures analogous to the protocol described in Wafford et al., Mol. Pharmacol., 1996, 50, 670-678. The procedure will suitably be carried out utilising cultures of stably transfected eukaryotic cells, typically of stably transfected mouse Ltk-fibroblast cells.
- The compounds according to the present invention may exhibit anxiolytic activity, as may be demonstrated by a positive response in the elevated plus maze and conditioned suppression of drinking tests (cf. Dawson et al., Psychopharmacology, 1995, 121, 109-117). Moreover, the compounds of the invention are likely to be substantially non-sedating, as may be confirmed by an appropriate result obtained from the response sensitivity (chain-pulling) test (cf. Bayley et al., J. Psychopharmacol., 1996, 10, 206-213).
- The compounds according to the present invention may also exhibit anticonvulsant activity. This can be demonstrated by the ability to block pentylenetetrazole-induced seizures in rats and mice, following a protocol analogous to that described by Bristol et al. in J. Pharmacol. Exp. Ther., 1996, 279, 492-501.
- Cognition enhancement can be shown by testing the compounds in the Morris watermaze as reported by McNamara and Skelton, Psychobiology, 1993, 21, 101-108. Further details of relevant methodology are described in
WO 96/25948 - Cognitive disorders for which the compounds of the present invention may be of benefit include delirium, dementia, amnestic disorders, and cognition deficits, including age-related memory deficits, due to traumatic injury, stroke, Parkinson's disease and Down Syndrome. Any of these conditions may be attributable to substance abuse or withdrawal. Examples of dementia include dementia of the Alzheimer's type with early or late onset, and vascular dementia, any of which may be uncomplicated or accompanied by delirium, delusions or depressed mood; and dementia due to HIV disease, head trauma, Parkinson's disease or Creutzfeld-Jakob disease.
- In order to elicit their behavioural effects, the compounds of the invention will ideally be brain-penetrant; in other words, these compounds will be capable of crossing the so-called "blood-brain barrier". Preferably, the compounds of the invention will be capable of exerting their beneficial therapeutic action following administration by the oral route.
- The invention also provides pharmaceutical compositions comprising one or more compounds of this invention in association with a pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. Typical unit dosage forms contain from 1 to 100 mg, for example 1, 2, 5, 10, 25, 50 or 100 mg, of the active ingredient. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
- The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.
- In the treatment of neurological disorders, a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.05 to 100 mg/kg per day, and especially about 0.05 to 5 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day.
- The compounds in accordance with the present invention may be prepared by a process which comprises reacting a compound of formula III with a compound of formula IV:
- The leaving group L1 is typically a halogen atom, e.g. iodo, bromo or chloro.
- The transition metal catalyst of use in the reaction between compounds III and IV is suitably tetrakis(triphenylphosphine)-palladium(0). The reaction is conveniently carried out at an elevated temperature in a solvent such as N,N-dimethylacetamide, 1,4-dioxane or tetrahydrofuran, advantageously in the presence of potassium phosphate, copper(I) iodide, sodium carbonate or cesium carbonate. Alternatively, the transition metal catalyst employed may be dichloro[1,1'-bis(diphenyl-phosphino)ferrocene]palladium(II), in which case the reaction is conveniently effected at an elevated temperature in a solvent such as N,N-dimethylformamide, advantageously in the presence of potassium phosphate.
- In an alternative procedure, the compounds according to the present invention may be prepared by a process which comprises reacting a compound of formula V with a compound of formula VI:
- In another procedure, the compounds according to the present invention may be prepared by a process which comprises reacting a compound of formula VII with a compound of formula VIII:
- In the compounds of formula VI and VII above, the leaving group L1 is typically trifluoromethanesulfonyloxy (triflyloxy); or a halogen atom, e.g. bromo.
- Alternatively, the compounds according to the present invention may be prepared by a process which comprises reacting a compound of formula IX with a compound of formula X:
- Where M1 in the intermediates of formula IV and IX above represents a boronic acid moiety -B(OH)2 or a cyclic ester thereof formed with pinacol or neopentyl glycol, the relevant compound IV or IX may be prepared by reacting bis(pinacolato)diboron or bis(neopentyl glycolato)diborane respectively with a compound of formula VI or VII as defined above; in the presence of a transition metal catalyst.
- The transition metal catalyst of use in the reaction between bis(pinacolato)diboron or bis(neopentyl glycolato)diborane and compound VI or VII is suitably dichloro[1,1'-bis(diphenylphosphino)ferrocene]-palladium(II). The reaction is conveniently carried out at an elevated temperature in a solvent such as 1,4-dioxane, optionally in admixture with dimethylsulfoxide, typically in the presence of 1,1'-bis(diphenylphosphino)ferrocene and/or potassium acetate.
- Where L1 in the intermediates of formula VII above represents triflyloxy, the relevant compound VII may be prepared by reacting the appropriate compound of formula XI:
- The intermediates of formula XI above may suitably be prepared from the appropriate methoxy-substituted precursor of formula XIII:
- Where M1 in the intermediates of formula V above represents -Sn(Alk)3 and Alk is as defined above, this compound may be prepared by reacting a compound of formula III as defined above with a reagent of formula (Alk)3Sn-Hal, in which Hal represents a halogen atom, typically chloro. The reaction is conveniently effected by treating compound III with isopropylmagnesium chloride, typically in a solvent such as tetrahydrofuran, with subsequent addition of the stannyl reagent (Alk)3Sn-Hal.
- In a further procedure, the compounds according to the present invention wherein R1 represents an aryl or heteroaryl moiety may be prepared by a process which comprises reacting a compound of formula XIV with a compound of formula XV:
- In the compounds of formula XV above, the leaving group L1 is typically triflyloxy; or a halogen atom, e.g. chloro.
- The transition metal catalyst of use in the reaction between compounds XIV and XV is suitably tetrakis(triphenylphosphine)-palladium(O), in which case the reaction is conveniently effected at an elevated temperature in a solvent such as tetrahydrofuran, 1,4-dioxane or N,N-dimethylformamide, typically in the presence of sodium carbonate. Alternatively, the transition metal catalyst may suitably be palladium bis(diphenylphosphinylbutane)dichloride, in which case the reaction is conveniently effected at an elevated temperature in a solvent such as tetrahydrofuran, typically in the presence of sodium carbonate.
- In a still further procedure, the compounds according to the present invention wherein R1 represents an aryl or heteroaryl moiety may be prepared by a process which comprises reacting a compound of formula XVI with a compound of formula XVII:
- The intermediates of formula XVII wherein M1 represents -Sn(Alk)3 and Alk represents C1-6 alkyl, e.g. methyl, may be prepared by reacting a compound of formula XV as defined above with a reagent of formula (Alk)3Sn-Sn(Alk)3. The reaction is conveniently effected in the presence of a transition metal catalyst, e.g. tetrakis(triphenylphosphine)palladium(O), with heating in a solvent such as 1,4-dioxane, typically in the presence of lithium chloride.
- In a yet further procedure, the compounds according to the present invention wherein R1 represents 1H-[1,2,3]triazol-4-yl may be prepared by a process which comprises reacting a compound of formula XVIII:
- The reaction is conveniently effected by stirring the reactants in a solvent such as N,N-dimethylformamide.
- The intermediates of formula XVIII may be prepared by reacting a compound of formula XV with TMS-acetylene, in the presence of a transition metal catalyst such as bis(triphenylphosphine)palladium(II) chloride. The reaction is conveniently effected by stirring in a solvent such as tetrahydrofuran, typically in the presence of triethylamine, triphenylphosphine and copper(I) chloride.
- The compounds according to the present invention wherein R1 represents -ORa may be prepared by a process which comprises reacting a compound of formula XV as defined above with a compound of formula Ra-OH, wherein Ra is as defined above. The reaction is conveniently carried out in the presence of a base such as sodium hydride or sodium ethoxide.
- The compounds according to the present invention wherein R1 represents -SRa may be prepared by a process which comprises reacting a compound of formula XV as defined above with a salt of formula RaS-Na+, wherein Ra is as defined above. The reaction is conveniently carried out in the presence of a solvent such as N,N-dimethylformamide.
- The compounds according to the present invention wherein R1 represents -NRaRb may be prepared by a process which comprises reacting a compound of formula XV as defined above with a compound of formula H-NRaRb, wherein Ra and Rb are as defined above. The reaction is conveniently effected by stirring at an elevated temperature, typically in a solvent such as tetrahydrofuran.
- The compounds according to the present invention wherein R1 represents -CO2Ra may be prepared by a process which comprises reacting a compound of formula XV as defined above with carbon monoxide and a compound of formula Ra-OH, wherein Ra is as defined above; in the presence of a transition metal catalyst.
- The transition metal catalyst of use in the foregoing reaction is ideally [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) chloride, in which case the reaction is conveniently carried out at an elevated temperature in a solvent such as N,N-dimethylformamide, optionally in admixture with dichloromethane, typically in the presence of sodium acetate.
- The intermediates of formula XV wherein L1 represents triflyloxy may be prepared by reacting a compound of formula XIX:
- Moreover, the intermediates of formula XV wherein L1 represents chloro may be prepared by treating the requisite compound of formula XIX with phosphorus oxychloride at an elevated temperature.
- The intermediates of formula XIX may be prepared by reacting a compound of formula IV as defined above with a compound of formula XX:
-
-
- The reaction is conveniently accomplished by stirring in a solvent such as diethyl ether.
- The intermediates of formula XXII may be prepared by saponifying a compound of formula I wherein R2 represents C2-6 alkoxycarbonyl, typically by treatment with potassium hydroxide in refluxing aqueous methanol.
-
- The reaction is conveniently effected by stirring in a solvent such as diethyl ether.
- The compounds of formula XI and XIII may therefore be prepared by any of the methods described above for the preparation of the compounds according to the invention.
- Where they are not commercially available, the starting materials of formula III, VIII, X, XIV, XVI, XX, XXI and XXIII may be prepared by methods analogous to those described in the accompanying Examples, or by standard methods well known from the art.
- It will be understood that any compound of formula I initially obtained from any of the above processes may, where appropriate, subsequently be elaborated into a further compound of formula I by techniques known from the art. For example, a compound of formula I initially obtained may be converted into the N-oxide derivative thereof by treatment with m-chloroperbenzoic acid.
- A compound of formula I wherein R1 represents C2-6 alkoxycarbonyl may be reduced with lithium aluminium hydride to the corresponding compound of formula I wherein R1 represents hydroxymethyl. A compound wherein R1 represents formyl may be reacted with a Grignard reagent of formula RaMgBr to afford a compound of formula I wherein R1 represents -CH(OH)Ra. A compound of formula I wherein R1 represents -CH(OH)Ra may be converted into the corresponding compound of formula I wherein R1 represents -CHFRa by treatment with (diethylamino)sulfur trifluoride (DAST). Similarly, a compound wherein R1 represents -CORa may be converted into the corresponding compound of formula I wherein R1 represents -CF2Ra by treatment with DAST. A compound wherein R1 represents -COCH3 may be treated with thioacetamide in the presence of pyridinium tribromide to furnish the corresponding compound of formula I wherein R1 represents 2-methylthiazol-5-yl. Moreover, a compound wherein R1 is formyl may be treated with (p-tolylsulfonyl)methyl isocyanide (TosMIC) in the presence of potassium carbonate to afford the corresponding compound of formula I wherein R1 represents oxazol-5-yl. A compound of formula I wherein R1 represents hydroxymethyl may be treated with carbon tetrabromide and triphenylphosphine to afford the corresponding compound of formula I wherein R1 represents bromomethyl. A compound wherein R1 represents chloro may be converted into the corresponding compound wherein R1 represents 2-oxopyrrolidin-1-yl by treatment with pyrrolidin-2-one in the presence of sodium hydride. A compound wherein R1 represents chloro may be converted into the corresponding compound wherein R1 represents 2-oxopyridin-1-yl by treatment with 2-hydroxypyridine in the presence of copper(I) iodide. A compound of formula I wherein Z is substituted with methoxy may be converted to the corresponding compound wherein Z is substituted with hydroxy by treatment with boron tribromide.
- Where a mixture of products is obtained from any of the processes described above for the preparation of compounds according to the invention, the desired product can be separated therefrom at an appropriate stage by conventional methods such as preparative HPLC; or column chromatography utilising, for example, silica and/or alumina in conjunction with an appropriate solvent system.
- Where the above-described processes for the preparation of the compounds according to the invention give rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The novel compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The novel compounds may, for example, be resolved into their component enantiomers by standard techniques such as preparative HPLC, or the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-1-tartaric acid, followed by fractional crystallization and regeneration of the free base. The novel compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.
- During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 3rd edition, 1999. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.
- The following Examples illustrate the preparation of compounds according to the invention.
- The compounds in accordance with this invention potently inhibit the binding of [3H]-flumazenil to the benzodiazepine binding site of human GABAA receptors containing the α2 and/or α3 and/or α5 subunit stably expressed in Ltk- cells.
-
- Phosphate buffered saline (PBS).
- Assay buffer: 10 mM KH2PO4, 100 mM KCl, pH 7.4 at room temperature.
- [3H]-Flumazenil (18 nM for α1β3γ2 cells; 18 nM for α2β3γ2 cells; 10 nM for α3β3γ2 cells; 10 nM for α5βp3γ2 cells) in assay buffer.
- Flunitrazepam 100 µM in assay buffer.
- Cells resuspended in assay buffer (1 tray to 10 ml).
- Supernatant is removed from cells. PBS (approximately 20 ml) is added. The cells are scraped and placed in a 50 ml centrifuge tube. The procedure is repeated with a further 10 ml of PBS to ensure that most of the cells are removed. The cells are pelleted by centrifuging for 20 min at 3000 rpm in a benchtop centrifuge, and then frozen if desired. The pellets are resuspended in 10 ml of buffer per tray (25 cm x 25 cm) of cells.
- Can be carried out in deep 96-well plates or in tubes. Each tube contains:
- 300 µl of assay buffer.
- 50 µl of [3H]-flumazenil (final concentration for α1β3γ2: 1.8 nM; for α2β3γ2: 1.8 nM; for α3β3γ2: 1.0 nM; for α5β3γ2: 1.0 nM).
- 50 µl of buffer or solvent carrier (e.g. 10% DMSO) if compounds are dissolved in 10% DMSO (total); test compound or flunitrazepam (to determine non-specific binding), 10 µM final concentration.
- 100 µl of cells.
- Assays are incubated for 1 hour at 40°C, then filtered using either a Tomtec or Brandel cell harvester onto GF/B filters followed by 3 x 3 ml washes with ice cold assay buffer. Filters are dried and counted by liquid scintillation counting. Expected values for total binding are 3000-4000 dpm for total counts and less than 200 dpm for non-specific binding if using liquid scintillation counting, or 1500-2000 dpm for total counts and less than 200 dpm for non-specific binding if counting with meltilex solid scintillant. Binding parameters are determined by non-linear least squares regression analysis, from which the inhibition constant Ki can be calculated for each test compound.
- The compounds of the accompanying Examples were tested in the above assay, and all were found to possess a Ki value for displacement of [3H]-flumazenil from the α2 and/or α3 and/or α5 subunit of the human GABAA receptor of 100 nM or less.
- 3-Phenyl-5-(tri-n-butylstannyl)pyridazine (100 mg, 0.22 mmol), bromobenzene (32 µl, 0.27 mmol) and tetrakis(triphenylphosphine)-palladium(0) (5 mg) in tetrahydrofuran, (2 ml) were combined and heated to 150°C for 600 s in a Smith Synthesiser microwave reactor (Personal Chemistry, Uppsala, Sweden). The reaction was diluted with CH2Cl2 (6 ml) and H2O (2 ml) then poured into a PTFE (5 µM) fritted syringe barrel. The organic phase was collected and concentrated to leave 100 mg of crude product. Part of the sample was purified by HPLC with mass triggered fraction collection to give the title compound as a gum (3.1 mg). δH (400 MHz, d6 DMSO) 7.55-7.64 (6H, m), 8.06 (2H, dd, J 8.0, 1.6), 8.28 (2H, dd, J 8.0, 1.6), 8.46-8.47 (1H, d, J 4.0), 9.62 (1H, d, J 4.0); m/z (ES+) 233 (MH+).
- 5-Iodo-3-phenylpyridazine (60 mg, 0.14 mmol), 2-fluoro-3-(pyridin-3-yl)phenylboronic acid (32 mg), tetrakis(triphenylphosphine)palladium(O) (5 mg) and 2N Na2CO3 (1 ml) in tetrahydrofuran (4 ml) were combined and heated to 150°C for 600 s in a Smith Synthesiser microwave reactor. The reaction was diluted with CH2Cl2 (6 ml) and H2O (2 ml) then poured into a PTFE (5 µM) fritted syringe barrel. The organic phase was collected, concentrated and recrystallised from methanol-CH2Cl2-isopropanol to give the title compound as a colourless solid (36 mg). δH (400 MHz, d6 DMSO) 7.55-7.66 (5H, m), 7.77-7.81 (1H, m), 7.91-7.95 (1H, m), 8.08-8.11 (1H, m), 8.25-8.27 (2H, m), 8.48 (1H, m), 8.66 (1H, dd, J 1.6, 4.7), 8.87 (1H, d, J 2.0), 9.53 (1H, t, J 2.2); m/z (ES+) 328 (MH+).
- The compounds in Table 1 were prepared, using the aryl halide, boronic acid or ester starting materials shown, in an analogous manner to that described in Reference Example 1 or Example 1. Samples were purified as described in Example 3 or by recrystallisation from methanol-ethyl acetate, CH2Cl2 or CH2Cl2-isopropanol.
Table 1 EX. NO. STARTING MATERIAL PRODUCT δH (400 MHz, d6 DMSO) m/z (ES+) 2 4,2'-Difluoro-5'-(6-phenyl-pyridazin-4-yl)biphenyl-2-carbonitrile 7:56-7.67 (4H, m), 7.79-7.86 (2H, m), 8.05-8.08 (1H, m), 8.26-8.32 (4H, m), 8.55 (1H, d, J 4), 9.69 (1H, d, J 4) 370 3 3-Phenyl-5-[3-(pyridin-3-yl)-phenyl]-pyridazine 7.48-7.66 (4H, m), 7.73 (1H, t, J 7.8), 7.92-7.94 (1H, m), 8.12-8.13 (1H, m), 8.26-8.33 (3H, m), 8.41 (1H, t, J 1.8), 8.62-8.64 (2H, m), 9.10 (1H, dd, J 2.0, 0.8), 9.75 (1H, d, J 2.3). 310 4 3-Phenyl-5-(3-[1,2,4]triazol-4-ylphenyl)pyrid-azine 7.56-7.66 (4H, m), 7.79 (1H, t, J 7.8), 7.90-7.93 (1H, m), 8.14-8.16 (1H, m), 8.29-8.31 (1H, dd, J 0.8, 0.8), 8.42 (1H, t, J 2.0), 8.61 (1H, d, J 2.0), 9.29 (2H, s), 9.76 (1H, d, J 2.3). 300 5 5-[2,4-Difluoro-3-(pyridin-4-yl)-phenyl]-3-phenyl-pyridazine 7.53-7.64 (6H, m), 8.04-8.10 (1H, m), 8.26 (2H, dd, J 1.8, 8.0), 8.46 (1H, d, J 0.8), 8.77 (2H, dd, J 1.4, 4.5), 9.50 (1H, t, J 1.8). 346 6 5-[3-(2-Methyl-2H-[1,2,4]triazol-3-ylmethoxy)-phenyl]-3-phenyl-pyridazine 3.94 (3H, s), 5.46 (2H, s), 7.25 (1H, dd, J 2.0, 7.6), 7.52-7.62 (4H, m), 7.70 (1H, d, J 8.4), 7.79-7.80 (1H, m), 7.96 (1H, s), 8.28-8.30 (2H, m), 8.48 (1H, d, J 4.0), 9.63 (1H, s). 344 7 6,2'-Difluoro-5'-(6-phenyl-pyridazin-4-yl)-biphenyl-2-carbonitrile 7.54-7.87 (6H, m), 7.98 (1H, dd, J 1.2, 7.4), 8.28-8.31 (2H, m), 8.34-8.38 (1H, m), 8.48 (1H, dd, J 2.5, 6.8), 8.55 (1H, d, J 2.0), 9.69 (1H, d, J 2.0). 312 8 5-[4-Fluoro-3-(pyridin-4-yl)-phenyl]-3-phenyl-pyridazine 7.54-7.68 (3H, m), 7.75-7.77 (2H, m), 8.21-8.25 (1H, m), 8.29-8.36 (3H, m), 8.60 (1H, d, J 2.3), 8.73-8.74 (2H, m), 9.73 (1H, d, J 2.3). 328 9 5-[4-Fluoro-3-(3-fluoro-pyridin-2-yl)-phenyl]-3-phenyl-pyridazine 7.53-7.68 (5H, m), 7.92-7.97 (1H, m), 8.26-8.35 (4H, m), 8.55 (1H, d, J 2.3), 8.63-8.65 (1H, m), 9.67 (1H, d, J 2.3). 346 10 3-Phenyl-5-[3-(pyridin-2-ylmethoxy)-phenyl]-pyridazine 5.33 (2H, s), 7.21-7.24 (1H, m), 7.30-7.40 (1H, m), 7.50-7.67 (6H, m), 7.76 (1H, t, J 2.0), 7.85-7.89 (1H, m), 8.29 (2H, d, J 1.6), 8.48 (1H, d, J 2.3), 8.60-8.65 (1H, m), 9.63 (1H, d, J 2.3). 340 11 5-[4-Fluoro-3-(3-fluoro-pyridin-4-yl)phenyl]-3-phenyl-pyridazine 7.54-7.68 (4H, m), 7.77 (1H, dd, J 5.1, 6.3), 8.29-8.36 (4H, m), 8.57 (1H, d, J 2.3), 8.63 (1H, dd, J 1.2, 5.1), 8.77 (1H, d, J 2.0), 9.71 (1H, d, J 2.3). 346 2 5-[2-Fluoro-3-(pyridin-4-yl)-phenyl]-3-phenyl-pyridazine 7.50-7.71 (6H, m), 7.79-7.83 (1H, m), 7.94-7.99 (1H, m), 8.25-8.27 (2H, m), 8.48 (1H, dd, J 0.8, 1.2), 8.72-8.73 (2H, m), 9.53 (1H, t, J 2.0). 328 13 5-[3-(3,5-Difluoro-pyridin-2-yl)-4-fluorophenyl]-3-phenyl-pyridazine 7.54-7.68 (4H, m), 8.16-8.22 (1H, m), 8.27-8.33 (4H, m), 8.54 (1H, d, J 2.0), 8.75 (1H, d, J 2.3), 9.66 (1H, d, J 2.3). 364 14 5-[4-Fluoro-3-(pyridin-3-yl)-phenyl]-3-phenyl-pyridazine pyridazine 7.54-7.64 (5H, m), 8.13-8.22 (2H, m), 8.30-8.33 (3H, m), 8.60 (1H, d, J 2.5), 8.68 (1H, dd, J 1.6, 4.7), 8.94 (1H, s), 9.73 (1H, d, J 2.5). 328 15 5,2'-Difluoro-5'-(6-phenyl-pyridazin-4-yl)-biphenyl-2-carbonitrile 7.54-7.80 (6H, m), 8.15-8.20 (1H, m), 8.29-8.36 (4H, m), 8.58 (1H, d, J 2.3), 9.72 (1H, d, J 2.3). 370 16 3,2'-Difluoro-5'-(6-phenyl-pyridazin-4-yl)-biphenyl-2-carbonitrile 7.54-7.62 (3H, m), 7.65-7.71 (3H, m), 7.95-8.00 (1H, m), 8.29-8.38 (4H, m), 8.60-8.65 (1H, m), 9.70 (1H, d, J 2.4). 370 - 5-Chloropyridazin-3-one (22 mg, 0.169 mmol), palladium bis-(diphenylphosphinylbutane)dichloride (10 mg), 6,2'-difluoro-5'-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)biphenyl-2-carbonitrile (50 mg, 0.15 mmol) and 2N Na2CO3 (0.3 ml) in toluene (3 ml) were combined and heated to 150°C for 600 s in a Smith Synthesiser microwave reactor. The reaction was diluted with CH2Cl2 (6 ml) and H2O (2 ml) then poured into PTFE (5 µM) fritted syringe barrels. The organic phase was collected, concentrated and recrystallised from isopropanol to give 29 mg (62%) 6,2'-difluoro-5'-(6-oxo-1,6-dihydropyridazin-4-yl)biphenyl-2-carbonitrile.
- The product from above was stirred with triethylamine (20 µl) and N-phenyltrifluoromethanesulfonimide (40 mg) in CH2Cl2 (5 ml) for 18 h. Further reagents were added and stirring continued for an additional 18 h. The reaction was concentrated and purified by column chromatography using 1:1 ethyl acetate/hexanes as eluent. Trifluoromethanesulfonic acid 5-(2'-cyano-6,6'-difluorobiphenyl-3-yl)pyridazin-3-yl ester was obtained as a yellow oil. m/z (ES+) 442.
- The product from above, 4-fluorophenylboronic acid (14 mg), palladium bis(diphenylphosphinylbutane)dichloride (4 mg) and 2N Na2CO3 (0.5 ml) in tetrahydrofuran (2 ml) were combined and heated to 150°C for 600 s in a Smith Synthesiser microwave reactor. The reaction was diluted with CH2Cl2 (6 ml) and H2O (2 ml) then poured into a PTFE (5 µM) fritted syringe barrel. The organic phase was collected, concentrated and purified by column chromatography using 1:1 ethyl acetate/hexanes as eluent. The title compound was recrystallised from isopropanol to give a colourless solid (3.9 mg). δH (400 MHz, d6 DMSO) 7.42 (2H, t, J 8.8), 7.70 (1H, t, J 9.2), 7.76-7.87 (2H, m), 7.98 (1H, dd, J 1.0, 7.6), 8.34-8.39 (3H, m), 8.35-8.40 (1H, m), 8.45-8.48 (1H, m), 9.69 (1H, d, J 2.0); m/z (ES+) 388.
- 4-Fluoro-3'-(6-oxo-1,6-dihydropyridazin-4-yl)biphenyl-2-carbonitrile (0.35g, 1.20 mmol) was suspended in phosphorus oxychloride (10 ml) and heated to 70°C for 1 h. The reaction was cooled to room temperature, poured onto ice water and stirred vigorously for 1 h. The beige solid was collected by filtration and azeotroped with methanol to give 3'-(6-chloropyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile (0.24 g). δH (400 MHz, d6 DMSO) 7.73-7.82 (3H, m), 7.83-7.87 (1H, m), 8.04 (1H, dd, J 2.7, 9.0), 8.12 (1H, dt, J 1.6, 7.8), 8.22 (1H, t, J 1.6), 8.40 (1H, d, J 2.0), 9.77 (1H, d, J 2.0); mlz (ES+) 310.
- The product from above (40 mg, 0.129 mmol), benzeneboronic acid (24 mg, 0.197 mmol), tetrakis(triphenylphosphine)palladium(0) and 2N Na2CO3 (0.5 ml) in tetrahydrofuran (1.5 ml) were combined and heated to 150°C for 10 min in a Smith Synthesiser microwave reactor. The reaction was diluted with CH2Cl2 (6 ml) and NH4Cl (2 ml) then poured into a PTFE (5 µM) fritted syringe barrel. The organic phase was concentrated while loading onto silica. Column chromatography using 40-50% ethyl acetate/hexanes gave the title compound as a white solid (20 mg). δH (400 MHz, d6 DMSO) 7.56-7.62 (3H, m), 7.74-7.80 (3H, m), 7.85-7.89 (1H, m), 8.03-8.06 (1H, m), 8.19 (1H, dt, J 1.8, 7.0), 8.29-8.32 (3H, m), 8.58 (1H, d, J 2.0), 9.71 (1H, d, J 2.0); m/z (ES+) 352.
- The compounds in Table 2 were prepared using the requisite boronic acids in an analogous manner to that described in Examples 17 and 18.
Table 2 EX. NO. PRODUCT δH (400 MHz, d6 DMSO unless specified otherwise) m/z (ES+) 19 6,2'-Difluoro-5'-[6-(thien-2-yl)pyridazin-4-yl]biphenyl-2-carbonitrile 7.27 (1H, dd, J 4.7, 3.9), 7.71 (1H, t, J 9.2), 7.79-7.87 (3H, m), 7.97 (1H, d, J 7.0), 8.13 (1H, d, J 3.1), 8.33-8.35 (1H, m), 8.41 (1H, dd, J 1.2, 4.7), 8.59 (1H, d, J 1.2), 9.58 (1H, d, J 1.2). 376 20 6,2'-Difluoro-5'-[6-(4-methoxyphenyl)-pyridazin-4-yl]biphenyl-2-carbonitrile 3.86 (3H, s), 7.13 (2H, d, J 9.0), 7.69 (1H, t, J 9.2), 7.76-7.87 (2H, m), 7.97 (1H, dd, J 1.4, 7.6), 8.27 (2H, d, J 9.0), 8.32-8.36 (1H, m), 8.45 (1H, dd, J 2.3, 6.7), 8.48 (1H, d, J 2.0), 9.61 (1H, d, J 2.3). 400 21 5'-[6-(3-Chlorophenyl)-pyridazin-4-yl]-6, 2'-difluorobiphenyl-2-carbonitrile 7.62-7.63 (2H, m), 7.69-7.73 (1H, m), 7.76-7.87 (2H, m), 7.96 (1H, d, J 1.6), 8.28-8.31 (1H, m), 8.36-8.40 (2H, m), 8.48 (1H, dd, J 2.5, 6.8), 8.62 (1H, d, J 2.0), 9.73 (1H, d, J 2.3). 404 22 6,2'-Diffuoro-5'-[6-(pyridin-3-yl)pyridazin-4-yl]biphenyl-2-carbonitrile 7.63 (1H, dd, J 4.7, 7.8), 7.70-7.88 (3H, m), 7.98 (1H, dd, J 1.2, 7.4), 8.36-8.40 (1H, m), 8.49 (1H, dd, J 2.3, 6.7), 8.64-8.68 (2H, m), 8.76 (1H, dd, J 1.2, 4.7), 9.45 (1H, d, J 1.6), 9.76 (1H, d, J 2.3). 371 23 5'-[6-(4-Chlorophenyl)-pyridazin-4-yl]-6,2'-difluorobiphenyl-2-carbonitrile 7.56-7.92 (5H, m), 7.98 (1H, dd, J 1.2, 7.4), 8.28-8.50 (4H, m), 8.59 (1H, d, J 2.3), 9.71 (1H, d, J 2.3). 404 24 6,2'-Difluoro-5'-[6-(pyridin-4-yl)pyridazin-4-yl]biphenyl-2-carbonitrile 7.70-7.88 (3H, m), 7.97 (1H, d, J 7.4), 8.28 (2H, dd, J 1.4, 4.5), 8.37-8.41 (1H, m), 8.49 (1H, dd, J 2.5, 6.8), 8.70 (1H, d, J 2.3), 8.81-8.84 (2H, m), 9.80 (1H, d, J 2.3). 371 25 5-[3-(3,5-Diffuoropyridin-2-yl)-4-fluorophenyl]-3-(4-fluorophenyl)pyridazine 7.42 (2H, t, J 9.0), 7.62 (1H, dd, J 8.6, 0.8), 8.17-8.22 (1H, m), 8.27-8.39 (4H, m), 8.55 (1H, d, J 2.3), 8.75 (1H, d, J 2.3), 9.66 (1H, d, J 2.3). 382 26 5-[4-Fluoro-3-(3-fluoro-pyridin-2-yl)phenyl]-3-(2-fluorophenyl)pyridazine 7.41-7.46 (2H, m), 7.53-7.66 (3H, m), 7.91-8.02 (2H, m), 8.20-8.27 (2H, m), 8.37 (1H, t, J 2.0), 8.63-8.64 (1H, m), 9.72 (1H, d, J 2.3). 364 27 5-[3-(3,5-Difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluorophenyl)pyridazine (CDCl3): 7.20-7.24 (1H, m), 7.34-7.41 (3H, m), 7.47-7.53 (1H, m), 7.80-7.84 (1H, m), 7.96 (1H, dd, J 2.3, 6.7), 8.13 (1H, t, J 2.0), 8.19-8.24 (1H, m), 8.52 (1H, d, J 2.3), 9.44 (1H, d, J 2.0). 382 28 5-[4-Fluoro-3-(3-fluoro-pyridin-2-yl)phenyl]-3-(pyridin-3-yl)pyridazine 7.60-7.67 (3H, m), 7.92-7.97 (1H, m), 8.28-8.38 (2H, m), 8.64-8.68 (3H, m), 8.76 (1H, dd, J 1.6, 4.7), 9.46 (1H, d, J 2.0), 9.74 (1H, d, J 2.0). 347 29 5-[3-(3,5-Difluoropyridin-2-yl)-4-ffuorophenyl]-3-(3-fluorophenyl)pyridazine (CDCl3): 7.20-7.25 (1H, m), 7.36-7.43 (2H, m), 7.50-7.55 (1H, m), 7.81-8.00 (5H, m), 8.52 (1H, d, J 2.3), 9.45 (1H, d, J 2.0). 382 30 3-(2,4-Difluorophenyl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-pyridazine (CDCl3): 6.96-7.02 (1H, m), 7.08-7.13 (1H, m), 7.36-7.42 (2H, m), 7.79-7.83 (1H, m), 7.95 (1H, dd, J 2.3, 6.3), 8.09 (1H, t, J 2.2), 8.23-8.29 (1H, m), 8.52 (1H, d, J 2.3), 9.44 (1H, d, J 2.3). 400 31 5-[3-(3,5-Difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-methoxyphenyl)-pyridazine (CDCl3): 3.93 (3H, s), 7.06-7.09 (1H, m), 7.36-7.47 (3H, m), 7.64 (1H, d, J 1.6), 7.79-7.84 (2H, m), 7.97 (1H, dd, J 2.3, 6.7), 8.01 (1H, d, J 2.3), 8.52 (1H, d, J 2.3), 9.43 (1H, d, J 2.3). 394 32 6,2'-Difluoro-5'-[6-(2-fluorophenyl)pyridazin-4-yl]biphenyl-2-carbonitrile 7.41-7.46 (2H, m), 7.59-7.72 (2H, m), 7.75-7.86 (2H, m), 7.94-8.01 (2H, m), 8.27-8.31 (1H, m), 8.39 (2H, q, J 2.1), 9.73 (1H, d, J 2.3). 388 33 6,2'-Difluoro-5'-[6-(3-fluorophenyl)pyridazin-4-yl]biphenyl-2-carbonitrile 7.38-7.43 (1H, m), 7.61-7.88 (4H, m), 7.96-8.05 (1H, m), 8.13-8.19 (2H, m), 8.35-8.40 (1H, m), 8.48 (1H, dd, J 2.5, 6.7), 8.61 (1H, d, J 2.1), 9.73 (1H, d, J 1.8). 388 34 5'-[6-(2-Chlorophenyl)-pyridazin-4-yl]-6,2'-difluorobiphenyl-2-carbonitrile 7.60-7.65 (2H, m), 7.73 (1H, t, J 9.1), 7.78-7.90 (2H, m), 7.98-8.05 (1H, m), 8.33 (2H, dd, J 1.9, 7.5), 8.36-8.41 (1H, m), 8.50 (1H, dd; J 2.3, 6.8), 8.58 (1H, d, J 2.1), 9.72 (1H, d, J 2.1). 35 4-Fluoro-3'-[6-(4-methoxy-phenyl)pyridazin-4-yl]-biphenyl-2-carbonitrile 3.86 (3H, s), 7.14 (2H, d, J 8.8), 7.73-7.79 (3H, m), 7.85-7.89 (1H, m), 8.03-8.06 (1H, m), 8.17 (1H; dt, J 2.0, 7.0), 8.27-8.28 (1H, m), 8.28 (2H, d, J 8.8), 8.51 (1H, d, J 2.3), 9.63 (1H, d, J 2.3). 382 36 5-[3-(3,5-Difluoropyridin-2-yl)-4-fluorophenyl]-3-(4-methoxyphenyl)-pyridazine (CDCl3): 3.90 (3H, s), 7.07 (2H, d, J 9.0), 7.36-7.41 (2H, m), 7.79-7.82 (1H, m), 7.94-7.96 (2H, m), 8.13 (1H, q, J 5.0), 8.12 (1H, d, J 9.0), 8.52 (1H, d, J 2.3), 9.36 (1H, d, J 2.3). 394 37 3-(4-Chlorophenyl)-5-[3- (3,5-difluoropyridin-2-yl)-4-fluorophenyl]-pyridazine 7.62-7.67 (3H, m), 8.17-8.22 (1H, m), 8.27-8.36 (4H, m), 8.58 (1H, d, J 2.0), 8.75 (1H, d, J 2.3), 9.68 (1H, d, J 2.3). 398 38 2-{5-[3-(3,5-Difluoro-pyridin-2-yl)-4-fluoro-phenyl]pyridazin-3-yl}-5-fluorobenzonitrile (CDCl3): 7.36-7.45 (2H, m), 7.50-7.59 (2H, m), 7.84-7.87 (1H, m), 7.99 (1H, dd, J 2.3, 6.3), 8.15 (1H, dd, J 5.5, 8.6), 8.18 (1H, d, J 2.0), 8.51 (1H, d, J 2.3), 9.54 (1H, d, J 2.3). 398 39 3-(4-Chlorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine (CDCl3): 7.38-7.46 (2H, m), 7.52-7.61 (3H, m), 7.80-7.84 (1H, m), 8.00 (1H, d, J 1.6), 8.01 (1H, d, J 2.3), 8.11 (2H, d, J 8.2), 8.60 (1H, d, J 4.3), 9.44 (1H, d, J 2.0). 380 40 5-[4-Fluoro-3-(3-fluoro-pyridin-2-yl)phenyl]-3-(furan-3-yl)pyridazine (CDCl3): 7.08-7.10 (1H, m), 7.36-7.46 (2H, m), 7.55-7.61 (2H, m), 7.76-7.81 (2H, m), 7.98 (1H, dd, J 2.5, 6.5), 8.23 (1H, s), 8.59-8.61 (1H, m), 9.34 (1H, d, J 2.3). 41 5-[4-Fluoro-3-(3-fluoro-pyridin-2-yl)phenyl]-3-(furan-2-yl)pyridazine (CDCl3): 6.63 (1H, q, J 1.8), 7.36-7.45 (3H, m), 7.55-7.60 (1H, m), 7.63-7.64 (1H, m), 7.80-7.84 (1H, m), 8.01 (1H, dd, J 2.5, 6.5), 8.04 (1H, d, J 2.0), 8.59-8.61 (1H, m), 9.34 (1H, d, J 2.3). 336 42 3-(2,3-Difluorophenyl)-5-[4-fluoro-3-(3-fluoro-pyridin-2-yl)phenyl]-pyridazine (CDCl3): 7.24-7.45 (4H, m), 7.52-7.60 (1H, m), 7.80-7.84 (1H, m), 7.94-8.02 (2H, m), 8.13 (1H, t, J 2.2), 8.59-8.61 (1H, m), 9.48 (1H, d, J 2.0). 382 43 5-[4-Fluoro-3-(3-fluoro-pyridin-2-yl)phenyl]-3-(thien-3-yl)pyridazine (CDCl3): 7.37-7.52 (3H, m), 7.55-7.61 (1H, m), 7.79-7.83 (1H, m), 7.86 (1H, dd, J 1.2, 5.1), 7.92 (1H, d, J 2.3), 7.99 (1H, dd, J 2.3, 6.3), 8.14 (1H, q, J 1.4), 8.59-8.61 (1H, m), 9.37 (1H, d, J 2.0). 352 44 5-[4-Fluoro-3-(3-fluoro-pyridin-2-yl)phenyl]-3-(thien-2-yl)pyridazine (CDCl3): 7.19 (1H, dd, J 3.7, 4.9), 7.37-7.46 (2H, m), 7.52-7.61 (2H, m), 7.77-7.82 (2H, m), 7.94 (1H, d, J 2.3), 7.99 (1H, dd, J 2.5, 6.5), 8.59-8.61 (1H, m), 9.33 (1H, d, J 2.0). 352 45 3-(2,5-Difluorophenyl)-5-[4-fluoro-3-(3-fluoro-pyridin-2-yl)phenyl]-pyridazine (CDCl3): 7.14-7.23 (2H, m), 7.37-7.45 (2H, m), 7.52-7.60 (1H, m), 7.80-7.84 (1H, m), 7.96-8.01 (2H, m), 8.16 (1H, t, J 2.2), 8.59-8.61 (1H, m), 9.47 (1H, d, J 2.3). 382 46 3-(3,4-Difluorophenyl)-5-[4-fluoro-3-(3-fluoro-pyridin-2-yl)phenyl]-pyridazine (CDCl3): 7.31-7.46 (3H, m), 7.56-7.61 (1H, m), 7.80-7.84 (1H, m), 7.87-7.91 (1H, m), 7.97-8.09 (3H, m), 8.59-8.61 (1H, m), 9.45 (1H, d, J 2.3). 382 47 4-{5-[4- Fluoro-3-(3-fluoro-pyridin-2-yl)phenyl]-pyridazin-3-yl}-benzonitrile (CDCl3): 7.39-7.47 (2H, m), 7.57-7.61 (1H, m), 7.82-7.87 (3H, m), 8.03 (1H, dd, J 2.5, 6.5), 8.06 (1H, d, J 2.0), 8.28 (1H, s), 8.30 (1H, t, J 1.8), 8.59-8.61 (1H, m), 9.51 (1H, d, J 2.3). 371 - N-[5-(3-Bromophenyl)pyridazin-3-yl]-N-ethylamine (0.1 g, 0.360 mmol), 2-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)-5-fluorobenzonitrile (0.1 g, 0.429 mmol), 2N Na2CO3 (0.5 ml) and tetrakis(triphenylphosphine)-palladium(0) (10 mg) in tetrahydrofuran (1.5 ml) were combined and heated to 150°C for 10 min in a Smith Synthesiser microwave reactor. The reaction was diluted with CH2Cl2 (6 ml) and NH4Cl (2 ml) then poured into a PTFE (5 µM) fritted syringe barrel. The organic phase was concentrated while loading onto silica and purified by column chromatography using 50% ethyl acetate/hexanes followed by ethyl acetate as eluent. The title compound was obtained as a white solid by recrystallising from ethyl acetate (46 mg). δH (400 MHz, d6 DMSO) 1.19 (3H, t, J 7.0), 3.41 (2H, qd, J 5.1, 7.0), 6.88 (1H, t, J 5.1), 7.05 (1H, d, J 1.6), 7.69-7.76 (3H, m), 7.79-7.83 (1H, m), 7.85-7.88 (1H, m), 7.94-7.95 (1H, m), 8.01-8.04 (1H, m), 8.85 (1H, d, J 1.6); m/z (ES+) 319.
- The compounds in Table 3 were prepared in an analogous manner to that described in Example 48.
Table 3 EX. NO. PRODUCT δH (400 MHz, d6 DMSO) m/z (ES+) 49 4-Fluoro-3'-(6-isopropylamino-pyridazin-4-yl)-biphenyl-2-carbonitrile 1.21 (6H, d, J 6.3), 4.14-4.22 (1H, m), 6.74 (1H, d, J 7.8), 7.03 (1H, d, J 2.0), 7.69-7.76 (3H, m), 7.79-7.82 (1H, m), 7.54-7.86 (1H, m), 7.92-7.94 (1H, m), 8.01-8.04 (1H, m), 8.83 (1H, d, J 2.0). 333 50 4-Fluoro-3'-(6-propylaminopyridazin-4-yl)biphenyl-2-carbonitrile 0.95 (3H, d, J 7.2), 1.56-1.67 (2H, m), 3.33-3.37 (2H, m), 6.89-6.93 (1H, m), 7.06-7.07 (1H, m), 7.69-7.88 (5H, m), 7.93-7.95 (1H, m), 8.00-8.04 (1H, m), 8.84-8.85 (1H, m). 333 51 3'-(6-Cyclopropyl-aminopyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile 0.48-0.52 (2H, m), 0.75-0.80 (2H, m), 2.65-2.71 (1H, m), 7.16 (1H, d, J 2.0), 7.35-7.37 (1H, m), 7.70-7.76 (3H, m), 7.80-7.84 (1H, m), 7.88-7.91 (1H, m), 7.98-7.99 (1H, m), 8.01-8.04 (1H, m), 8.92 (1H, d, J 2.0). 331 52 3'-(6-Allylamino-pyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile 4.04-4.07 (2H, m), 5.09-5.13 (1H, m), 5.23-5.28 (1H, m), 5.93-6.02 (1H, m), 7.07-7.09 (1H, m), 7.10 (1H, d, J 1.6), 7.70-7.76 (3H, m), 7.79-7.83 (1H, m), 7.85- 7.88 (1H, m), 7.94-7.95 (1H, m), 8.01-8.04 (1H, m), 8.80 (1H, d, J 1.6). 331 53 3'-(6-Benzylamino-pyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile 4.64 (2H, d, J 5.9), 7.14 (1H, d, J 2.0), 7.22-7.26 (1H, m), 7.31-7.35 (2H, m), 7.38-7.41 (2H, m), 7.45 (1H, t, J 5.2), 7.69-7.76 (3H, m), 7.78-7.82 (1H, m), 7.84-7.87 (1H, m), 7.92-7.94 (1H, m), 8.01-8.04 (1H, m), 8.89 (1H, d, J 2.0). 381 54 4-Fluoro-3'-(6-methylamino-pyridazin-4-yl)-biphenyl-2-carbonitrile 2.92 (3H, d, J 5.1), 6.88 (1H, t, J 5.1), 7.06 (1H, d, J 2.0), 7.69-7.76 (3H, m), 7.79-7.83 (1H, m), 7.86-7.89 (1H, m), 7.95-7.96 (1H, m), 8.00-8.04 (1H, m), 8.87 (1H, d, J 2.0). 305 55 4-Fluoro-3'-(6-methoxypyridazin-4-yl)biphenyl-2-carbonitrile 4.09 (3H, s), 7.61 (1H, d, J 2.0), 7.70-7.77 (3H, m), 7.82-7.86 (1H, m), 8.01-8.04 (2H, m), 8.13 (1H, t, J 1.6), 9.39 (1H, d, J 2.0). 306 56 3'-(6-Ethoxypyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile 1.42 (3H, t, J 7.0), 4.55 (2H, q, J 7.0), 7.59 (1H, d, J 2.0), 7.70-7.77 (3H, m), 7.83-7.86 (1H, m), 8.01-8.04 (2H, m), 8.13-8.14 (1H, m), 9.37 (1H, d, J 2.0). 320 51 3'-(6-Benzyloxy-pyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile 5.59 (2H, s), 7.34-7.44 (3H, m), 7.52-7.55 (2H, m), 7.70 (1H, d, J 2.0), 7.71-7.77 (3H, m), 7.82-7.86 (1H, m), 8.01-8.06 (2H, m), 8.14-8.15 (1H, m), 9.41 (1H, d, J 2.0). 382 - To a solution of 5-(4-fluoro-3-methoxyphenyl)-3-phenylpyridazine (0.6 g, 2.14 mmol) in dichloromethane cooled to -70°C was added boron tribromide (0.81 ml, 8.56 mmol). The reaction mixture was stirred at -70°C for 30 min then allowed to warm to room temperature and stirred for 2 h. The reaction was cooled to 0°C, then 1 ml of methanol was added. The reaction mixture was poured onto a solution of sodium hydrogencarbonate, the precipitate obtained was collected by filtration, washed with water and dried (MgSO4) to give the title compound (400 mg). δH (400 MHz, CDCl3) 7.37 (1H, dd, J 8.4, 11.2), 7.47-7.61 (5H, m), 8.26-8.28 (2H, m), 8.37 (1H, d, J 2.0), 9.50 (1H, d, J.2.0), 10.25-10.40 (1H, br s); m/z (ES+) 267.
- To a solution of 5-(4-fluoro-3-hydroxyphenyl)-3-phenylpyridazine (80 mg, 0.3 mmol) in N,N-dimethylformamide (2 ml) was added sodium hydride (30 mg, 0.6 mmol). After stirring for 10 min (2-methyl-2H-[1,2,4]triazol-3-yl)methanol (50 mg, 0.3 mmol) was added. The reaction mixture was heated at 60°C for 30 min. The reaction mixture was poured into water, and the precipitate obtained was collected by filtration, washed with water and dried (MgSO4). The solid was dissolved in ethyl acetate, adsorbed onto silica and purified by flash chromatography using ethyl acetate/hexane (20:1) as eluent. The appropriate fractions were combined and evaporated under reduced pressure to give the title compound as a solid. δH (400 MHz, CDCl3) 4.05 (3H, s), 5.44 (2H, s), 7.27-7.37 (3H, m), 7.51-7.61 (3H, m), 7.92 (2H, dd, J 11.3, 2.3), 8.16 (2H, dd, J 6.3, 1.6), 9.34 (1H, d, J 1.6); m/z (ES+) 362.
- To a slurry of 5-(4-fluoro-3-hydroxyphenyl)-3-phenylpyridazine (80 mg, 0.3 mmol), (1-methyl-3-tritluoromethyl-1H-pyrazol-4-yl)methanol (81 mg, 0.45 mmol) and triphenylphosphine (118 mg, 0.45 mmol) in tetrahydrofuran (2 ml) was added diisopropyl azodicarboxylate (91 mg, 0.45 mmol). The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was adsorbed onto silica and purified by flash chromatography using a gradient elution of isohexane/ethyl acetate 20:1 to 1:20 as eluent. The appropriate fractions were combined and evaporated under reduced pressure to give a solid which was recrystallized from acetonitrile to give the title compound (45 mg). δH (400 MHz, CDCl3) 3.96 (3H, s), 5.21 (2H, s), 7.27-7.34 (3H, m), 7.51-7.61 (4H, m), 7.91 (1H, d, J 2.3), 8.13-8.14 (2H, m), 9.35 (1H, d, J 2.3); m/z (ES+) 429.
- The compounds in Table 4 were prepared in an analogous manner to that described in Example 58.
Table 4 EX. NO. PRODUCT δH (400 MHz, CDCL3) m/z (ES+) 60 5-[4-Fluoro-3-(pyridin-4-ylmethoxy)phenyl]-3-phenylpyridazine 5.27 (2H, s), 7.28-7.34 (3H, m), 7.42 (2H, d, J 6.3), 7.51-7.59 (3H, m), 7.88 (1H, d, J 2.0), 8.11-8.13 (2H, m), 8.66-8.68 (2H, m), 9.32 (1H, d, J 2.0). 358 61 5-[4-Fluoro-3-(pyridin-3-ylmethoxy)phenyl]-3-phenylpyridazine 5.26 (2H, s), 7.27-7.39 (4H, m), 7.51-7.59 (3H, m), 7.83-7.86 (1H, m), 7.90 (1H, d, J 2.3), 8.12-8.14 (2H, m), 8.63 (1H, d, J 3.9), 8.74 (1H, s), 9.33 (1H, d, J 2.0). 358 - To 3-chloro-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine (0.2 g, 0.66 mmol) in 1,4-dioxane (2 ml) was added 4-tri-n-butylstannylpyridine (0.484 g, 1.31 mmol) followed by tetrakis(triphenylphosphine)palladium(0) (0.076 g, 0.065 mmol) and the mixtures heated at 150°C in a Smith Synthesiser microwave reactor for 12 min. The reaction was diluted with dichloromethane, filtered and evaporated to give a brown solid. The crude product was chromatographed on silica eluting with 1-5% methanol/CH2Cl2. Appropriate fractions were pooled and evaporated to give the title compound as a cream-coloured solid. δH (400 MHz, CDCl3) 7.40-7.47 (2H, m), 7.57-7.61 (1H, m), 7.82-7.86 (1H, m), 8.02-8.09 (4H, m), 8.60-8.62 (1H, m), 8.82-8.84 (2H, m), 9.53 (1H, d, J 2.3); m/z (ES+) 347.
- The compounds in Table 5 were prepared using the requisite heterocyclic stannanes in an analogous manner to that described in Example 62 above.
Table 5 EX. NO. PRODUCT δH (400 MHz, CDCl3) m/z (ES+) 63 5-[4-Fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(pyrazin-2-yl)-pyridazine 7.38-7.46 (2H, m), 7.56-7.61 (1H, m), 7.87-7.92 (1H, m), 8.09 (1H, dd, J 2.3, 6.7), 8.59 (1H, m), 8.68-8.75 (3H, m), 9.55 (1H, d, J 2.3), 9.97 (1H, d, J 1.2). 348 64 5-[4-Fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(thiazol-2-yl)pyridazine 7.37-7.46 (2H, m), 7.55-761 (2H, m), 7.86-7.90 (1H, m), 8.02 (1H, d, J 3.5), 8.08 (1H, dd, J 2.3, 6.7), 8.56 (1H, d, J 2.3), 8.59-8.61 (1H, m), 9.49 (1H, d, J 2.3). 353 65 5-[4-Fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(pyridin-2-yl)pyridazine 7.54-7.67 (3H, m), 7.92-7.97 (1H, m), 8.05-8.09 (1H, m), 8.24 (1H, s), 8.26 (1H, s), 8.61-8.66 (2H, m), 8.78 (1H, d, J 2.3), 8.80 (1H, dd, J 0.8, 4.3), 9.77 (1H, d, J 2.3). 347 66 5-[4-Fluoro-3-(3-fluoropyridin-2-yl)-phenyl]-3-(3-fluoro-pyridin-4-yl)-pyridazine 7.39-7.46 (2H, m), 7.56-7.61 (1H, m), 7.81-7.85 (1H, m), 8.02 (1H, dd, J 2.5, 6.5), 8.23 (2H, s), 8.60 (1H, d, J 4.3), 8.67 (2H, dd, J 0.8, 7.0), 9.54 (1H, d, J 1.6). 365 - A degassed solution of 3-chloro-5-[4-fluoro-3-(3-fluoropyridin-2-yl)-phenyl]pyridazine (200 mg, 0.66 mmol) was formed in tetrahydrofuran (3 ml). (Trimethylsilyl)acetylene (0.14 ml, 0.99 mmol), triethylamine (0.14 ml, 1 mmol), bis(triphenylphosphine)palladium(II) chloride (23 mg, 0.03 mmol) and triphenylphosphine (4 mg, 0.015 mmol) were added in that order and the mixture left to stir for 20 min at room temperature. Copper(I) iodide (2 mg, 0.01 mmol) was added and the mixture stirred at room temperature for 18 h. The solvent was removed and the residue purified by flash column chromatography over silica using 80% ethyl acetate:20% isohexane as eluent to give 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-trimethylsilanylethynylpyridazine as a brown solid (210 mg). δH (400 MHz, CDCl3) 0.31 (9H, s), 7.34-7.45 (2H, m), 7.55-7.60 (1H, m), 7.74-7.78 (1H, m), 7.79 (1H, d, J 2.3), 7.95 (1H, dd, J 2.5, 6.5), 8.58-8.61 (1H, m), 9.39 (1H, d, J 2.3).
- Sodium azide (19 mg, 0.29 mmol) was added to a solution of 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-trimethylsilanylethynylpyridazine (100 mg, 0.26 mmol) in N,N-dimethylformamide (1 ml) and the mixture stirred at room temperature for 16 h, then at 70°C for 4 h. The reaction mixture was allowed to cool to room temperature and was added to water (20 ml) then extracted with ethyl acetate (5 x 10 ml). The combined organics were dried over anhydrous magnesium sulphate, filtered and evaporated to a brown solid. Purification by preparative thin-layer chromatography using 10% methanol:90% dichloromethane as eluent gave the title compound as a tan solid. δH (400 MHz, d6-DMSO) 7.63 (1H, t, J 9.8), 8.16-8.27 (3H, m), 8.49 (1H, d, J 2.3), 8.69 (1H, s), 8.75 (1H, d, J 2.3), 9.66 (1H, d, J 2.0); m/z (ES+) 355.
- A solution of 3-chloro-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-pyridazine (100 mg, 0.33 mmol) was formed in ethanol (10 ml) with N,N-dimethylformamide (2 ml). Sodium acetate (54 mg, 0.66 mmol) was added and the mixture degassed with nitrogen. [1,1'-Bis(diphenylphosphino)-ferrocene]palladium(II) chloride (1:1 complex with dichloromethane) (20 mg, 0.03 mmol) was added and carbon monoxide was bubbled through the solution as the mixture was heated to 90°C and maintained at that temperature for 45 min. The mixture was allowed to cool to room temperature and the solvent was removed. The residue was purified by flash column chromatography over silica, using 80% ethyl acetate:20% isohexane as eluent, then recrystallisation from dichloromethane and isohexane, to give the title compound as a white solid (30 mg). δH (400 MHz, CDCl3) 1.51 (3H, t, J 7.0), 4.59 (2H, q, J 7.2), 7.38-7.46 (2H, m), 7.55-7.61 (1H, m), 7.81-7.86 (1H, m), 8.03 (1H, dd, J 2.5, 6.5), 8.41 (1H, d, J 2.3), 8.59-8.61 (1H, m), 9.62 (1H, d, J 2.3); m/z (ES+) 342.
- To a mixture of 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluorophenyl)pyridazine (50 mg, 0.13 mmol) in CH2Cl2 (2 ml) was added m-chloroperbenzoic acid (50%; 68 mg, 0.20 mmol). The solution was left to stand at room temperature for 22 h. 10% Sodium carbonate solution (1 ml) was added and the solution poured into a PTFE (5 µM) fritted syringe barrel. The organic phase was evaporated and the crude product purified by preparative TLC using a solvent system of 5% methanol in CH2Cl2 to yield a white solid. The solid was further purified by prep HPLC using a solvent system of 30-80% acetonitrile in 0.1% triffuoroacetic acid in water. Appropriate fractions were combined to give the title compound as a white solid (3 mg). δH (400 MHz, CDCl3) 7.19-7.25 (1H, m), 7.29-7.41 (3H, m), 7.47-7.53 (1H, m), 7.73-7.76 (1H; m), 7.78 (1H, t, J 1), 7.91 (1H, dd, J 3, 7), 8.06-8.10 (1H, m), 8.42 (1H, d, J 1), 8.51 (1H, d, J 2); m/z (ES+) 398.
- To a degassed mixture of 3-chloro-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine (0.25 g, 0.82 mmol), hexamethylditin (0.323 g, 0.98 mmol) and lithium chloride (0.1024 g, 2.46 mmol) in 1,4-dioxane (12 ml) was added tetrakis(triphenylphosphine)palladium(0) (0.048 g, 0.041 mmol) and the mixture heated at 100°C for 3 h. Mass spectroscopy showed formation of the intended stannane. 1-Bromo-2,6-difluorobenzene (0.3177 g, 0.187 ml, 1.65 mmol) was added, followed by tetrakis(triphenylphosphine)palladium(0) (0.01 g, 0.0082 mmol), and the mixture heated at 100°C for 6 h. The reaction was cooled to room temperature, filtered and evaporated and the crude product purified by preparative TLC (2 plates; 4% methanol-CH2Cl2). Appropriate bands were collected and processed to give the title compound as an off-white solid which was recrystallised from ethyl acetate/isohexane to give a white solid (42 mg). δH (400 MHz, CDCl3) 7.05-7.12 (2H, m), 7.32-7.59 (4H, m), 7.79-7.85 (2H, m), 8.00 (1H, dd, J 2.5, 6.5), 8.58-8.60 (1H, m), 9.51 (1H,d,J 2.3).
- 3-Chloro-5-[3-(3,5-diffuoropyridin-2-yl)-4-fluorophenyl]pyridazine was coupled to 1-bromo-4-chloro-2-fluorobenzene by the method of Example 108 to give 3-(4-chloro-2-fluorophenyl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine as a white solid: δH (500 MHz, DMSO) 7.54 (1H, m), 7.61-7.65 (1H, m), 7.70 (1H, dd, J 10.0, 0.5), 8.03-8.06 (1H, m), 8.16-8.24 (3H, m), 8.37 (1H, s), 8.74 (1H, s), 9.73 (1H, s); m/z (ES+) 416:418 (3:1).
- 3-Chloro-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine was coupled to 4-bromo-3-fluorobenzotrifluoride by the method of Example 108 to give 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluoro-4-trifluoromethylphenyl)pyridazine as a white solid: δH (500 MHz, DMSO) 7.64 (1H, t, J 9.0), 7.82 (1H, d, J 8.1), 7.95 (1H, d, J 10.5), 8.16-8.26 (3H, m), 8.24 (1H, s), 8.46 (1H, s), 8.74 (1H, s), 9.78 (1H, s); m/z (ES+) 450..
- 3-Chloro-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine was coupled to 4-bromo-3-fluorotoluene by the method of Example 108 to give 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluoro-4-methylphenyl)pyridazine as a white solid: δH (500 MHz, DMSO) 2.42 (3H, s), 7.25 (2H, s), 7.62 (1H, t, J 9.4), 7.93 (1H, m), 8.21 (3H, m), 8.30 (1H, s), 8.74 (1H, d, J 0.5), 9.68 (1H, s); m/z (ES+) 396.
- 3-Chloro-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine was coupled to 2-bromo-3,5-difluoropyridine by the method of Example 108 to give 3-(3,5-difluoropyridin-2-yl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine as a white solid: δH (500 MHz, DMSO) 7.61-7.65 (1H, m), 8.16-8.24 (4H, m), 8.48 (1H, s), 8.75 (2H, d, J 12.2), 9.79 (1H, s); m/z (ES+) 401.
- A suspension of 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-2H pyridazin-3-one (1.29 g, 4.52 mmol) was formed in dry pyridine (20 ml) and cooled to 0°C. Trifluoromethanesulfonic anhydride (1.14 ml, 6.78 mmol) was added dropwise. The mixture was then allowed to warm to room temperature and after 30 min formed a dark red solution. The mixture was poured into water (100 ml) and extracted with dichloromethane (2 x 100 ml). The combined organics were dried over anhydrous magnesium sulphate, filtered and evaporated to a brown solid. Purification by flash column chromatography over silica using 80% dichloromethane:20% ethyl acetate as eluent then recrystallization from dichloromethane using isohexane gave trifluoromethanesulfonic acid 5-[4-fluoro-3-(3-fluoro-pyridin-2-yl)phenyl]pyridazin-3-yl ester as a white solid: δH (400 MHz, CDCl3) 7.40-7.47 (2H, m), 7.56-7.61 (2H, m), 7.78-7.82 (1H, m), 8.00 (1H, dd, J 2 and 6), 8.59-8.61 (1H, m), 9.55 (1H, d, J 2); m/z (ES+) 418.
- A solution of 3-chloro-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-pyridazine (50 mg, 0.16 mmol) was formed in N,N-dimethylformamide (1 ml). Sodium ethanethiolate (28 mg, 0.33 mmol) was added and the mixture stirred at room temperature for 8 h. The reaction was poured into water (20 ml) and extracted with ethyl acetate (2 x 20 ml). The combined organics were dried over anhydrous magnesium sulphate, filtered and evaporated to an orange solid. Purification by preparative thin layer chromatography using ethyl acetate as eluent gave 3-ethylsulfanyl-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine as a white solid (10 mg): δH (400 MHz, CDCl3) 1.47 (3H, t, J 7), 3.43 (2H, q, J 7), 7.35 (1H, t, J 9), 7.40-7.44 (1H, m), 7.48 (1H, d, J 2), 7.54-7.59 (1H, m), 7.70-7.74 (1H, m), 7.92 (1H, dd, J 2 and 6), 8.57-8.60 (1H, m), 9.17 (1H, d, J 2); m/z (ES+) 330.
- 3-Chloro-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine (50 mg, 0.16 mmol) and sodium 2-methyl-2-propanethiolate (37 mg, 0.33 mmol) were reacted as in Example 114 to give 3-tert-butylsulfanyl-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine as a tan solid (13 mg): δH (400 MHz, CDCl3) 1.66 (9H, s), 7.35 (1H, t, J 9), 7.40-7.44 (1H, m), 7.53 (1H, d, J 2), 7.54-7.59 (1H, m), 7.70-7.74 (1H, m), 7.91 (1H, dd, J 3 and 7), 8.58-8.60 (1H, m), 9.21 (1H, d, J 2); m/z (ES+) 302 (M+H-tBu) and 358 (M+H).
- 3-Chloro-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine (100 mg, 0.31 mmol) was coupled to 3-fluoro-4-tributylstannylpyridine (144 mg, 0.37 mmol) using the method in Example 100 to give 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-fluoropyridin-4-yl)pyridazine as a white solid (31 mg): δH (400 MHz, CDCl3) 7.36-7.44 (2H, m), 7.81-7.85 (1H, m), 7.97 (1H, dd, J 2 and 7), 8.21-8.24 (2H, m), 8.52 (1H, d, J 2), 8.64-8.68 (2H, m), 9.53 (1H, d, J 2); m/z (ES+) 383.
- 3-Chloro-5-[3-(3,5-diffuoropyridin-2-yl)-4-fluorophenyl]pyridazine (139 mg, 0.43 mmol) was coupled to 3-fluoro-2-tributylstannylpyridine (200 mg, 0.51 mmol) using the method in Example 100 to give 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-fluoropyridin-2-yl)pyridazine as a white solid (70 mg): δH (500 MHz, CDCl3) 7.36-7.41 (2H, m), 7.46-7.49 (1H, m), 7.66 (1H, t, J 10), 7.85-7.89 (1H, m), 8.01 (1H, dd, J 2 and 7), 8.41 (1H, s), 8.52 (1H, s), 8.61 (1H, d, J 4), 9.53 (1H, s); m/z (ES+) 383.
- 3-Chloro,5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine (216 mg, 0.71 mmol) was coupled to 3-fluoro-2-tributylstannylpyridine (300 mg, 0.78 mmol) using the method in Example 100 to give 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoropyridin-2-yl)pyridazine as a white solid (106 mg): δH (400 MHz, CDCl3) 7.35-7.48 (3H, m), 7.55-7.61 (1H,m), 7.63-7.68 (1H, m), 7.84-7.89 (1H, m), 8.05 (1H, dd, J 3 and 7), 8.41 (1H, d, J 2), 8.58-8.62 (2H, m), 9.54 (1H, d, J 2); m/z (ES+) 365.
- A solution of 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoropyridin-4-yl)pyridazine (100 mg, 0.27 mmol) was formed in dichloromethane (4 ml). A solution of m-chloroperoxybenzoic acid (74 mg, 77%, 0.33 mmol) in dichloromethane (1 ml) was added and the mixture stirred at room temperature overnight. The reaction was quenched into aqueous sodium carbonate (2M, 10 ml) and extracted with dichloromethane (10 ml). The organic phase was washed with aqueous sodium carbonate (1M, 2 x 10 ml) then dried over anhydrous magnesium sulphate, filtered and evaporated to a tan solid. Purification by preparative HPLC gave 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoropyridin-4-yl)pyridazine 1-oxide as a white solid (14 mg): δH (400 MHz, CDCl3) 7.39-7.47 (2H, m), 7.56-7.61 (1H, m), 7.74-7.78 (1H, m), 7.86 (1H, s), 7.96 (1H, dd, J 3 and 7), 8.02 (1H, t, J 5), 8.49 (1H, d, J 1), 8.58-8.68 (3H, m); m/z (ES+) 381.
- A solution of 3-fluoro-4-tributylstannylpyridine (1.0 g, 2.6 mmol) was formed in dichloromethane (5 ml). A solution of m-chloroperoxybenzoic acid (696 mg, 77%, 3.1 mmol) in dichloromethane (3 ml) was added and the mixture stirred at room temperature for 2 h. A further 10 ml of dichloromethane was added and the mixture was washed with saturated aqueous sodium bicarbonate (2 x 20 ml) then dried over anhydrous magnesium sulphate, filtered and evaporated to a yellow oil. Purification by flash column chromatography over silica using ethyl acetate as eluent gave 3-fluoro-4-tributylstannylpyridine 1-oxide as a colourless oil (1.0 g).
- 3-Chloro-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine (80 mg, 0.26 mmol) was coupled to 3-fluoro-4-tributylstannylpyridine 1-oxide (117 mg, 0.29 mmol) using the method in Example 100 to give 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoro-1-oxypyridin-4-yl)pyridazine as a tan solid (31 mg): δH (400 MHz, CDCl3) 7.39-7.47 (2H, m), 7.56-7.62 (1H, m), 7.80-7.84 (1H, m), 8.00 (1H, dd, J 3 and 7), 8.18-8.22 (2H, m), 8.29 (1H, dd, J 2 and 7), 8.39 (1H, dd, J 7 and 9), 8.59-8.61 (1H, m), 9.50 (1H, d, J 2); m/z (ES+) 381.
- A degassed solution of 2-bromo-3,5-difluoropyridine (4.0 g, 20.6 mmol), 2,6-difluorophenylboronic acid (3.9 g, 24.7 mmol) and potassium fluoride (4.3 g, 74.2 mmol) was formed in tetrahydrofuran (40 ml) with water (4 ml). Tris(dibenzylideneacetone)dipalladium(0) (189 mg, 0.21 mmol) followed by tri-tert-butylphosphine (0.8 ml, 0.51M in hexane, 0.42 mmol) were added and the mixture heated to 60°C for 18 h. The solvent was removed and the residue purified by flash column chromatography over silica using dichloromethane 60%:isohexane 40% as eluent to give 3,5-difluoro-2-(2,6-difluorophenyl)pyridine as a white solid (2.2 g): δH (400 MHz, CDCl3) 6.99-7.06 (2H, m), 7.32-7.46 (2H, m), 8.50 (1H, d, J 2.3).
- A solution of 3,5-difluoro-2-(2,6-difluorophenyl)pyridine (1.65 g, 7.26 mmol) was formed in concentrated sulphuric acid (10 ml) and cooled to 0°C. 1,3-Dibromo-5,5-dimethylhydantoin (2.08 g, 7.26 mmol) was added portionwise and the mixture left to stir at 0°C for 2 h. The reaction was quenched into ice (250 ml) and extracted with dichloromethane (2 x 100 ml). The combined organics were dried over anhydrous magnesium sulphate, filtered and evaporated to a yellow oil. Purification by flash column chromatography over silica using 60% isohexane:40% dichloromethane as eluent gave 2-(3-bromo-2,6-difluorophenyl)-3,5-difluoropyridine as a colourless oil (1.95 g): δH (400 MHz, CDCl3) 6.94-6.99 (1H, m), 7.34-7.39 (1H, m), 7.61-7.67 (1H, m), 8.50 (1H, d, J2.3).
- A degassed solution of 2-(3-bromo-2,6-difluorophenyl)-3,5-difluoropyridine (1.95 g, 6.37 mmol), bis(neopentyl glycolato)diborane (1.58 g, 7.01 mmol) and potassium acetate (1.25 g, 12.7 mmol) was formed in 1,4-dioxane (20 ml) with dimethylsulphoxide (0.4 ml). [1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (1:1) (100 mg) was added and the mixture heated at 80°C for 18 h. The solvent was removed and the residue stirred with aqueous sodium hydroxide (2N, 100 ml) for 30 min, then filtered. The filtrate was washed with diethyl ether (2 x 50 ml) then cooled to 0°C before being neutralised with concentrated aqueous hydrochloric acid, then extracted with dichloromethane (2 x 50 ml). The combined organics were dried over anhydrous magnesium sulphate, filtered and evaporated to give 3,5-difluoro-2-[2,6-difluoro-3-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)phenyl]pyridine as a pale yellow oil: δH (400 MHz, CDCl3) 1.03 (6H, s), 3.78 (4H, s), 5.30 (1H, s), 6.97-7.02 (1H, m), 7.29-7.35 (1H, m), 7.80-7.86 (1H, m), 8.48 (1H, d, J 2.3).
- A degassed solution of 3-chloro-5-methoxypyridazine (473 mg, 3.27 mmol), 3,5-difluoro-4-trimethylstannanylpyridine (1.0 g, 3.6 mmol), copper(I) iodide (31 mg, 0.2 mmol) and lithium chloride (416 mg, 9.8 mmol) was formed in 1,4-dioxane (10 ml). Tetrakis(triphenylphosphine)-palladium(0) (100 mg) was added and the mixture heated to 80°C for 16 h. The solvent was removed and the residue was purified by flash column chromatography over silica using 40% isohexane:60% ethyl acetate to give 3-(3,5-diffuoropyridin-4-yl)-5-methoxypyridazine as a pale yellow solid (220 mg): δH (400 MHz, CDCl3) 7.10-7.12 (1H, m), 8.54 (2H, s), 9.02 (1H, d, J 3.1); m/z (ES+) 224.
- A solution of 3-(3,5-difluoropyridin-4-yl)-5-methoxypyridazine (210 mg, 0.94 mmol) was formed in aqueous hydrobromic acid (5 ml, 48%) and refluxed for 2 h. The mixture was cooled in an ice bath and neutralised with aqueous sodium hydroxide to ∼ pH 2 then with solid sodium hydrogencarbonate to neutral. The resulting white precipitate was filtered and dried under vacuum over phosphorus pentoxide to give 6-(3,5-difluoropyridin-4-yl)-1H-pyridazin-4-one as a white solid (110 mg): m/z (ES+) 210.
- A suspension of 6-(3,5-difluoropyridin-4-yl)-1H-pyridazin-4-one (60 mg, 0.28 mmol) was formed in phosphorus oxychloride (0.8 ml) and heated to 80°C for 30 min to give a yellow solution. The phosphorus oxychloride was removed under reduced pressure and the residue diluted with dichloromethane (5 ml) and washed with water (3 x 10 ml) and saturated aqueous sodium hydrogencarbonate (10 ml) then dried over anhydrous magnesium sulphate, filtered and evaporated to give 5-chloro-3-(3,5-difluoropyridin-4-yl)pyridazine as a yellow solid (63 mg): δH (400 MHz, CDCl3) 7.76-7.78 (1H, m), 8.58 (2H, s), 9.31 (1H, d, J 2.3).
- A solution of 5-chloro-3-(3,5-difluoropyridin-4-yl)pyridazine (107 mg, 0.47 mmol) and 3,5-difluoro-2-[2,6-difluoro-3-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)phenyl]pyridine (191 mg, 0.56 mmol) was formed in 1,4-dioxane (4 ml) with aqueous sodium carbonate (1 ml, 2 M). Tetrakis(triphenylphosphine)palladium(0) (50 mg) was added and the mixture heated to 150°C for 700 s in a Smith Synthesiser microwave reactor. The solvent was evaporated and the residue purified by flash column chromatography over silica using dichloromethane:ethyl acetate (1:1). Recrystallization from dichloromethane using isohexane gave 5-[2,4-difluoro-3-(3,5-difluoropyridin-2-yl)phenyl]-3-(3,5-difluoropyridin-4-yl)pyridazine as a white solid (106 mg): δH (400 MHz, CDCl3) 7.25-7.29 (1H, m), 7.38-7.43 (1H, m), 7.66-7.72 (1H, m), 7.90-7.91 (1H, m), 8.54 (1H, d, J 2.3), 8.57 (2H, s), 9.50-9.51 (1H, m); m/z (ES+) 419.
- The compounds in Table 2A were prepared using the requisite boronic acids in an analogous manner to that described in Examples 17 and 18.
Table 2A EX. NO. PRODUCT δH m/z (ES+) 84 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluoro-4-methoxyphenyl)-pyridazine (500 MHz, DMSO): 3.98 (3H, s), 7.42 (1H, s), 7.65 (1H, dd, J 8.7, 9.2), 7.89-7.91 (1H, m), 8.05 (1H, d, J 8.1), 8.17-8.21 (1H, m), 8.29 (1H, s), 8.30 (1H, s), 8.55 (1H, s), 8.75 (1H, s), 9.65 (1H, s). 412 85 5-[4-Fluoro-3-(3-fluoropyridin-2-yl)-phenyl]-3-(2-fluoro-4-methoxyphenyl)-pyridazine (400 MHz, CDCl3): 3.89 (3H, s), 6.77 (1H, dd, J 2.3, 13.3), 6.91 (1H, dd, J 2.3, 8.6), 7.36-7.44 (2H, m), 7.55-7.60 (1H, m), 7.79-7.82 (1H, m), 7.99 (1H, dd, J 2.3, 6.7), 8.10 (1H, t, J 2.0), 8.21 (1H, t, J 9.0), 8.58-8.60 (1H, m), 9.39 (1H, d, J 2.0). 394 - The compounds in Table 5A were prepared using the requisite heterocyclic stannanes in an analogous manner to that described in Example 62.
Table 5A EX. NO. PRODUCT δH m/z (ES+) 86 3-(3,5-Difluoropyridin-4-yl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine (400 MHz, d6DMSO) 7.63-7.68 (2H, m), 7.95 (1H, m), 8.23-8.29 (2H, m), 8.55 (1H, br s), 8.64 (1H, m), 8.81 (2H, s), 9.88 (1H, d, J 1.8). 87 3-(3,5-Difluoropyridin-2-yl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine (400 MHz, d6DMSO) 7.61-7.67 (2H, m), 7.95 (1H, m), 8.22-8.27 (3H, m), 8.49 (1H, d, J 1.8), 8.65 (1H, m), 8.77 (1H, d, J 1.8), 9.81 (1H, d, J 1.9). 383 88 3-(3,5-Difluoropyridin-4-yl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine (400 MHz, CDCl3): 7.36-7.43 (2H, m), 7.80-7.84 (1H, m), 7.89 (1H, t, J 1.0), 7.97 (1H, dd, J 2.3, 6.7), 8.51 (1H, d, J 2.3), 8.57 (2H, s), 9.57 (1H, d, J 2.3). 401 - A solution of 3,5-difluoro-4-trimethylstannanylpyridine (2.0 g, 7.2 mmol) was formed in dichloromethane (10 ml). A solution of 3-chloroperoxybenzoic acid (1.94 g, approx. 8.6 mmol) in dichloromethane (10 ml) was added dropwise and the solution stirred overnight at room temperature. The reaction mixture was poured into aqueous sodium carbonate (2M, 50 ml) and extracted with dichloromethane (2 x 50 ml). The combined organic phases were washed with water (50 ml), dried over anhydrous magnesium sulphate, filtered and evaporated to give crude 3,5-difluoro-4-trimethylstannanylpyridine 1-oxide as a white solid (1.31 g). 3,5-Difluoro-4-trimethylstannanylpyridine 1-oxide (438 mg, 1.5 mmol) was coupled to 3-chloro-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-pyridazine (400 mg, 1.24 mmol) using the method in Example 100 to give 3-(3,5-difluoro-1-oxypyridin-4-yl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine as a white solid (50 mg): δH (400 MHz, CDCl3) 7.36-7.44 (2H, m), 7.79-7.83 (1H, m), 7.86-7.87 (1H, m), 7.95 (1H, dd, J 2.5, 6.5), 8.18-8.21 (2H, m), 8.51 (1H, d, J 2.3), 9.55 (1H, d, J 2.3); m/z (ES+) 417.
- 2'-Fluoro-5'-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)biphenyl-2-carbonitrile (2.50 g, 7.8 mmol) was coupled to 5-chloro-2H-pyridazin-3-one (1.32 g, 10.0 mmol) using the method in Example 33 to give 2'-fluoro-5'-(6-oxo-1,6-dihydropyridazin-4-yl)biphenyl-2-carbonitrile (2.36 g): m/z (ES+) 292.
- 2'-Fluoro-5'-(6-oxo-1,6-dihydropyridazin-4-yl)biphenyl-2-carbonitrile (2.36 g) was reacted with phosphorus oxychloride (50 ml) using the method in Example 34 to give 5'-(6-chloropyridazin-4-yl)-2'-fluoro-biphenyl-2-carbonitrile (1.89 g): m/z (ES+) 310.
- A solution of 3,5-difluoro-4-trimethylsilylpyridine (202 mg, 1.08 mmol) in dry diethyl ether (2 ml) was added dropwise to a pre-formed solution of butyllithium (0.7 ml, 1.6M in hexanes, 1.13 mmol) and dry N,N,N',N'-tetramethylethylenediamine (0.2 ml, 1.35 mmol) in dry diethyl ether (2 ml) at -78°C. The yellow solution was stirred at -78°C for 1 h before dropwise addition of zinc chloride (1.6 ml, 1M in ether, 1.6 mmol). The resulting white precipitate was stirred at -78°C for 30 min then allowed to warm to room temperature over 2 h to give a solution of 3,5-difluoro-4-trimethylsilylpyridin-2-ylzinc chloride. A degassed solution of 5'-(6-chloropyridazin-4-yl)-2'-fluorobiphenyl-2-carbonitrile (200 mg, 0.65 mmol) and tetrakis(triphenylphosphine)palladium(0) (20 mg) in N,N-dimethylformamide (5 ml) was added to this solution and after further degassing the mixture was stirred at 80°C for 18 h. The mixture was poured into water (50 ml) and extracted with dichloromethane (2 x 50 ml). The combined organics were dried over anhydrous magnesium sulphate, filtered and evaporated to a brown oil. Purification by flash column chromatography over silica, using a mixtures of 20% ethyl acetate:80% dichloromethane as eluent, gave 5'-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]-2'-fluorobiphenyl-2-carbonitrile as a tan solid (80 mg): δH (400 MHz, CDCl3) 7.41-7.48 (2H, m), 7.54-7.60 (2H, m), 7.71-7.75 (1H, m), 7.81-7.87 (3H, m), 8.35 (1H, d, J 2.3), 8.52 (1H, d, J 2.3), 9.52 (1H, d, J 2.3); m/z (ES+) 389.
- 5'-(6-Chloropyridazin-4-yl)-2'-fluorobiphenyl-2-carbonitrile (500 mg, 1.6 mmol) was coupled to 3,5-difluoro-4-trimethylstannanylpyridine (538 mg, 1.9 mmol) using the method in Example 100 to give 5'-[6-(3,5-difluoro-pyridin-4-yl)pyridazin-4-yl]-2'-fluorobiphenyl-2-carbonitrile as a tan solid (327 mg): δH (400 MHz, CDCl3) 7.43-7.48 (1H, m), 7.55-7.60 (2H, m), 7.71-7.75 (1H, m), 7.78-7.89 (4H, m), 8.58 (2H, s), 9.57 (1H, d, J 1.6); m/z (ES+) 389.
- 4,2'-Difluoro-5'-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-biphenyl-2-carbonitrile (5 g, 14.7 mmol) was coupled to 5-chloro-2H-pyridazin-3-one (1.59 g, 12.2 mmol) using the method in Example 33 to give 4,2'-difluoro-5'-(6-oxo-1,6-dihydropyridazin-4-yl)biphenyl-2-carbonitrile: m/z (ES+) 310.
- 4,2'-Difluoro-5'-(6-oxo-1,6-dihydropyridazin-4-yl)biphenyl-2-carbonitrile (4 g) was reacted with phosphorus oxychloride (20 ml) using the method in Example 34 to give 5'-(6-chloropyridazin-4-yl)-4,2'-difluoro-biphenyl-2-carbonitrile: m/z (ES+) 328.
- 5'-(6-Chloropyridazin-4-yl)-4,2'-difluorobiphenyl-2-carbonitrile (200 mg, 0.61 mmol) was coupled to 3,5-difluoro-4-trimethylstannanylpyridine (204 mg, 0.73 mmol) using the method in Example 100 to give 4,2'-difluoro-5'-[6-(3,5-difluoropyridin-4-yl)pyridazin-4-yl]biphenyl-2-carbonitrile as a tan solid (75 mg): δH (400 MHz, d6-DMSO) 7.65-7.70 (1H, m), 7.77-7.85 (2H, m), 8.08 (1H, dd, J 2.3, 8.6), 8.22-8.25 (2H, m), 8.54-8.55 (1H, m); 8.82 (2H, s), 9.90 (1H, d, J 2.3); m/z (ES+) 407.
- 5'-(6-Chloropyridazin-4-yl)-4,2'-difluorobiphenyl-2-carbonitrile (300 mg, 0.92 mmol) was coupled to 3,5-difluoro-4-trimethylsilylpyridin-2-yl-zinc chloride (1.55 mmol) using the method in Example 128 to give 4,2'-difluoro-5'-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]biphenyl-2-carbonitrile as a pale pink solid (88 mg): δH (400 MHz, CDCl3) 7.42-7.48 (3H, m), 7.53-7.60 (2H, m), 7.80 (1H, dd, J 2.5, 6.8), 7.83-7.88 (1H, m), 8.34 (1H, d, J 2.0), 8.52 (1H, d, J 2.3), 9.52 (1H, d, J 2.3); m/z (ES+) 407.
- 2-[2-Fluoro-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)phenyl]-nicotinonitrile (4.86 g, 15 mmol) was coupled to 5-chloro-2H pyridazin-3-one (1.78 g, 13.7 mmol) using the method in Example 33 to give 2-[2-fluoro-5-(6-oxo-1,6-dihydropyridazin-4-yl)phenyl]nicotinonitrile (2.4 g): m/z (ES+) 293.
- 2-[2-Fluoro-5-(6-oxo-1,6-dihydropyridazin-4-yl)phenyl]-nicotinonitrile (2.4 g, 8.2 mmol) was reacted with phosphorus oxychloride (20 ml) using the method in Example 34 to give 2-[5-(6-chloropyridazin-4-yl)-2-fluorophenyl]nicotinonitrile (1.39 g): m/z (ES+) 311.
- 2-[5-(6-Chloropyridazin-4-yl)-2-fluorophenyl]nicotinonitrile (300 mg, 0.97 mmol) was coupled to 3,5-difluoro-4-trimethylstannanylpyridine (322 mg, 1.16 mmol) using the method in Example 100 to give 2-{5-[6-(3,5-difluoropyridin-4-yl)pyridazin-4-yl]-2-fluorophenyl)nicotinonitrile as a tan solid (95 mg): δH (400 MHz, CDCl3) 7.46-7.55 (2H, m), 7.86-7.90 (2H, m), 7.97 (1H, dd, J 2.3, 6.7), 8.15 (1H, dd, J 1.6, 7.8), 8.58 (2H, s), 8.96 (1H, dd, J 1.8, 4.9), 9.58 (1H, d, J 2.3); m/z (ES+) 390.
- 2-[5-(6-Chloropyridazin-4-yl)-2-fluorophenyl]nicotinonitrile (300 mg, 0.97 mmol) was coupled to 3,5-difluoro-4-trimethylsilylpyridin-2-ylzinc chloride (1.93 mmol) using the method in Example 128 to give 2-{5-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]-2-fluorophenyl}nicotinonitrile as a white solid (70 mg): δH (400 MHz, CDCl3) 7.43-7.54 (3H, m), 7.90-7.94 (1H, m), 8.01 (1H, dd, J 2.3, 6.7), 8.15 (1H, dd, J 2.0, 7.8), 8.37 (1H, d, J 2.0), 8.52 (1H, d, J 2.3), 8.96 (1H, dd, J 1.8, 4.9), 9.54 (1H, d, J 2.3); mlz (ES+) 390.
- A solution of 2-pyrrolidinone (60 mg, 0.71 mmol) was formed in N,N-dimethylformamide (5 ml) and cooled to 0°C. Sodium hydride (60% in mineral oil, 28 mg, approx. 0.71 mmol) was added and the suspension stirred at room temperature for 30 min. 5'-(6-Chloropyridazin-4-yl)-2'-fluorobiphenyl-2-carbonitrile (200 mg, 0.64 mmol) was added and the mixture heated at 50°C overnight. The reaction was quenched into water (50 ml) and extracted with ethyl acetate (3 x 50 ml). The combined organics were dried over anhydrous magnesium sulphate, filtered and evaporated to a brown oil. Purification by flash column chromatography over silica using a mixture of 20% ethyl acetate:80% dichloromethane as eluent, then recrystallization from dichloromethane using isohexane, gave 2'-fluoro-5'-[6-(2-oxopyrrolidin-1-yl)pyridazin-4-yl]biphenyl-2-carbonitrile as a tan solid (18 mg): δH (400 MHz, CDCl3) 2.21.2.27 (2H, m), 2.72 (2H, t, J 8.1), 4.33 (2H, t, J 7.2), 7.40 (1H, t, J 9.0), 7.53-7.58 (2H, m), 7.69-7.84 (4H, m), 8.94 (1H, d, J 2.0), 9.23 (1H, d, J 2.0); m/z (ES+) 359.
- A mixture of 5'-(6-chloropyridazin-4-yl)-2'-fluorobiphenyl-2-carbonitrile (310 mg, 1.0 mmol), 2-hydroxypyridine (143 mg, 1.5 mmol), copper(I) iodide (19 mg, 0.1 mmol) and potassium carbonate (207 mg, 1.5 mmol) in N,N-dimethylformamide were heated to 150°C overnight. Mixture was allowed to cool to room temperature then aqueous ammonia (50 ml, ~5%) was added and the mixture extracted with ethyl acetate (2 x 50 ml). The combined organics were washed with brine (50 ml) then dried over anhydrous magnesium sulphate, filtered and evaporated to a brown solid. Purification by flash column chromatography over silica using ethyl acetate as eluent, then recrystallization from ethyl acetate, gave 2'-fluoro-5'-(6-(2-oxo-2H-pyridin-1-yl)pyridazin-4-yl]biphenyl-2-carbonitrile: δH (400 MHz, CDCl3) 6.38-6.42 (1H, m), 6.68 (1H, d, J 8.8), 7.40-7.50 (2H, m), 7.54-7.58 (2H, m), 7.70-7.74 (1H, m), 7.78-7.85 (3H, m), 8.12-8.14 (1H, m), 8.45 (1H, d, J 2.0), 9.45 (1H, d, J 2.2); m/z (ES+) 369.
- 6,2'-Diffuoro-5'-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-biphenyl-2-carbonitrile (5.0 g, 14.7 mmol) was coupled to 5-chloro-2H-pyridazin-3-one (1.74 g, 13.3 mmol) using the method in Example 33 to give 6,2'-difluoro-5'-(6-oxo-1,6-dihydropyridazin-4-yl)biphenyl-2-carbonitrile (4.2 g): m/z (ES+) 310.
- 6,2'-Difluoro-5'-(6-oxo-1,6-dihydropyridazin-4-yl)biphenyl-2-carbonitrile (4.2-g, 13.6 mmol) was reacted with phosphorus oxychloride (30 ml) using the method in Example 34 to give 5'-(6-chloropyridazin-4-yl)-6,2'-difluorobiphenyl-2-carbonitrile (2.02 g): mlz (ES+) 328.
- 5'-(6-Chloropyridazin-4-yl)-6,2'-difluorobiphenyl-2-carbonitrile (500 mg, 1.53 mmol) was coupled to 3,5-difluoro-4-trimethylsilylpyridin-2-yl-zinc chloride (3.05 mmol) using the method in Example 128 to give 6,2'-difluoro-5'-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]biphenyl-2-carbonitrile as a tan solid (100 mg): δH (400 MHz, CDCl3) 7.42-7.51 (3H, m), 7.55-7.60 (1H, m), 7.65-7.67 (1H, m), 7.82 (1H, dd, J 2.3, 6.3), 7.87-7.91 (1H, m), 8.34 (1H, d, J 2.0), 8.52 (1H, d, J 2.3), 9.52 (1H, d, J 2.3); m/z (ES+) 407.
- 2-(4-Fluoro-3-trifluoromethylphenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (3.0 g, 10.3 mmol) was coupled to 5-chloro-2H-pyridazin-3-one (1.13 g, 8.62 mmol) using the method in Example 33 to give 5-(4-fluoro-3-trifluoromethylphenyl)-2H pyridazin-3-one (1.93 g): m/z (ES+) 259.
- 5-(4-Fluoro-3-trifluoromethylphenyl)-2H-pyridazin-3-one (1.93 g, 7.48 mmol) was reacted with phosphorus oxychloride (10 ml) using the method in Example 34 to give 3-chloro-5-(4-fluoro-3-trifluoromethyl-phenyl)pyridazine (1.42 g): m/z (ES+) 277.
- 3-Chloro-5-(4-fluoro-3-trifluoromethylphenyl)pyridazine (500 mg, 1.81 mmol) was coupled to 3,5-difluoro-4-trimethylsilylpyridin-2-ylzinc chloride (3.62 mmol) using the method in Example 128 to give 3-(3,5-difluoropyridin-2-yl)-5-(4-fluoro-3-trifluoromethylphenyl)pyridazine as a light brown solid (40 mg): δH (400 MHz, CDCl3) 7.41-7.49 (2H, m), 7.93-8.01 (2H, m), 8.34 (1H, d, J 2.3), 8.54 (1H, d, J 2.3), 9.49 (1H, d, J 2.0); m/z (ES+) 356.
- 4-Fluorophenylboronic acid was coupled to 5-chloro-2H-pyridazin-3-one using the method in Example 33 to give 5-(4-fluorophenyl)-2H-pyridazin-3-one: mlz (ES+) 191.
- 5-(4-Fluorophenyl)-2H-pyridazin-3-one was reacted with phosphorus oxychloride using the method in Example 34 to give 3-chloro-5-(4-fluorophenyl)pyridazine: m/z (ES+) 209.
- 3-Chloro-5-(4-fluorophenyl)pyridazine was coupled to 3,5-difluoro-4-trimethylsilylpyridin-2-ylzinc chloride using the method in Example 128 to give 3-(3,5-difluoropylidin-2-yl)-5-(4-fluorophenyl)pyridazine: m/z (ES+) 288.
- 3-(3,5-Difluoropyridin-2-yl)-5-(4-fluorophenyl)pyridazine (0.314 g, 1.1 mmol) was dissolved in concentrated sulfuric acid (4 ml) and 1,3-dibromo-5,5-dimethylhydantoin (0.311 g, 1.1 mmol) added and the mixtures stirred for 20 min. The reaction mixture was poured onto ice (50 g) and adjusted to pH 11 with sodium hydroxide solution. The aqueous phase was extracted with dichloromethane (2 x 100 ml), and the combined organics dried over MgSO4, filtered and evaporated to give a brown solid. The crude product was chromatographed on silica eluting with ethyl acetate to give 5-(3-bromo-4-fluorophenyl)-3-(3,5-difluoropyridin-2-yl)-pyridazine as a white solid (0.111 g): mlz (ES+) 366:368 (1:1).
- 5-(3-Bromo-4-fluorophenyl)-3-(3,5-difluoropyridin-2-yl)pyridazine was coupled to 2-trifluoromethylphenylboronic acid by the method of Example 34 to give 3,(3,5-difluoropyridin-2-yl)-5-(6-fluoro-2', trifluoromethylbiphenyl-3-yl)pyridazine: δH (500 MHz, CDCl3) 7.35 (1H, t, J 8.7), 7.40-7.47 (2H, m), 7.58 (1H, t, J 7.8), 7.63-7.69 (2H, m), 7.79-7.84 (2H, m), 8.31 (1H, d, J 2.0), 8.51 (1H, d, J 1.5), 9.49 (1H, d, J 1.7); m/z (ES+) 432.
- 5-(3-Bromo-4-fluorophenyl)-3-(3,5-difluoropyridin-2-yl)pyridazine was coupled to 2-fluorophenylboronic acid by the method of Example 34 to give 5-(6,2'-difluorobiphenyl-3-yl)-3-(3,5-difluoropyridin-2-yl)pyridazine: δH (500 MHz, CDCl3) 7.21-7.24 (1H, m), 7.28-7.29 (1H, m), 7.36-7.47 (4H, m), 7.75-7.83 (2H, m), 8.33 (1H, d, J 2.2), 8.52 (1H, d, J 2.2), 9.51 (1H, d, J 2.2); m/z (ES+) 382.
- 5-(3-Bromo-4-fluorophenyl)-3-(3,5-difluoropyridin-2-yl)pyridazine was coupled to 2,4-difluorophenylboronic acid by the method of Example 34 to give 3-(3,5-difluoropyridin-2-yl)-5-(6,2',4'-trifluorobiphenyl-3-yl)-pyridazine: δH (500 MHz, CDCl3) 6.96-7.05 (2H, m), 7.36-7.47 (3H, m), 7.75-7.80 (2H, m), 8.33 (1H, d, J 2.2), 8.52 (1H, d, J 2.2), 9.50 (1H, d, J 2.4); m/z (ES+) 400.
- 3-Chloro-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine was coupled to 1-bromo-2,4,6-trifluorobenzene by the method of Example 108 to give 5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2,4,6-trifluorophenyl)pyridazine: δH (500 MHz, CDCl3) 6.86 (2H, t, J 8.2), 7.34-7.41 (2H, m), 7.81 (2H, t, J 6.4), 7.94 (1H, dd, J 2.2, 6.4), 8.51 (1H, d, J 2.2), 9.47-9.57 (1H, m); m/z (ES+) 418.
- 3-Chloro-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine was prepared via the coupling of 5-chloro-2H-pyridazin-3-one with 3-(3-fluoropyridin-2-yl)-4-fluorophenylboronic acid (prepared according to
WO 0238568 - 3-chloro-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine (0.2g, 0.66 mmol), dry dioxane (5 ml), lithium chloride (0.22g), and Copper (I) iodide (0.020g), were combined and degassed under nitrogen. 3,5-difluoro-2-trimethylstannylpyridine (0.318g; 1.11memol) was added followed by tetrakis(triphenylphosphine)palladium (0) (0.100g), the mixtures thoroughly degassed under a nitrogen atmosphere, then heated at 85°C for 48 h. The reaction was cooled to ambient temperature, diluted with dichloromethane (30 ml), and washed with 25% aqueous ammonium hydroxide (30 ml). The organic phase was separated and evaporated at reduced pressure. The residue was subjected to chromatography on silica gel eluent 5% methanol in dichloromethane. The product was dissolved in warm methanol and applied to an SCX acidic ion exchange resin cartridge. Elution with methanol, followed by a solution of ammonia in methanol (2 molar), afforded clean product, which was recrystallised from hot aqueous methanol. (400 MHz, d6DMSO) 7.61-7.67 (2H, m), 7.95 (1H, m), 8.22-8.27 (3H, m), 8.49 (1H, d, J 1.8), 8.65 (1H, m), 8.77 (1H, d, J 1.8), 9.81 (1H, d, J 1.9); m/z (ES+) 383.
- To a degassed suspension of 5-chloro-2H-pyridazin-3-one (7.1198g; 54.54mmol) and 3-(3,5-difluoro-pyridin-2-yl)-4-fluorophenylboronic acid (prepared according to
WO 0238568 - 5-[3-(3,5-Difluoro-pyridin-2-yl)-4-fluoro-phenyl]-2H-pyridazin-3-one (4.5g; 14.8397mmol) was added to phosphorus oxychloride (80 ml) and the mixture placed in an oil bath pre-heated at 80°C. After stirring for 40 minutes volatiles were removed under vacuum and the brown residue treated with ice (150 g), trituration of the brown oil gave a powdery solid. The mixture was neutralised by the addition of saturated sodium hydrogen carbonate solution. The aqueous phase was extracted with ethyl acetate (3x300 ml), and the combined organics washed with brine (200 ml), dried over MgSO4, filtered and evaporated to give 3-chloro-5-[3-(3,5-difluoro-pyridin-2-yl)-4-fluoro-phenyl]-pyridazine as a beige coloured powdery solid. m/z (ES+) 322:324 (2:1).
- To a degassed suspension of 3-chloro-5-[3-(3,5-difluoro-pyridin-2-yl)-4-fluoro-phenyl]-pyridazine (3.045g; 9.46mmol), 3,5-difluoro-4-trimethylstannylpyridine (3.15g; 11.35mmol), copper (I) iodide (0.09g ; 0.473mmol) and lithium chloride (0.80g ; 18.93mmol) in dioxan (30ml) was added tetrakis(triphenylphosphine)palladium (0) (0.5469g; 0.473mmol) and the mixture heated at 85°C for 18 h. The reaction was cooled to ambient temperature, diluted with ethyl acetate (70 ml) and filtered through a catalyst filter. The filtrate was absorbed onto silica and chromatographed eluting with ethyl acetate:iso-hexane 1:1, to give the product as an off white solid. Recrystallisation from ethyl acetate isohexane gave a white solid (3.13g). (400 MHz, CDCl3): 7.36-7.43 (2H, m), 7.80-7.84 (1H, m), 7.89 (1H, t, J 1.0), 7.97 (1H, dd, J 2.3, 6.7), 8.51 (1H, d, J 2.3), 8.57 (2H, s), 9.57 (1H, d, J 2.3); m/z (ES+) 401.
- To a stirred solution of the 2-bromo-3,5-difluoropyridine (0.5g; 2.57mmol) in ether (5 ml) at -78°C was added n-butyllithium (1.77ml; 2.83mmol; 1.6 M in hexanes) and the mixture stirred for 15 min, zinc chloride (3.866ml; 3.8664mmol; 1M soln in ether) was added and the mixture stirred at -78°C for 15 min then allowed to warm to room temperature. 3-Chloro-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-pyridazine (0.33g; 1.03mmol) was dissolved in DMF (6 ml) and degassed for 15 minutes, tetrakis(triphenylphosphine)palladium (0) (0.148g; 0.128mmol) was added and the mixture added to the aryl zinc prepared above and heated at 80°C for 14 h. The reaction was partitioned between water (50 ml) and DCM (100 ml). The organic phase was separated dried (MgSO4) filtered and evaporated to give a brown oil. The product was chromatographed on silica elututed with DCM to 40% ethyl acetate in DCM to give the product as a white solid (182 mg) δH (500 MHz, DMSO) 7.61-7.65 (1H, m), 8.16-8.24 (4H, m), 8.48 (1H, s), 8.75 (2H, d, J 12.2), 9.79 (1H, s); m/z (ES+) 401.
- To a degassed mixture of 3-chloro-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine (0.3 g, 0.95 mmol), hexamethylditin (0.366 g, 1.1 mmol) and lithium chloride (0.116 g, 2.7 mmol) in 1,4-dioxane (12 ml) was added tetrakis(triphenylphosphine)palladium(0) (0.053 g, 0.04 mmol) and the mixture heated at 100°C for 2 h. Mass spectroscopy showed formation of the intended stannane. 1-Bromo-2,4,6-trifluorobenzene (0.393 g, 1.8 mmol) was added, followed by tetrakis(triphenylphosphine)palladium(0) (0.01 g, 0.0082 mmol), and the mixture heated at 100°C for 18 h. The reaction was cooled to room temperature, filtered and evaporated. The crude product was chromatographed on silica eluted with 30% ethyl acetate in DCM to give a brown solid, which was triturated with diethyl ether and the solid collected by filtration to give the product as an off-white solid (12 mg). δH (500 MHz, CDCl3) 6.86 (2H, t, J 8.2), 7.34-7.41 (2H, m), 7.81 (2H, t, J 6.4), 7.94 (1H, dd, J 2.2, 6.4), 8.51 (1H, d, J 2.2), 9.47-9.57 (1H, m); m/z (ES+) 418.
Claims (13)
- A compound of formula I, or an N-oxide thereof or a pharmaceutically acceptable salt thereof:
X1 represents hydrogen, halogen, C1-6 alkyl, trifluoromethyl or C1-6 alkoxy;
X2 represents hydrogen or halogen;
Z represents an optionally substituted aryl or heteroaryl group;
R1 represents hydrocarbon, a heterocyclic group, -ORa, -OSO2CF3, -SRa, -NRaRb or -CO2Ra;
R2 represents hydrogen or C2-6 alkoxycarbonyl; and
Ra is C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl or aryl(C1-6)alkyl (optionally substituted by C1-6alkoxy);
Rb is hydrogen or C1-6alkyl;
heteroaryl is pyridinyl, quinolinyl, isoquinolinyl, pyridazinyl, pyrimidinyl, pyrazinyl, furyl, benzofuryl, dibenzofuryl, thienyl, benzthienyl, pyrrolyl, indolyl, pyrazolyl, indazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, benzimidazolyl, oxadiazolyl, thiadiazolyl, triazolyl or tetrazolyl. - A compound as claimed in claim 1 represented by formula IIA, and N-oxides thereof and pharmaceutically acceptable salts thereof:
Z is as defined in claim 1;
X11 represents hydrogen, fluoro, chloro, methyl, trifluoromethyl or methoxy;
X12 represents hydrogen or fluoro; and
R11 represents phenyl, halophenyl, dihalophenyl, trihalophenyl, (C1-6 alkyl)(halo)phenyl, (trifluoromethyl)(halo)phenyl, C1-6 alkoxyphenyl, (C1-6 alkoxy)(halo)phenyl, cyanophenyl, (cyano)(halo)phenyl, C3-7 heterocycloalkyl (optionally substituted by oxo), C3-7 heterocycloalkenyl, heteroaryl (optionally substituted by one or more halogen atoms, and/or by oxo), C1-6 alkoxy, C2-6 alkenyloxy, axyl(C1-6)alkoxy, triflyloxy, C1-6 alkylthio, C1-6 alkylamino, C2-6 alkenylamino, C3-7 cycloalkylamino, aryl(C1-6)alkylamino (optionally substituted by C1-6 alkoxy) or C2-6 alkoxycarbonyl. - A compound as claimed in claim 5 represented by formula IIE, and N-oxides thereof and pharmaceutically acceptable salts thereof:
V represents N and W represents CF; or
V represents CF and W represents N; or
V and W both represent CF;
X12 is as defined in claim 2; and
R5 is as defined in claim 5. - A compound according to any preceding claim selected from:5-[2-fluoro-3-(pyridin-3-yl)phenyl]3-phenylpyridazine;4,2'-difluoro-5'-(6-phenylpyridazin-4-yl)biphenyl-2-carbonitrile;3-phenyl-5-[3-(pyridin-3-yl)phenyl]pyridazine;3-phenyl-5-(3-[1,2,4]triazol-4-ylphenyl)pyridazine;5-[2,4-difluoro-3-(pyridin-4-yl)phenyl]-3-phenylpyridazine;5-[3-(2-methyl-2H-[1,2,4]triazol-3-ylmethoxy)phenyl]-3-phenylpyridazine;6,2'-difluoro-5'-(6-phenylpyridazin-4-yl)biphenyl-2-carbonitrile;5-[4-fluoro-3-(pyridin-4-yl)phenyl]-3-phenylpyridazine;5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-phenylpyridazine;3-phenyl-5-[3-(pyridin-2-ylmethoxy)phenyl]pyridazine;5-[4-fluoro-3-(3-fluoropyridin-4-yl)phenyl]-3-phenylpyridazine;5-[2-fluoro-3-(pyridin-4-yl)phenyl]-3-phenylpyridazine;5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-phenylpyridazine;5-[4-fluoro-3-(pyridin-3-yl)phenyl]-3-phenylpyridazine;5,2'-difluoro-5'-(6-phenylpyridazin-4-yl)biphenyl-2-carbonitrile;3,2'-difluoro-5'-(6-phenylpyridazin-4-yl)biphenyl-2-carbonitrile;6,2'-difluoro-5'-[6-(4-fluorophenyl)pyridazin-4-yl]biphenyl-2-carbonitrile;4-fluoro-3'-(6-phenylpyridazin-4-yl)biphenyl-2-carbonitrile;6,2'-difluoro-5'-[6-(thien-2-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;6,2'-difluoro-5'-[6-(4-methoxyphenyl)pyridazin-4-yl]biphenyl-2-carbonitrile;5'-[6-(3-chlorophenyl)pyridazin-4-yl]-6,2'-difluorobiphenyl-2-carbonitrile;6,2'-difluoro-5'-[6-(pyridin-3-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;5'-[6-(4-chlorophenyl)pyridazin-4-yl]-6,2'-difluorobiphenyl-2-carbonitrile;6,2'-difluoro-5'-[6-(pyridin-4-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(4-fluorophenyl)-pyridazine;5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(2-fluorophenyl)pyridazine;5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluorophenyl)-pyridazine;5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(pyridin-3-yl)pyridazine;5-[3-(3,5-difluoropyridin-2-yl),4-fluorophenyl]-3-(3-fluorophenyl)-pyridazine;3-(2,4-difluorophenyl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-pyridazine;5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-methoxyphenyl)-pyridazine;6,2'-difluoro-5'-[6-(2-fluorophenyl)pyridazin-4-yl]biphenyl-2-carbonitrile;6,2'-difluoro-5'-[6-(3-fluorophenyl)pyridazin-4-yl]biphenyl-2-carbonitrile;5'-[6-(2-chlorophenyl)pyridazin-4-yl]-6,2'-difluorobiphenyl-2-carbonitrile;4-fluoro-3'-[6-(4-methoxyphenyl)pyridazin-4-yl]biphenyl-2-carbonitrile;5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(4-methoxyphenyl)-pyridazine;3-(4-chlorophenyl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-pyridazine;2-{5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazin-3-yl}-5-fluorobenzonitrile;3-(4-chlorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine;5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(furan-3-yl)pyridazine;5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(furan-2-yl)pyridazine;3-(2,3-difluorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-pyridazine;5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(thien-3-yl)pyridazine;5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(thien-2-yl)pyridazine;3-(2,5-difluorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-pyridazine;3-(3,4-difluorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-pyridazine;4-{5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazin-3-yl}benzonitrile;3'-(6-ethylaminopyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile;4-fluoro-3'-(6-isopropylaminopyridazin-4-yl)biphenyl-2-carbonitrile;4-fluoro-3'-(6-propylaminopyridazin-4-yl)biphenyl-2-carbonitrile;3'-(6-cyclopropylaminopyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile;3'-(6-allylaminopyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile;3'-(6-benzylaminopyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile;4-fluoro-3'-(6-methylaminopyridazin-4-yl)biphenyl-2-carbonitrile;4-fluoro-3'-(6-methoxypyridazin-4-yl)biphenyl-2-carbonitrile;3'-(6-ethoxypyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile;3'-(6-benzyloxypyridazin-4-yl)-4-fluorobiphenyl-2-carbonitrile;5-[4-fluoro-3-(2-methyl-2H-[1,2,4]triazol-3-ylmethoxy)phenyl]-3-phenylpyridazine;5-[4-fluoro-3-(1-methyl-3-trifluoromethyl-1H-pyrazol-4-ylmethoxy)phenyl]-3-phenylpyridazine;5-[4-fluoro-3-(pyridin-4-ylmethoxy)phenyl]-3-phenylpyridazine;5-[4-fluoro-3-(pyridin-3-ylmethoxy)phenyl]-3-phenylpyridazine;5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(pyridin-4-yl)pyridazine;5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(pyrazin-2-yl)pyridazine;5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(thiazol-2-yl)pyridazine;5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(pyridin-2-yl)pyridazine;5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoropyridin-4-yl)pyridazine;5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(1H-[1,2,3]triazol-4-yl)pyridazine;5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine-3-carboxylic acid ethyl ester;5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluorophenyl)-pyridazine-1-oxide;3-(2,6-difluorophenyl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-pyridazine;and pharmaceutically acceptable salts thereof.
- A compound according to any one of claims 1 to 6 selected from:3-(4-chloro-2-fluorophenyl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine;5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluoro-4-trifluoromethylphenyl)pyridazine;5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluoro-4-methylphenyl)-pyridazines;3-(3,5-difluoropyridin-2-yl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine;trifluoromethanesulfonic acid 5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazin-3-yl ester;3-ethylsulfanyl-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine;3-tert-butylsulfanyl-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine;5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-fluoropyridin-4-yl)-pyridazine;5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(3-fluoropyridin-2-yl)-pyridazine;5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoropyridin-2-yl)-pyridazine;5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoropyridin-4-yl)-pyridazine 1-oxide;5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(3-fluoro-1-oxypyridin-4-yl)-pyridazine;5-[2,4-difluoro-3-(3,5-difluoropyridin-2-yl)phenyl]-3-(3,5-difluoropyridin-4-yl)pyridazine;5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2-fluoro-4-methoxyphenyl)pyridazine;5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]-3-(2-fluoro-4-methoxyphenyl)-pyridazine;3-(3,5-difluoropyridin-4-yl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine;3-(3,5-difluoropyridin-2-yl)-5-[4-fluoro-3-(3-fluoropyridin-2-yl)phenyl]pyridazine;3-(3,5-difluoropyridin-4-yl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine;and pharmaceutically acceptable salts thereof.
- A compound according to any one of claims 1 to 6 selected from:3-(3,5-difluoro-1-oxypyridin-4-yl)-5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]pyridazine;5'-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]-2'-fluorobiphenyl-2-carbonitrile;5'-[6-(3,5-difluoropyridin-4-yl)pyridazin-4-yl]-2'-fluorobiphenyl-2-carbonitrile;4,2'-difluoro-5'-[6-(3,5-difluoropyridin-4-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;4,2'-difluoro-5'-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;2-{5-[6-(3,5-difluoropyridin-4-yl)pyridazin-4-yl]-2-fluorophenyl}-nicotinonitrile;2-{5-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]-2-fluorophenyl}-nicotinonitrile;2'-fluoro-5'-[6-(2-oxopyrrolidin-1-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;2'-fluoro-5'-[6-(2-oxo-2H-pyridin-1-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;6,2'-difluoro-5'-[6-(3,5-difluoropyridin-2-yl)pyridazin-4-yl]biphenyl-2-carbonitrile;3-(3,5-difluoropyridin-2-yl)-5-(4-fluoro-3-trifluoromethylphenyl)pyridazine;3-(3,5-difluoropyridin-2-yl)-5-(6-fluoro-2'-trifluoromethylbiphenyl-3-yl)-pyridazine;5-(6,2'-difluorobiphenyl-3-yl)-3-(3,5-difluoropyridin-2-yl)pyridazine;3-(3,5-difluoropyridin-2-yl)-5-(6,2',4'-trifluorobiphenyl-3-yl)pyridazine;5-[3-(3,5-difluoropyridin-2-yl)-4-fluorophenyl]-3-(2,4,6-trifluorophenyl)-pyridazine;and pharmaceutically acceptable salts thereof.
- A pharmaceutical composition comprising a compound of formula I according to any preceding claim, or an N-oxide thereof or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.
- The use of a compound as defined in any one of claims 1 to 9, or an N-oxide thereof or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment and/or prevention of neurological disorders.
- A process for the preparation of a compound as claimed in claim 1, which comprises:(A) reacting a compound of formula III with a compound of formula IV:(B) reacting a compound of formula V with a compound of formula VI:(C) reacting a compound of formula VII with a compound of formula VIII:(D) reacting a compound of formula IX with a compound of formula X:(E) reacting a compound of formula XI with a compound of formula XII:(F) reacting a compound of formula XIV with a compound of formula XV:(G) reacting a compound of formula XVI with a compound of formula XVII:(H) reacting a compound of formula XVIII:(J) reacting a compound of formula XV as defined above with a compound of formula Ra-OH, wherein Ra is as defined in claim 1; or(K) reacting a compound of formula XV as defined above with a salt of formula RaS-Na+, wherein Ra is as defined in claim 1; or(L) reacting a compound of formula XV as defined above with a compound of formula H-NRaRb, wherein Ra and Rb are as defined in claim 1; or(M) reacting a compound of formula XV as defined above with carbon dioxide and a compound of formula Ra-OH, wherein Ra is as defined in claim 1; in the presence of a transition metal catalyst; or(N) reacting a compound of formula VII above wherein L1 represents a halogen atom with zinc cyanide; in the presence of a transition metal catalyst; or(P) reacting a compound of formula XXII:(Q) reacting a compound of formula XXIII:(R) subsequently, if required, converting a compound of formula I initially obtained into a further compound of formula I by standard methods.
- A compound as defined in any one of claims 1 to 9, or an N-oxide thereof or pharmaceutically acceptable salt thereof, for use in a method of treatment of the human body by therapy.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0218874 | 2002-08-13 | ||
GB0218874A GB0218874D0 (en) | 2002-08-13 | 2002-08-13 | Therapeutic agents |
GB0229591A GB0229591D0 (en) | 2002-12-19 | 2002-12-19 | Therapeutic agents |
GB0229591 | 2002-12-19 | ||
PCT/GB2003/003376 WO2004014865A1 (en) | 2002-08-13 | 2003-08-04 | Phenylpyridazine derivatives as ligands for gaba receptors |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1532120A1 EP1532120A1 (en) | 2005-05-25 |
EP1532120B1 true EP1532120B1 (en) | 2009-01-14 |
Family
ID=31716927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03784243A Expired - Lifetime EP1532120B1 (en) | 2002-08-13 | 2003-08-04 | Phenylpyridazine derivatives as ligands for gaba receptors |
Country Status (8)
Country | Link |
---|---|
US (1) | US20060235021A1 (en) |
EP (1) | EP1532120B1 (en) |
JP (1) | JP2006507237A (en) |
AT (1) | ATE420867T1 (en) |
AU (1) | AU2003246979B8 (en) |
CA (1) | CA2495285A1 (en) |
DE (1) | DE60325865D1 (en) |
WO (1) | WO2004014865A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1799659A1 (en) * | 2004-10-13 | 2007-06-27 | PTC Therapeutics, Inc. | Compounds for nonsense suppression, and methods for their use |
AU2006322707B2 (en) * | 2005-12-07 | 2011-09-15 | Sumitomo Chemical Company, Limited | Pyridazine compound and use thereof |
US7465795B2 (en) | 2005-12-20 | 2008-12-16 | Astrazeneca Ab | Compounds and uses thereof |
ES2391472T3 (en) | 2005-12-20 | 2012-11-27 | Astrazeneca Ab | Substituted cinnoline derivatives as GABAA receptor modulators and method for their synthesis |
BRPI0908837A2 (en) * | 2008-03-11 | 2015-07-21 | Neurosearch As | Triaryl derivative, pharmaceutical composition, use of a triaryl derivative, and method for treating, preventing or relieving a disease, disorder or condition of a living animal body |
AU2011328993B2 (en) | 2010-11-15 | 2017-03-02 | Agenebio, Inc. | Pyridazine derivatives, compositions and methods for treating cognitive impairment |
US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
JP6883988B2 (en) | 2013-12-20 | 2021-06-09 | エージンバイオ, インコーポレイテッド | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
CN104356053B (en) * | 2014-10-21 | 2017-01-18 | 天津大学 | Preparation method of 2-(3-halogen phenyl) pyridine derivative |
EA036844B1 (en) | 2015-06-19 | 2020-12-28 | Эйджинбайо, Инк. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
EP3483142A1 (en) * | 2016-07-05 | 2019-05-15 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof |
BR112019012821A2 (en) | 2016-12-19 | 2019-11-26 | Agenebio Inc | benzodiazepine derivatives, compositions and methods for the treatment of cognitive impairment |
WO2019128918A1 (en) | 2017-12-29 | 2019-07-04 | 广州再极医药科技有限公司 | Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application |
JP7514534B2 (en) | 2018-06-19 | 2024-07-11 | エージンバイオ, インコーポレイテッド | Benzodiazepine derivatives, compositions and methods for treating cognitive disorders |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2510998B1 (en) * | 1981-08-07 | 1986-01-10 | Sanofi Sa | NOVEL AMINO DERIVATIVES OF PYRIDAZINE, PROCESS FOR THEIR PREPARATION AND DRINKING ACTS THEREOF |
FR2562071B1 (en) * | 1984-03-30 | 1986-12-19 | Sanofi Sa | TRIAZOLO (4,3-B) PYRIDAZINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
WO1998004559A2 (en) * | 1996-07-25 | 1998-02-05 | Merck Sharp & Dohme Limited | Substituted triazolo-pyridazine derivatives as ligands for gaba receptors |
HUP0302173A2 (en) * | 2000-09-15 | 2003-09-29 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
AU1253002A (en) * | 2000-11-10 | 2002-05-21 | Merck Sharp & Dohme | Imidazo-triazine derivatives as ligands for gaba receptors |
-
2003
- 2003-08-04 AT AT03784243T patent/ATE420867T1/en not_active IP Right Cessation
- 2003-08-04 CA CA002495285A patent/CA2495285A1/en not_active Abandoned
- 2003-08-04 JP JP2004527013A patent/JP2006507237A/en not_active Withdrawn
- 2003-08-04 WO PCT/GB2003/003376 patent/WO2004014865A1/en active Application Filing
- 2003-08-04 AU AU2003246979A patent/AU2003246979B8/en not_active Ceased
- 2003-08-04 US US10/524,173 patent/US20060235021A1/en not_active Abandoned
- 2003-08-04 EP EP03784243A patent/EP1532120B1/en not_active Expired - Lifetime
- 2003-08-04 DE DE60325865T patent/DE60325865D1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2495285A1 (en) | 2004-02-19 |
AU2003246979A1 (en) | 2004-02-25 |
EP1532120A1 (en) | 2005-05-25 |
WO2004014865A1 (en) | 2004-02-19 |
ATE420867T1 (en) | 2009-01-15 |
AU2003246979B8 (en) | 2009-08-06 |
JP2006507237A (en) | 2006-03-02 |
DE60325865D1 (en) | 2009-03-05 |
US20060235021A1 (en) | 2006-10-19 |
AU2003246979B2 (en) | 2009-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1343788B1 (en) | Imidazo-triazine derivatives as ligands for gaba receptors | |
AU2002212530A1 (en) | Imidazo-triazine derivatives as ligands for GABA receptors | |
CA2461426C (en) | Imidazo-pyrimidine derivatives as ligands for gaba receptors | |
EP1511747B1 (en) | Imidazo-pyridine derivatives as ligands for gaba receptors | |
EP1121361B1 (en) | Pyrazolo-triazine derivatives as ligands for gaba receptors | |
EP1383768B1 (en) | Imidazo-pyrimidine derivatives as ligands for gaba receptors | |
US6642229B2 (en) | 3-Phenyl-imidazo-pyrimidine derivatives as ligands for GABA receptors | |
US6900215B2 (en) | Imidazo-pyrimidine derivatives as ligands for gaba receptors | |
EP1532120B1 (en) | Phenylpyridazine derivatives as ligands for gaba receptors | |
EP1511748B1 (en) | 8-fluorimidazo(1,2-a)pyridine derivatives as ligands for gaba receptors | |
AU2002241138A1 (en) | Imidazo-pyrimidine derivatives as ligands for GABA receptors | |
US6960598B2 (en) | (1,8) naphthyridines as gaba ligands, their pharmaceutical compositions and uses | |
US6969716B2 (en) | 5-phenyl[1,2,4]triazines as ligands for GABA-A α2/α3 receptors for treating anxiety or depression | |
US7381725B2 (en) | Pyridazine derivatives as ligands for GABA receptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050314 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
RAX | Requested extension states of the european patent have changed |
Extension state: LT Payment date: 20050314 Extension state: LV Payment date: 20050314 |
|
17Q | First examination report despatched |
Effective date: 20060724 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: LT LV |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: SERVOPATENT GMBH |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 60325865 Country of ref document: DE Date of ref document: 20090305 Kind code of ref document: P |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090114 |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20090114 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090114 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090114 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090425 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090114 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090414 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090615 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090114 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090114 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090114 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090114 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20090806 Year of fee payment: 7 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090114 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090114 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20090811 Year of fee payment: 7 Ref country code: DE Payment date: 20090831 Year of fee payment: 7 Ref country code: GB Payment date: 20090611 Year of fee payment: 7 |
|
26N | No opposition filed |
Effective date: 20091015 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090414 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090831 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090804 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090415 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090114 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20100804 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090804 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100831 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100831 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20110502 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 60325865 Country of ref document: DE Effective date: 20110301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090715 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100831 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090114 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100804 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090114 |